FBXO31 ligands

Chemical entities binding to FBXO31 enable the reprogramming of this E3 ligase for targeted protein degradation, overcoming limitations of cereblon-based MGDs and PROTACs by expanding therapeutic target space and efficacy.

WO2026234130A1PCT designated stage Publication Date: 2026-11-12MONTE ROSA THERAPEUTICS AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063165
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-22
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current MGDs and PROTACs primarily rely on the E3 ligase cereblon, limiting the target space and pharmacodynamics for protein degradation, necessitating the discovery of alternative E3 ligases like FBXO31 to expand therapeutic indications.

Method used

Development of chemical entities that form non-covalent interactions with FBXO31, enabling the reprogramming of this ligase for targeted protein degradation through MGDs and PROTACs.

Benefits of technology

Expands the therapeutic target space by allowing the degradation of undruggable proteins across diverse tissues, enhancing the efficacy of MGDs and PROTACs beyond cereblon-based drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000007_0001
    Figure IMGF000007_0001
  • Figure IMGF000008_0001
    Figure IMGF000008_0001
Patent Text Reader

Abstract

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that bind to F-box protein 31 (FBXO31). The FBXO31-binding chemical entities are useful, e.g., for treating a disease or condition in a subject (e.g., a human subject). This disclosure also features compositions containing these chemical entities as well as methods of using said entities.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] FBXO31 LIGANDS

[0002] TECHNICAL FIELD

[0003] This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that bind to F-box protein 31 (FBX031). The FBX031 -binding chemical entities are useful, e.g., for treating a disease or condition in a subject (e.g., a human subject). This disclosure also features compositions containing these chemical entities as well as methods of using said entities.

[0004] BACKGROUND

[0005] The ubiquitin proteasome system can be reprogrammed by small molecules to trigger degradation of specific proteins of interest. Promoting the targeted degradation of pathogenic proteins using small molecule degraders is emerging as a new modality in the treatment of diseases. One such modality relies on redirecting the activity of E3 ligases such as CRL4CRBN(Cullin-4 RINGE3 ligase containing the substrate receptor cereblon) using low molecular weight compounds, termed molecular glue degraders (MGDs), to promote the poly-ubiquitination and proteasomal degradation of new protein substrates involved in the development of diseases (a phenomenon known as E3 reprogramming). MGDs induce proximity between an E3 ligase and a target protein by binding the E3 ligase and mediating a reshaping of the ligase surface that enables an interaction with the target protein that does not happen in the absence of the MGD. This bypasses the need for a binding pocket on the target and allows elimination of previously undruggable protein classes.

[0006] Examples of MGDs for the E3 ligase cereblon are the IMiD (immunomodulatory imide drugs) class including Thalidomide, Lenalidomide and Pomalidomide. These IMiDs have been approved by the FDA for use in haematological cancers. In recent years, the clinical target space of cereblon has expanded to undruggable proteins in multiple therapeutic indications, for example diverse autoinflammatory and autoimmune diseases (e.g. VAV1, NEK7), and inherited blood disorders (e.g. WIZ)1,2. In addition to MGDs, so-called PROTACs (Proteolysis Targeting Chimeras, usually higher molecular weight >800 Da) that are heterobifunctional small molecules combining an E3 ligase binder connected via a linker to a target ligand, are also being clinically developed for a range of disease indications3,4.Compounds capable of binding FBXO31 would thus be critical for the development of novel MGDs and / or PROTACs.

[0007] To date, cereblon is the only E3 ligase that has been reprogrammed for targeted protein degradation resulting in clinically approved drugs. However, new E3 ligases that possess alternative surface features for protein-protein interactions and differential activity across diverse tissue lineages are needed to expand the target space and pharmacodynamics of MGDs and PROTACs beyond that of cereblon-based drugs. Therefore, the discovery of new E3 ligase binders is required to enable reprogramming of novel ligases and open up the potential to degrade additional undruggable targets. FBX031 represents one such ligase and is a substrate receptor belonging to the CRL1 E3 ligase complex family (distinct to the CRL4 family that cereblon belongs to) and has been shown to bind to C-terminally amidated peptides in a binding pocket on the surface of the protein5.

[0008] As shown in FIG. 9, FBX031 is broadly expressed across all tissue types and thus has the potential to degrade therapeutic targets of interest in a range of tissues relevant to diverse disease indications.

[0009] References

[0010] 1. Petzold G, Gainza P, Annunziato S, et al. Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition. Science. 2025;389(6755). doi: 10.1126 / science.adt6736

[0011] 2. Pamela Y. Ting et al. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction. Science. 2024; 385:91-99

[0012] 3. Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181-200. doi:10.1038 / s41573-021- 00371-6

[0013] 4. Xu Y., Li X. Y., et al. PROTACs in 2025: from the laboratory concept to clinical breakthrough. Future Medicinal Chemistry, 2026; 1-3. https: / / doi.org / 10.1080 / 17568919.2026.2655682

[0014] 5. Muhar M. F., Famung J., Cernakova M. et al. C-terminal amides mark proteins for degradation via SCF-FBXO31. Nature. 2025; 638: 519-527SUMMARY

[0015] This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that bind to F-box protein 31 (FBX031). The FBX031 -binding chemical entities are useful, e.g., for treating a subject (e.g., a human subject), e.g., having a disorder or disease that can be treated by reducing the level of a target protein. The FBX031-binding chemical entities are also useful in the development of MGDs and / or PROTACs. The inventors have discovered that the tetrahydroisoquinoline amide moiety forms non-covalent interactions with FBX031 which constitute the driving force for the binding properties of the compounds described herein.

[0016] In an aspect, the invention provides a compound of Formula (I):

[0017]

[0018] Formula (I)

[0019] or a pharmaceutically acceptable salt thereof;

[0020] wherein:

[0021] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[0022] L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0023] Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, or Cs-9heteroaryl which may be optionally substituted with halo or Ci-3alkyl;

[0024] L3is absent; (a) -NHC(=O)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=0)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;

[0025] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[0026] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -Cs-ecycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);

[0027] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci.3alkyl)(Ci.3alkyl); -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -Cs-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0028] R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-shaloalkyl; or Ci-salkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[0029] R7aisH; OH; CN; NH2; halo; Ci-salkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-salkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0030] R7bisH; OH; CN; NH2; halo; Ci-salkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-salkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0031] R7Cis H; OH; CN; NH2; halo; Ci-salkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); -N(Ci.3alkyl)(Ci.3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0032] R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;

[0033] R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[0034] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[0035] R8fand R8gare each, independently H; or Ci-3alkyl;

[0036] m is 1-4;

[0037] n is 0, 1 or 2;

[0038] o is 1-8;

[0039] p is 1-5;

[0040] q is 1-5;

[0041] r is 0, 1 or 2;

[0042] t is 1-5;

[0043] Z is:

[0044] (I) halo;

[0045] (II) Ci-2oalkyl;

[0046] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0047] (IV) -OCi-3alkyl;

[0048] (V) Ci-shaloalkyl;

[0049] (VI) Cs-ncycloalkyl which may be optionally substituted with halo; -C(O)OCi-3alkyl; Ci-salkoxy; Ci-3haloalkyl; and / or Ci-salkyl-Cearyl;

[0050] (VII) Ci-3alkoxy;

[0051] (VIII) C6-15aryl which may be optionally substituted with (a) C1-6alkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) C1-5alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-ealkylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (o) -C2-ealkenylene-heteroaryl, wherein the heteroarylcontains 5 to 8 ring atoms; (p) -C2-6alkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (s) -OC4-8alkylene-NH2; (t) -OC4-8alkylene-NHC(=O)R56; (u) -SO2NH2; (v) -OCearyl; (w) C3-8cycloalkyl; (x) -OCi-salkyleneCi-shaloalkyl; (y) -SCi-salkyl; (z) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (ai) Ci-4hydroxyalkyl; (bi) -SO2NHCi-3alkyl; (ci) -SChCi-salkyl; (di) -OC4-8alkylene-NHC(=O)R32; (ei) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms;

[0052] (fi) -OCearyl, wherein said Cearyl may be optionally substituted with halo; (gi) Cearyl, wherein said Cearyl may be optionally substituted with halo; (hi) -Ci-4alkyleneNHC(=0)0Ci-ealkyl; (ii) -NHCearyl; (ji) -OCs-ecycloalkyl; (ki) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (li) -C5-9alkyleneNHC(=O)-B, wherein B is R56or R93; (mi) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ni) -C(=0)NHCi-5alkyl; (oi) -N(Ci-3alkyl)(Ci-3alkyl); and / or (pi) NO2;

[0053] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-3alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -C1-5alkyleneC3-8cycloalkyl; (g) -NHC(=0)Ci-3alkyl; (h) Ci-shaloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); and / or (m) oxo;

[0054] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -Ci-3alkyleneCearyl;

[0055] (b) -C(O)NHCi-4alkyl; (c) Ci-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)Ci-5alkyl;

[0056] (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=0)Ci-4alkyl; and / or (1) -NHCi-3alkylene-Ci-3haloalkyl; or (XI) Ci5-i9cycloalkenyl which may be optionally substituted with oxo and / or Ci-3alkyl;

[0057] R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[0058]

[0059] The invention further provides compounds of subformulae (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1 A, or a pharmaceutically acceptable salt thereof.

[0060] The compounds of formula (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is),(It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof are useful as binders of FBX031. Thus, the invention further provides pharmaceutical compositions comprising these compounds, and their use in various methods, as described further below.

[0061] Further aspects

[0062] In an aspect, the invention provides a PROTAC of Formula (V):

[0063] W-L-Bm

[0064] Formula (V);

[0065] or a pharmaceutically acceptable salt thereof, wherein:

[0066] W is a warhead of Formula (W-l):

[0067]

[0068] Formula (W-l)

[0069] wherein:

[0070] Ring A is phenyl; or a 5-6 membered heteroaryl ring, wherein 1-4 ring atoms are each independently selected from N, O or S; wherein said phenyl or 5-6 membered heteroaryl ring may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl) and / or -N(Ci-3alkyl)(Ci-3alkyl);

[0071] n is 0 or 1;

[0072] R8aand R8bare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), or Cearyl;

[0073] R8Cand R8dare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);

[0074] R8eis H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or

[0075] -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[0076] R8fand R8gare each, independently H; or Ci-3alkyl;L is a linker; and

[0077] Bm is a moiety that binds to a target protein.

[0078] Ring A may be selected from the following:

[0079]

[0080] In an aspect, the invention provides a PROTAC of Formula (V):

[0081] W-L-Bm

[0082] Formula (V);

[0083] or a pharmaceutically acceptable salt thereof;

[0084] wherein W is a warhead of Formula (W-5):

[0085]

[0086] Formula (W-5)

[0087] wherein:

[0088] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); and / or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=O)OCi-6alkyl;

[0089] Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -CN; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (i) -Ci-3alkyl, (ii) -Ci-salkylene-Cearyl wherein said Cearyl may be optionally substituted with -Ci-3alkoxy, (iii) -C(=O)OC1-6alkyl, (iv) -C(=O)Ci-3alkyl, (v) -C(=O)C3-8cycloalkyl, (vi) -C(=O)NH-C3-8cycloalkyl, (vii) -C(=O)C3-8heterocycloalkyl wherein said heterocycloalkyl may be optionally substituted with -C(=O)OC1-6alkyl, (viii) -C(=O)OCi-4alkylene-C3-8heterocycloalkyl, (ix) -C(=O)C6aryl wherein said C6aryl may be optionally substituted with halo, (x) -C(=O)Ci-3alkylene-Cearyl, (xi) -C(=O)OC6aryl, (xii) -C(=O)OCi-4alkylene-Cearyl, (xiii) -C(=O)NH-Cearyl, (xiv) -C(=O)-N(Ci-3alkyl)-Cearyl, (xv) -C(=O)NHCi-4alkylene-Cearyl, (xvi) -SO2-Cearyl, (xvii) -C(=O)C5-9heteroaryl, and / or (xviii) Cs-9heteroaryl which may be optionally substituted with halo and / or Ci-3alkyl;

[0090] L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;

[0091] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[0092] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; (w) -Cs-ecycloalkylene- which may be optionallysubstituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (x) -NHC(=O)N(Ci-4alkylene-C6aryl)-; and / or (y) -N(Cearyl)-;

[0093] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=0)NH2; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; -SO2-; or -C3-6cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); R4aand R4bare each, independently for each occurrence, H; OH; Ci-salkyl; Ci-3haloalkyl; or Ci -3 alkyl -heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[0094] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0095] R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0096] R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[0097] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0098] R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;

[0099] R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[0100] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[0101] R8fand R8gare each, independently H; or Ci-3alkyl;

[0102] m is 1-4;

[0103] n is 0, 1 or 2;o is 1-8;

[0104] p is 1-5;

[0105] q is 1-5;

[0106] r is 0, 1 or 2;

[0107] t is 1-5;

[0108] Z is H or:

[0109] (I) halo;

[0110] (II) Ci-2oalkyl;

[0111] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0112] (IV) -OCi-3alkyl;

[0113] (V) Ci-shaloalkyl;

[0114] (VI) C3-12cycloalkyl which may be optionally substituted with halo; -C(O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;

[0115] (VII) Ci-3alkoxy;

[0116] (VIII) Ce-isaryl which may be optionally substituted with (a) Ci-ealkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-4alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2.6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene- heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene- Cearyl, wherein said Cearyl may be optionally substituted with halo; (o)

[0117] -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2. ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t)

[0118] -SO2NH2; (U) -OCearyl; (v) C3-8cycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2Ci-3alkyl; (ci) -O- heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo or Ci-3alkoxy; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -Ci-4alkyleneNHC(=O)OCi- ealkyl; (gi) -NHC6aryl; (hi) -OC3-ecycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3 alkyl; (ji) -C5-9alkyleneNHC(=O)OCi-4alkyl; (ki) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (li) -C(=O)NHCi-5alkyl; (mi) -N(Ci-3alkyl)(Ci-3alkyl); (ni) NO2; (oi) -C(=O)OH; (pi) -Ci- 3alkylene-N(Ci-3alkyl) (Ci-3alkyl); (qi) -OC1-3alkylene-C6aryl; (ri) -C4-8alkylene-NH2; (si) -OC4-8alkylene-NHC(=O)OC1-4alkyl; (ti) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-4alkyl; (ui) -C2-4hydroxyalkynyl; (vi) heterocycloalkenyl, wherein the heterocycloalkenyl contains 4 to 6 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl; and / or (wi) heterocycloalkyl which may be optionally substituted with -Ci-4alkylene-heterocycloalkyl and / or -Ci-4alkylene-heterocycloalkylene-C(=O)OCi-4alkyl wherein any of said heterocycloalkyl or heterocycloalkylene contain 4 to 6 ring atoms;

[0119] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -C1-5alkyleneC3-8cycloalkyl; (g) -NHC(=0)Ci-3alkyl; (h) Ci-shaloalkyl; (i) C1-5alkoxy; (j) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)3; (k) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl); (1) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl); (m) oxo; (n) -C(=O)OCi-4alkyl; (o) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (p) -Ci-salkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (q) -O-Cearyl; (r) -Ci-3alkyl optionally substituted with OH; (s) -C(=O)Cearyl; (t) C4-8cycloalkyl; (u) -C4-8alkyl optionally substituted with NH2; (V) -C(=O)NH-Cearyl, wherein the Ce aryl may be optionally substituted with halo; (w) -C5-9alkylene-NHC(=O)OCi-4alkyl; (x) Ci-4hydroxyalkyl; (y) -C2-4hydroxyalkynyl; (z) -Ci-4alkylene-O-Ci-3alkyl; and / or (ai) -Ci-4alkylene-O-Ci-shaloalkyl;

[0120] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -Ci-salkyleneCearyl; (b) -C(0)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-shaloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein theheterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=0)Ci-4alkyl; (1) -NHCi-salkylene-Ci-shaloalkyl; (m) Ce aryl optionally substituted with halo; (n) -C(=O)-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and / or (o) -SO2C1-3alkyl;

[0121] (XI) Ci5-i9cycloalkenyl which may be optionally substituted with oxo and / or Ci- salkyl;

[0122] (XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9;

[0123] (XIII) -C(=O)OH; or

[0124] R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[0125] L is a linker; and

[0126] Bm is a moiety that binds to a target protein.

[0127] In an aspect, the invention provides a compound of Formula (1):

[0128]

[0129] Formula (1)

[0130] or a pharmaceutically acceptable salt thereof;

[0131] wherein:

[0132] Li is -C(=O)-;

[0133] L2 is absent; -(CRlaRlb) m”, -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);Rlaand Rlbare each, independently for each occurrence, H; Ci-salkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)OC6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci-3alkyleneC6aryl, -C(=O)NH-Cearyl, -NHC(=O)-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)NH-Ci-3alkylene-C6aryl, -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo or Ci-3alkyl, wherein any of said Cearyl may be optionally substituted with halo and / or C 1-3 alkoxy;

[0134] L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NCi-3alkyl-; (j) -O-;

[0135] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[0136] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -C3-6cycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);

[0137] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -C3-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo;

[0138] R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-3haloalkyl; or Ci-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form Cs-iocycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[0139] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0140] R7bis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0141] R7cisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[0142] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0143] R8aand R8bare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or C6aryl;

[0144] m is 1-4;

[0145] n is 0 or 1;

[0146] 0 is 1-8;

[0147] p is 1-5;

[0148] q is 1-5;

[0149] r is 0, 1 or 2;

[0150] t is 1-5;

[0151] Z is:

[0152] (I) halo;

[0153] (II) Ci-2oalkyl;

[0154] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0155] (IV) -OCi-3alkyl;

[0156] (V) Ci-shaloalkyl;

[0157] (VI) Cs-ncycloalkyl which may be optionally substituted with halo; -C(O)OCi-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; and / or Ci-salkyl-Cearyl;

[0158] (VII) Ci-3alkoxy;(VIII) Ce-isaryl which may be optionally substituted with (a) Ci-ioalkyl which may be optionally substituted with OH and / or NH2; (b) -OH; (c) -CN; (d) -NH2; (e) halo on 1, 3 or 4 atoms of each ring; (f) Ci-salkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (o) -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2-6alkynylene-C6aryl, wherein said C6aryl may be optionally substituted with halo; (q) -C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OC6aryl; (v) C3. scycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl, oxo, -C(=O)OCi-8alkyl, and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2Ci-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-9alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-ecycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (ji) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ki) -C(=O)NHC1-5alkyl; (li) -N(Ci-3alkyl)(Ci-3alkyl); (mi) NO2; (ni) C2-5alkynyl which may be optionally substituted with OH and / or NH2; (oi) C2-5alkenyl which may be optionally substituted with OH and / or NH2; or (pi) -C3-9alkylene-NH2;

[0159] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo; (f) -Ci-3alkyleneC3-5cycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-5alkoxy; (j) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)3; (k) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl); (1) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl); (m) oxo; (n) -OCi-salkyleneCearyl; (o) OH; (p) Ci-3hydroxyalkyl; (q) -OCearyl; (r) -Ci-salkylene-Cearyl; (s) -Ci-3alkylene-O-Ci-3alkyl; or (t) Ci-4haloalkoxy;

[0160] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -C1-5alkyleneC6aryl; (b) -C(0)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) - C(=O)Ci-6alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=0)Ci-4alkyl; (1) -NHCi- 3alkylene-Ci-3haloalkyl; (m) oxo; (n) -OCearyl; (o) -Cs-9alkylene-NH2; (p) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms; (q) C5- 7cycloalkyl; (r) -Ci-3alkylene-O-Ci-3alkyl; (s) Ci-4haloalkoxy; and / or (t) Cearyl;

[0161] (XI) C15-19cycloalkenyl which may be optionally substituted with oxo and / or C1-3alkyl; or

[0162] (XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9; and

[0163] R9is NH2, -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=0)NH2;

[0164] wherein when Li is -C(=O)-, L2 is -(CRlaRlb)m- and m is 1, then:

[0165] (i) L3, if present, cannot be -NH(C=O)-; (ii) L4 cannot be -NHC(=O)- if L3 is absent; and (iii) Z cannot be NH2 if L3 and L4 are absent.

[0166] In an aspect, the invention provides a synthetic intermediate of Formula (W-6-Int):

[0167]

[0168] Formula (W-6-Int)

[0169] or a pharmaceutically acceptable salt thereof; wherein Li, L2, L3, L4 and n are as defined herein; andZ is Cearyl; 6-10 membered heteroaryl; 6-10 membered heteroaryl-Cearyl; 6-10 membered heteroaryl-Ci-3alkyleneCearyl; 5-6 membered heterocycloalkyl, 5-6 membered heterocycloalkenyl-Cearyl; or 5-6 membered heterocycloalkenyl-Ci-3alkyleneCearyl; wherein any of said Cearyl, 6-10 membered heteroaryl, 6-10 membered heteroaryl-Cearyl, 6-10 membered heteroaryl-Ci-3alkyleneCearyl, 5-6 membered heterocycloalkenyl, 5-6 membered heterocycloalkenyl-Cearyl, or 5-6 membered heterocycloalkenyl-Ci-salkyleneCearyl may be optionally substituted with Ci-3alkyl, oxo, and / or a reactive group, for example -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;

[0170] n is 0 or 1; and

[0171] u is 1-5.

[0172] In an aspect, the invention provides a synthetic intermediate of Formula (W-7-Int):

[0173]

[0174] Formula (W-7-Int)

[0175] or pharmaceutically acceptable salt thereof, wherein:

[0176] R7a, R7b, R7Cand R7dare each, independently, H, OH, Ci-salkyl or Ci-3alkoxy;

[0177] L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci.3alkyl)C(=O)Ci.3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl,

[0178] -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci- salkyleneCearyl, -C(=O)NH-Cearyl, and / or -NHC(=O)-Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;

[0179] L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; -Cs-ecycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;

[0180] Z is -NH2; Ci-salkyl; Ci-3haloalkyl; Ci-3alkoxy; Cearyl optionally substituted with (i) OH, (ii) halo, (iii) -C2-ealkylene-Cearyl, (iv) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (v) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (vi) -Cs-9alkylene-NH2, and / or (vii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-salkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; heteroaryl wherein the heteroaryl contains 5 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -Ci-3alkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; Ce-iocycloalkyl optionally substituted with halo; or heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-3alkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl;

[0181] and wherein, for Z, any of said aryl, alkylene, alkyl, heterocycloalkyl, heteroaryl, heterocycloalkyl, hydroxyalkyl, cycloalkyl or haloalkoxy may be optionally substituted with a reactive group, for example -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;

[0182] m is 1-2;n is 0 or 1;

[0183] o is 1-8;

[0184] r is 0-2; and

[0185] u is 1-5.

[0186] In an aspect, the invention provides a synthetic intermediate of Formula (W-8-Int):

[0187]

[0188] Formula (W-8-Int)

[0189] or a pharmaceutically acceptable salt thereof; wherein:

[0190] L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-salkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;

[0191] L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;

[0192] L4 is absent, or -C 1-3 alkylene-;

[0193] Z is Ce-ioaryl which may be optionally substituted with halo, Ci-3alkyl, and / or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-salkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;

[0194] and wherein, for Z, any of said aryl, alkyl, heteroaryl, alkylene or heterocycloalkenyl may be optionally substituted with a reactive group, for example, -NH2, -CN, -C(=O)OH, -C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;

[0195] n is 0 or 1;

[0196] m is 1-2; and

[0197] u is 1-5.

[0198] In an aspect, the invention provides a synthetic intermediate of Formula (W-9-Int):

[0199]

[0200] Formula (W-9-Int)

[0201] or a pharmaceutically acceptable salt thereof, wherein:

[0202] L2is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-6cycloalkyl, wherein said C3-6cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-3alkyl;

[0203] L3is absent, -NHC(=O)- or -C(=O)NH-;

[0204] Z is Ce-ioaryl, heteroaryl, wherein said heteroaryl contains 5 to 10 ring atoms, heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 10 ring atoms, or heterocycloalkenyl, wherein said heterocycloalkenyl contains 4 to 10 ring atoms wherein said Ce-ioaryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl may be optionally substituted with oxo, phenyl, and / or a reactive group, for example, -NH2, C1-9alkylene-NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]u-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]u-NH2;

[0205] m is 1-3;

[0206] n is 0 or 1; and

[0207] u is 1-5.

[0208] In an aspect, the invention provides a synthetic intermediate of Formula (W-10-Int):

[0209]

[0210] Formula (W-10-Int)

[0211] or a pharmaceutically acceptable salt thereof, wherein:

[0212] Z is phenyl, 6-10 membered heteroaryl, C1-10alkyl, C2-5alkynyl, C2-5alkenyl, 5-7 membered heterocycloalkyl, 5-7 membered heterocycloalkenyl, 5-7 membered heterocycloalkyl-Ci-3alkylene-6-membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl-Ci-3alkylene-6-membered heterocycloalkyl;

[0213] wherein said phenyl, 6-10 membered heteroaryl, C1-10alkyl, C2-5alkynyl, C2-5alkenyl, 5-7 membered heterocycloalkyl, 5-7 membered heterocycloalkenyl, 5-7 membered heterocycloalkyl-Ci-3alkylene-6-membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl-Ci-3alkylene-6-membered heterocycloalkyl may be optionally substituted with a reactive group, for example, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, - C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]u-NH2, or Ci- walkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2;

[0214] o is 0-3; and

[0215] u is 1-5.In an aspect, the invention provides a method of making a PROTAC comprising reacting a warhead of Formula (W-l-ii):

[0216]

[0217] Formula (W-l-ii)

[0218] or a pharmaceutically acceptable salt thereof with a linker and a moiety that binds to a target protein;

[0219] wherein Ring A is phenyl; or a 5-6 membered heteroaryl ring, wherein 1-4 ring atoms are each independently selected from N, O or S; wherein said phenyl or 5-6 membered heteroaryl ring may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, NH(Ci-3alkyl) and / or -N(Ci-3alkyl)(Ci-3alkyl);

[0220] n is 0 or 1;

[0221] R8aand R8bare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(C1-3alkyl), -N(C1-3alkyl)(C1-3alkyl), or C6aryl;

[0222] R8cand R8dare each, independently, H, OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);

[0223] R8eis H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or

[0224] -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[0225] R8fand R8gare each, independently H; or Ci-3alkyl; and

[0226] RGforms a reactive group with the warhead that forms a linkage with the linker.In an aspect, the invention provides a method of making a PROTAC of Formula (V-i):

[0227]

[0228] Formula (V-i)

[0229] comprising reacting a compound of Formula (W-5) as defined herein with a linker and a moiety that binds to a target protein, wherein:

[0230] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[0231] L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); and / or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=O)OCi-6alkyl;

[0232] Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -CN; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (i) -Ci-3alkyl, (ii) -Ci-salkylene-Cearyl wherein said Cearyl may be optionally substituted with -Ci-3alkoxy, (iii) -C(=O)OC1-6alkyl, (iv) -C(=O)Ci-3alkyl, (v) -C(=O)C3-8cycloalkyl, (vi) -C(=O)NH-C3-8cycloalkyl, (vii) -C(=O)C3-8heterocycloalkyl wherein said heterocycloalkyl may be optionally substituted with -C(=O)OC1-6alkyl, (viii) -C(=O)OCi-4alkylene-C3-8heterocycloalkyl, (ix) -C(=O)C6aryl wherein said C6aryl may be optionally substituted with halo, (x) -C(=O)Ci-3alkylene-Cearyl, (xi) -C(=O)OC6aryl, (xii)-C(=O)OC1-4alkylene-C6aryl, (xiii) -C(=O)NH-C6aryl, (xiv) -C(=O)-N(C1-3alkyl)-C6aryl, (xv) -C(=O)NHC1-4alkylene-C6aryl, (xvi) -SO2-C6aryl, (xvii) -C(=O)C5-9heteroaryl, and / or (xviii) C5-9heteroaryl which may be optionally substituted with halo and / or Ci-3alkyl;

[0233] L3is absent; (a) -NHC(=O)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=0)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -0-;

[0234] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[0235] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; (w) -C3-6cycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (x) -NHC(=O)N(Ci-4alkylene-C6aryl)-; and / or (y) -N(Cearyl)-;

[0236] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=0)NH2; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; -SO2-; or -C3-6cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); R4aand R4bare each, independently for each occurrence, H; OH; C1-5alkyl; C1-3haloalkyl; or C1-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[0237] R7ais H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); or -N(C1-3alkyl)(C1-3alkyl);

[0238] R7bis H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); or -N(C1-3alkyl)(C1-3alkyl);

[0239] R7Cis H; OH; CN; NH2; halo; Ci-salkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or -(OCH2CH2)p-R9;

[0240] R7dis H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); or -N(C1-3alkyl)(C1-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or C6aryl;

[0241] R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[0242] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[0243] R8fand R8gare each, independently H; or Ci-3alkyl;

[0244] m is 1-4;

[0245] n is 0, 1 or 2;

[0246] o is 1-8;

[0247] p is 1-5;

[0248] q is 1-5;

[0249] r is 0, 1 or 2;

[0250] t is 1-5;

[0251] Z is absent or:

[0252] (I) -Ci-2oalkylene-;

[0253] (II) -NH; or -N(Ci-3alkyl)-;

[0254] (III) -OCi-3alkylene;

[0255] (IV) -Ci-shaloalkylene-;

[0256] (V) -C3-11cycloalkylene- which may be optionally substituted with halo; -C(=O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;

[0257] (VI) -C6-18arylene- which may be optionally substituted with (a) C1-6alkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) C1-3alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-4alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene- heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-6alkenylene-C6aryl, wherein said C6aryl may be optionally substituted with halo; (o)

[0258] -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2- ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)p-R9; (s) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OC6aryl; (v) C3-C3-8cycloalkyl; (w) -OC1-3alkyleneC1-3haloalkyl; (x) -SC1-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxy alkyl; (ai) -SO2NHC1-3alkyl; (bi) -SO2C1-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo or Ci-3alkoxy; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-4alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-6cycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with C1-3 alkyl; (ji) -C5-9alkyleneNHC(=O)OC1-4alkyl; (ki) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (li) -C(=O)NHC1-3alkyl; (mi) -N(Ci-3alkyl)(Ci-3alkyl); (ni) NO2; (oi) -C(=O)OH; (pi) -Ci-3alkylene-N(Ci-3alkyl) (Ci-3alkyl); (qi) -OC1-3alkylene-C6aryl; (ri) -C4-8alkylene-NH2; (si) -OC4-8alkylene-NHC(=O)OC1-4alkyl; (ti) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-4alkyl; (ui) -C2-4hydroxyalkynyl; (vi) heterocycloalkenyl, wherein the heterocycloalkenyl contains 4 to 6 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl; and / or (wi) heterocycloalkyl which may be optionally substituted with -Ci-4alkylene-heterocycloalkyl and / or -Ci-4alkylene-heterocycloalkylene-C(=O)OCi-4alkyl wherein any of said heterocycloalkyls and heterocycloalkylene contain 4 to 6 ring atoms; (VII) -heteroarylene-, wherein the heteroarylene contains 4 to 15 ring atoms, and wherein said heteroarylene may be optionally substituted with (a) halo; (b) C1-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) C6aryl which may be optionally substituted with halo and / or C1-3alkyl; (f) -C1-3alkyleneC3-8cycloalkyl; (g) -NHC(=O)C1-3alkyl; (h) Ci-3haloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); (m) oxo; (n) -C(=O)OC1-4alkyl; (o) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (p) -C1-3alkylene-C6aryl, wherein the C6aryl may be optionally substituted with halo; (q) -O-C6aryl; (r) -C1-3alkyl optionally substituted with OH; (s) -C(=O)C6aryl; (t) C4-8cycloalkyl; (u) -C4-8alkyl optionally substitutedwith NH2; (v) -C(=O)NH-C6aryl, wherein the C6aryl may be optionally substituted with halo; (w) -C5-9alkylene-NHC(=O)OC1-4alkyl; (x) C1-4hydroxyalkyl; (y) -C2-4hydroxyalkynyl; (z) -C1-4alkylene-O-C1-3alkyl; and / or (ai) -C1-4alkylene-O-C1-3haloalkyl;

[0259] (VIII) -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 15 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with (a) -C1-3alkyleneC6aryl; (b) -C(=O)NHC1-4alkyl; (c) C1-3alkyl; (d) halo; (e) -OC1-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) C1-3haloalkyl; (j) -C1-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)C1-4alkyl; (l)

[0260] -NHC1-3alkylene-C1-3haloalkyl; (m) C6aryl optionally substituted with halo; (n) -C(=O)-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and / or (o) -SO2C1-3alkyl;

[0261] (IX) -C15-19cycloalkenylene- which may be optionally substituted with oxo and / or C1-3alkyl;

[0262] (X) heterocycloalkenylene containing 6-10 ring atoms which may be optionally substituted with C1-6alkyl, oxo, -OH, -CN, -NH2, halo, C1-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, -C(=O)OC1-3alkyl, -NHC(=O)OC1-8alkyl, -C(=O)NH2, or -(OCH2CH2)p-R9; or

[0263] (XI) -C(=O)O-; and

[0264] R9is -C1-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[0265] L is a linker; and

[0266] Bm is a moiety that binds to a target protein;

[0267] wherein one of Li, L2, L3, L4 or Z of said warhead is a reactive group that attaches to the linker, or is derivatised to form a reactive group that attaches to the linker.

[0268] In an aspect, the invention provides the use of a PROTAC, compound, or pharmaceutically acceptable salt thereof as defined herein for the manufacture of a medicament.

[0269] In an aspect, the invention provides a PROTAC, compound, or pharmaceutically acceptable salt thereof as defined herein for use in therapy.

[0270] In an aspect, the invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a PROTAC.In an aspect, the invention provides the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a molecular glue degrader.

[0271] In an aspect, the invention provides a pharmaceutical dosage form comprising a PROTAC, compound or pharmaceutically acceptable salt thereof as defined herein, wherein the pharmaceutical dosage form is a pill, tablet or capsule.

[0272] DEFINITIONS

[0273] The term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds of the present disclosure include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.Pharmaceutically acceptable salts include those derived from suitable inorganic and organic acids and bases. In particular, “pharmaceutically acceptable salts” encompasses any multicomponent form comprising a compound as defined herein and a suitable (in)organic acid or base, including salts in which the proton is completely transferred from the acid to the base, and cocrystals in which the proton remains in the acid molecule, and together the base and the acid form a unique crystal structure.

[0274] A “subject” to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g, infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and / or a non-human animal, e.g., a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. Preferably, the subject is a human.

[0275] Disease, disorder, and condition are used interchangeably herein.

[0276] As used herein, and unless otherwise specified, the terms “treat,” “treating” and “treatment” contemplate an action that occurs before or while a subject is suffering from the specified disease, disorder or condition, which reduces the likelihood of the disease, disorder or condition, reduces the severity of the disease, disorder or condition, or retards or slows the progression of the disease, disorder or condition (“therapeutic treatment”).

[0277] In general, the “effective amount” of a compound refers to an amount sufficient to elicit the desired biological response. As will be appreciated by those of ordinary skill in this art, the effective amount of a compound of the present disclosure may vary depending on such factors as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and condition of the subject.

[0278] As used herein, and unless otherwise specified, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder or condition, or to delay or minimize one or more symptoms associated with the disease, disorder or condition. A therapeutically effective amount of a compound means an amount of a FBX031 ligand which provides a therapeutic benefit in the treatment of the disease, disorder or condition when used according to the invention. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of disease or condition.

[0279] The term “PROTAC” as used herein refers to a bifunctional compound comprising a FBX031 -recruiting warhead, a linker, and a ligand that binds to a protein of interest (e.g. “Lig”or “Bm”). A PROTAC as defined herein may achieve a maximum degradation of a protein of interest (Dmax) of 20% or more, such as 40% or more or 60% or more.

[0280] A “reactive group” as defined herein is a group capable of forming a linkage with a linker. For example, a reactive group may be -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, or -[O(CH2)2]U-NH2. The reactive group can be attached directly to Z or a substituent thereof. For example, in the context of Formula (W-7-int), the reactive group may be -NH2, such that Z may be

[0281]

[0282] (because Z may be Cearyl optionally substituted with -C2-6alkylene-C6aryl).

[0283] A “reactive derivative thereof’ as defined herein refers to e.g. a warhead of Formula (W-5) wherein a substituent, preferably Z, is substituted with a reactive group, for example -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2, wherein u is 1-5.

[0284] The compounds described herein also include isotopically labeled compounds which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as2H,3H,13C,14C,15N,18O,17O,31P,32P,35S,18F, and36C1, respectively. For example, a compound of the invention may have one or more H atom replaced with deuterium. A compound of the invention may have all H atoms replaced with deuterium.

[0285] The term "halo" refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I).

[0286] The term "aliphatic" or "aliphatic group", as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle”, “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments,aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a C3-6 monocyclic, carbocyclic ring that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. In some embodiments, a carbocyclic ring may be a 5-12 membered bicyclic, bridged bicyclic, or spirocyclic ring. A carbocyclic ring may include one or more oxo (=0) or thioxo (=S) substituent. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0287] The term "alkyl" refers to a saturated acyclic hydrocarbon radical that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-10 indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. Alkyl groups can either be unsubstituted or substituted with one or more substituents. Non-limiting examples include methyl, ethyl, z.w-propyl, tert-butyl, zz-hexyl. The term “saturated” as used in this context means only single bonds present between constituent carbon atoms and other available valences occupied by hydrogen and / or other substituents as defined herein.

[0288] The term "alkylene" refers to a divalent alkyl (e.g., -CH2-).

[0289] The term “hydroxyalkyl” refers to a monovalent alkyl group substituted with one or more hydroxyl (-OH) groups. The alkyl portion may be linear or branched and typically contains 1 to about 20 carbon atoms, unless otherwise specified. Common examples include hydroxymethyl (-CH2OH), 2 -hydroxy ethyl (-CH2CH2OH), and 3-hydroxypropyl (-CH2CH2CH2OH). The hydroxyl group(s) may be located at any position on the alkyl chain, and the hydroxyalkyl group may be further substituted, e.g., with one or more substituents as defined herein.

[0290] The term "haloalkyl" refers to an alkyl, in which one or more hydrogen atoms is / are replaced with an independently selected halo.

[0291] The term “haloalkoxy” refers to a haloalkyl group which is attached to another moiety via an oxygen atom such as, e.g., -OCHF2 or -OCF3.

[0292] The term "alkoxy" refers to an -O-alkyl radical (e.g., -OCH3).

[0293] The term "alkenyl" refers to an acyclic hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C2-6 indicates that the group mayhave from 2 to 6 (inclusive) carbon atoms in it. Alkenyl groups can either be unsubstituted or substituted with one or more substituents.

[0294] The term “alkenylene” refers to a divalent hydrocarbon group containing at least one carbon-carbon double bond (-C=C-), derived from an alkene by the removal of two hydrogen atoms, typically one from each of two carbon atoms. Alkenylene groups may be linear or branched, and may include cis- or trans- (E / Z) isomers. Examples include -CH=CH-(ethenylene), -CH=CHCH2-, and -CH=CHCH=CH- Unless otherwise specified, alkenylene groups may be unsubstituted or substituted with one or more substituents.

[0295] The term "alkynyl" refers to an acyclic hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C2-6 indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it. Alkynyl groups can either be unsubstituted or substituted with one or more substituents.

[0296] The term “alkynylene” refers to a divalent hydrocarbon group containing at least one carbon-carbon triple bond (-C=C-), derived from an alkyne by the removal of two hydrogen atoms, typically from different carbon atoms. Alkynylene groups may be linear or branched and typically contain 2 to about 20 carbon atoms, unless otherwise specified. Examples include — C=C— (ethynylene), CH2OCCH2. Alkynyl groups can either be unsubstituted or substituted with one or more substituents.

[0297] The term "aryl" refers to a mono-, bi-, tri- or polycyclic group wherein at least one ring in the system is aromatic (e.g., 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system). 0, 1, 2, 3, or 4 atoms of each ring may be optionally substituted e.g., by one or more substituents as defined herein. Examples of aryl groups include phenyl, naphthyl, tetrahydronaphthyl, dihydro- IH-indenyl and the like.

[0298] The term “arylene” refers to a divalent aryl group as defined above, derived from an aryl group by the removal of two hydrogen atoms, typically from carbon atoms in the aromatic ring. Arylene groups may be optionally substituted, e.g., with one or more substituents as defined herein. Common examples include phenylene (-C6H4-), such as 1,2-phenylene, 1,3-phenylene, and 1,4-phenylene, and naphthylene (e.g., -CioHe— ).

[0299] The term "cycloalkyl" as used herein refers to cyclic saturated hydrocarbon groups having, e.g., 3 to 20 ring carbons, 3 to 16 ring carbons, 3 to 12 ring carbons, 3-10 ring carbons, or 3-6 ring carbons, wherein the cycloalkyl group may be optionally substituted, e.g., with a substituent as defined herein. Examples of cycloalkyl groups include, without limitation,cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl may include multiple fused and / or bridged rings. Non-limiting examples of fused / bridged cycloalkyl includes: bicyclofl.1.0]butanyl, bicyclo[2.1.0]pentanyl, bicyclo[l.l.l]pentanyl, bicyclo[3.1.0]hexanyl, bicyclo[2.1.1]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[4.1.0]heptanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[4.2.0]octanyl, bicyclo[3.2.1]octanyl, bicyclo[2.2.2]octanyl, and the like. Cycloalkyl also includes spirocyclic rings (e.g., spirocyclic bicycle wherein two rings are connected through just one atom). Non-limiting examples of spirocyclic cycloalkyls include spiro[2.2]pentanyl, spiro[2.5]octanyl, spiro[3.5]nonanyl, spiro[3.5]nonanyl, spiro[3.5]nonanyl, spiro[4.4]nonanyl, spiro[2.6]nonanyl, spiro[4.5]decanyl, spiro[3.6]decanyl, spiro[5.5]undecanyl, and the like. The term “saturated” as used in this context means only single bonds present between constituent carbon atoms.

[0300] The term “cycloalkylene” refers to a divalent saturated cyclic hydrocarbon group derived from a cycloalkane by the removal of two hydrogen atoms from non-adjacent or adjacent carbon atoms in the ring. Cycloalkylene groups may contain from 3 to 20 ring carbons, 3 to 16 ring carbons, 3 to 12 ring carbons, 3-10 ring carbons, or 3-6 ring carbons, and may be monocyclic, fused polycyclic, spirocyclic or bridged structures. Examples include cyclopentylene (-CsHs-), cyclohexylene (-CeHw-), and bicyclo[2.2.1]heptylene. Cycloalkylene groups may be unsubstituted or substituted, e.g., with one or more substituents as defined herein.

[0301] The term “heteroaryl”, as used herein, means a mono-, bi-, tri- or polycyclic group having e.g., 5 to 20 ring atoms, alternatively 5, 6, 9, 10, or 14 ring atoms; and having 6, 10, or 14 pi electrons shared in a cyclic array; wherein at least one ring in the system is aromatic, and at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, and S (but does not have to be a ring which contains a heteroatom, e.g. tetrahydroisoquinolinyl, e.g., tetrahydroquinolinyl). Heteroaryl groups can either be unsubstituted or substituted, e.g., with one or more substituents as defined herein. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotri azolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4-b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromanyl, 2,3-dihydrobenzofb] [ 1,4]dioxinyl, benzofd] [ 1,3 ]dioxolyl, 2,3 -dihydrobenzofuranyl,tetrahydroquinolinyl, 2,3-dihydrobenzo[b][l,4]oxathiinyl, isoindolinyl, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, isoindolinyl, pyranyl, pyrazinyl, and pyrimidinyl.

[0302] The term “heteroarylene” refers to a divalent heteroaryl group as defined above, derived from a heteroaryl group by the removal of two hydrogen atoms. Examples include 2,5-thienylene, 3,5-pyridylene, and 2,6-quinolylene. Heteroarylene groups may be unsubstituted or substituted, e.g., with one or more substituents as defined herein, and may include isomeric forms unless otherwise specified.

[0303] The term "cycloalkenyl" as used herein means partially unsaturated cyclic hydrocarbon groups having, e.g., 3 to 20 ring carbons, 3 to 16 ring carbons, 3 to 12 ring carbons, 3-10 ring carbons, or 3-6 ring carbons, wherein the cycloalkenyl group may be optionally substituted, e.g., with one or more substituents as defined herein. Examples of cycloalkenyl groups include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. As partially unsaturated cyclic hydrocarbon groups, cycloalkenyl groups may have any degree of unsaturation provided that one or more double bonds is present in the ring, none of the rings in the ring system are aromatic, and the cycloalkenyl group is not fully saturated overall. Cycloalkenyl may include multiple fused and / or bridged and / or spirocyclic rings.

[0304] The term "heterocycloalkyl" refers to a mon-, bi-, tri-, or polycyclic saturated ring system with e.g., 3-16 ring atoms (e.g., 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system) having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic or polycyclic, said heteroatoms selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms ofN, O, or S if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted, e.g., by a substituent as defined herein. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like. Heterocyclyl may include multiple fused and bridged rings. Non-limiting examples of fused / bridged heteorocyclyl includes: 2-azabicyclo[1.1.0]butanyl, 2-azabicyclo[2.1.0]pentanyl, 2-azabicyclo[l.l.l]pentanyl, 3-azabicyclo[3.1.0]hexanyl, 5-azabicyclo[2.1.1]hexanyl, 3-azabicyclo[3.2.0]heptanyl, octahydrocyclopenta[c]pyrrolyl, 3-azabicyclo[4.1.0]heptanyl, 7-azabicyclo[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 7-azabicyclo[4.2.0]octanyl, 2-azabicyclo[2.2.2]octanyl, 3-azabicyclo[3.2.1]octanyl, 2-oxabicyclo[1.1.0]butanyl, 2-oxabicyclo[2.1.0]pentanyl, 2-oxabicyclo[l.l.l]pentanyl, 3-oxabicyclo[3.1.0]hexanyl, 5-oxabicyclo[2.1.1]hexanyl, 3-oxabicyclo[3.2.0]heptanyl, 3-oxabicyclo[4.1.0]heptanyl, 7-oxabicyclo[2.2.1]heptanyl, 6-oxabicyclo[3.1.1]heptanyl, 7-oxabicyclo[4.2.0]octanyl, 2-oxabicyclo[2.2.2]octanyl, 3-oxabicyclo[3.2.1]octanyl, and the like. Heterocyclyl also includes spirocyclic rings (e.g., spirocyclic bicycle wherein two rings are connected through just one atom). Non-limiting examples of spirocyclic heterocyclyls include 2-azaspiro[2.2]pentanyl, 4-azaspiro [2.5 ] octany 1, 1 -azaspiro[3.5]nonanyl, 2-azaspiro[3.5]nonanyl, 7-azaspiro[3.5]nonanyl, 2-azaspiro[4.4]nonanyl, 6-azaspiro[2.6]nonanyl, 1,7-di azaspiro [4.5 ] decanyl, 7-azaspiro[4.5 ] decanyl 2,5-diazaspiro[3.6]decanyl, 3-azaspiro [ 5.5 ]undecany 1, 2-oxaspiro[2.2]pentanyl, 4-oxaspiro[2.5]octanyl, 1-oxaspiro[3.5]nonanyl, 2-oxaspiro[3.5]nonanyl, 7-oxaspiro[3.5]nonanyl, 2-oxaspiro[4.4]nonanyl, 6-oxaspiro[2.6]nonane, l,7-dioxaspiro[4.5]decanyl, 2,5-dioxaspiro[3,6]decanyl, l-oxaspiro[5.5]undecanyl, 3-oxaspiro[5.5]undecanyl, 3-oxa-9-azaspiro [ 5.5 ]undecany 1 and the like. The term “saturated” as used in this context means only single bonds present between constituent ring atoms and other available valences occupied by hydrogen and / or other substituents as defined herein.

[0305] The term “heterocycloalkylene” refers to a divalent heterocycloalkyl group as defined above, derived from a heterocycloalkyl group by removal of two hydrogen atoms. Examples include morpholinylene (e.g., -OCH2CH2CH2CH2N-), piperidinylene, and tetrahydrofurylene. The heterocycloalkylene group may be unsubstituted or substituted, e.g., with one or more substituents as defined herein.

[0306] As used herein, when a ring is described as “aromatic”, it means said ring has a continuous, delocalized 7t-electron system. Typically, the number of out of plane 7t-electrons corresponds to the Huckel rule (4n+2). Examples of such rings include: benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyridone, pyrrole, pyrazole, oxazole, thioazole, isoxazole, isothiazole, and the like.

[0307] When a group is “absent”, it is to be understood that the groups that would be bound to either side of said absent group when present are directly linked to one another. For instance, when L2is absent, Li and L3 are directly linked. If L2 and L3 are absent, Li and L4 are directly linked, and so on.

[0308] In the context of a linker, L, suitable monovalent substituents on a substitutable carbon atom of an “optionally substituted” group are independently halogen; -(CH2)o-4R°; -(CH2)o-4OR°; -0(CH2)O-4R°; -0-(CH2)O-4C(0)OR°; -(CH2)O-4CH(OR°)2; -(CH2)O-4SR°; -(CH2)0-4Ph, which may be substituted with R°; -(CH2)o-40(CH2)o-iPh which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)o-40(CH2)o-ipyridyl which may be substituted with R°; -NO2; -CN: -N3; -(CH2)o.4N(R0)2; -(CH2)o.4N(R0)C(0)R0; -N(R°)C(S)R°: -(CH2)O-4N(R0)C(0)N(R°)2;-N(R°)C(S)N(R°)2; -(CH2)0-4N(RO)C(O)ORO; N(R°)N(R°)C(O)R°: -N(R°)N(RO)C(O)N(RO)2; -N(R°)N(R0)C(O)OR°; -(CH2)o-4C(0)R°; -C(S)R°; -(CH2)o-4C(0)OR°: -(CH2)0-4C(O)SR°; -(CH2)o-4C(0)OSi(R0)3; -(CH2)0-4OC(O)R°; -OC(O)(CH2)0-4SR°; -(CH2)0-4SC(O)R°: -(CH2)o-4C(O)N(RO)2: -C(S)N(RO)2; -C(S)SR°: -SC(S)SR°, -(CH2)O-IOC(0)N(R°)2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)O-4SSR°;-(CH2)O-4S(0)2R°; -(CH2)O-4S(O)2ORO; -(CH2)O-4OS(0)2R°; -S(O)2NRO2; -(CH2)0-4S(O)R°; -N(R°)S(O)2N(R°)2; -N(R° )S(O)2R°; -N(OR°)R°; -C(NH)N(RO)2; -(CH2)O-4P(0)2R°; -(CH2)O-4P(0)(R°)2; -(CH=)O-4OP(O)(RO)2; -(CH2)O-4OP(0)(OR°)2: Si(R°)3; -(Ci-4straight or branched alkylene)O-N(R°)2: or -(Ci-4straight or branched alkylene)C(O)O-N(R°)2, wherein each R° may be substituted as defined below and is independently hydrogen, C1-6aliphatic, -CH2Ph, -0(CH2)o-iPh, -CH2-(5-6 membered heteroaryl ring), or a 3-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R° taken together with their intervening atom(s), form a 3-12-membered saturated, partially unsaturated, or aryl mono-or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted as defined below.

[0309] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)o-2R', -(haloR"), -(CH2)O.2OH, -(CH2)O-2OR', -(CH2)0.2CH(OR')2; -O(haloR’), -CN, -N3, -(CH2)0-2C(O)R-, -(CH2)O-2C(0)OH, -(CH2)O-2C(0)OR-, -(CH2)O-2SR-, -(CH2)O.2SH, -(CH2)O.2NH2, -(CH2)O-2NHR', -(CH2)O-2N(R’)2, -NO2, -Si(R’)3, -OSi(R’)3, -C(O)SR', -(Ci-4straight or branched alkylene)C(O)OR', or -SSR' wherein each R' is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently selected from Ci-4aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.

[0310] Suitable divalent substituents on a saturated carbon atom of an “optionally substituted” group include the following: =0, =S, =NNR*2, =NNHC(0)R*, =NNHC(0)0R*, =NNHS(O)2R*, =NR*, =N0R*, O(C(R*2))2.3S-. or -S(C(R*2))2.3S-, wherein each independent occurrence of R* is selected from hydrogen, C1-6aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR*2)2.3O-, wherein each independent occurrence of R* is selected from hydrogen,C1-6aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0311] Suitable substituents on the aliphatic group of R* include halogen, -R’, -(haloR’), -OH, -OR’, -O(haloR’), -CN, -C(O)OH, -C(O)OR’, -NH2, -NHR’, -N(R’)2, or -NO2, wherein each R’ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0312] Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include -R¥, -N(R¥)2, -C(O)R¥, -C(O)OR¥, -C(O)C(O)R¥, -C(O)CH2C(O)R¥, -S(O)2R¥, -S(O)2N(R¥)2, -C(S)N(R¥)2, -C(NH)N(R¥)2, or -N(R¥)S(O)2R¥; wherein each R¥is independently hydrogen, C1-6aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R¥, taken together with their intervening atom(s) form an unsubstituted 3-12-membered saturated, partially unsaturated, or aryl mono or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0313] Suitable substituents on the aliphatic group of R¥are independently halogen, -R’, -(haloR"), -OH, -OR’, -O(haloR’), -CN, -C(O)OH, -C(O)OR', -NH2, -NHR; -N(R’)2, or -NO2, wherein each R’ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci-4 aliphatic, -CH2Ph, -0(CH2)o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0314] The term “C1-6hydrocarbon chain” refers to a sequence of 1 to 6 carbon atoms that may include -C-C-, -C=C- or -C=C- bonds between carbon atoms. For example, the term

[0315] “C1-6hydrocarbon chain” encompasses groups such as

[0316]

[0317] , and

[0318]

[0319] The hydrocarbon chain may be straight or branched, and 1-3 methylene units may optionally and independently be replaced by -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or

[0320]

[0321] When the term “Lig” is defined with reference to a specific compound e.g., sirolimus or tacrolimus, it is understood that the specific compound is attached via any suitable atom.

[0322] For example, when Lig

[0323]

[0324] understood that, for example, the hoc group may be removed and the resulting carboxylic acid coupled to L, such that JQ1 is attached to L via the -C(=O) group in JQ1.

[0325] The term “Lig”, in the context of compounds of Formula (Ila), (lib), (lie) and (lid), refers to a ligand in a PROTAC that binds to a target protein. In this context, “binds to a target protein” refers to the binding of the ligand to a specific binding site on the target protein. This binding is typically non-covalent and reversible.

[0326] The terms “Lig” and “Bm” are used interchangeably.

[0327] The term “ZL0580” refers to a compound of the following structure:

[0328]

[0329] A bond between L and ZL00580 (e.g., between Li, L2, L3, L4 or L5 and ZLO580) may be between any chemically sensible atoms, for example a -C-C- bond.

[0330] The term “OTX015” refers to a compound of the following structure:

[0331]

[0332] . A bond between L and OTX015 (e.g., between Li, L2, L3, L4 or L5 and OTX015) may be between any chemically sensible atoms, for example a -C-C- bond.The compounds generically or specifically disclosed herein include all stereoisomeric forms, including all diastereomeric and entantiomeric forms, unless it is specifically stated or the context indicates otherwise. Compounds with chiral centers can occur as racemates, individual enantiomers (e.g. as the (R) enantiomer or (S) entantiomer) or diastereomers, and mixtures thereof. All such stereoisomeric forms are included within the embodiments disclosed herein, including mixtures thereof.

[0333] Preferably, in the compounds of the invention, the chiral centre at the 3 position of the tetrahydroisoquinoline ring has the following configuration:

[0334]

[0335] Preferably, in the PROTACs, warheads, compounds, or pharmaceutically acceptable salts thereof of the invention, the chiral centre at the 3 position of the tetrahydroisoquinoline ring has the following configuration:

[0336]

[0337] R8emay be H, and the chiral center at position 3 of the tetrahydroisoquinoline ring may be in the (S) configuration.

[0338] For example, the compounds of the invention may comprise the (S) stereoisomer at position 3 of the tetrahydroisoquinoline ring. For example, a compound of Formula (I) or pharmaceutically acceptable salt thereof may be:

[0339]

[0340] Formula (I)

[0341] Similarly, a compound of Formula (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip),(Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid), (Ildi), or (III), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof, may comprise the (S) isomer at the 3 position of the tetrahydroisoquinoline ring (for example, when R8eis H). In another embodiment, in the compounds of the invention, the chiral centre at the 3 position of the tetrahydroisoquinoline ring may have the following configuration:

[0342]

[0343] Therefore, a compound of Formula (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid), (Ildi), or (III), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof, may comprise the (R) isomer at the 3 position of the tetrahydroisoquinoline ring (for example, when R8eis H). As used herein, the phrase “optionally substituted” when used in conjunction with a structural moiety (e.g., alkyl) is intended to encompass both the unsubstituted structural moiety (i.e., none of the substitutable hydrogen atoms are replaced with one or more non-hydrogen substituents) and substituted structural moieties (where one or more of the substitutable hydrogen atoms are replaced with the indicated range of non-hydrogen substituents). For example, L2 may be -(CRlaRlb)m, wherein Rlaand Rlbtogether with the carbon atom to which they are attached form (a) Cs-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with Ci-salkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, or -C(=O)C6aryl. The above-mentioned phrase “wherein said Cs-scycloalkyl may be optionally substituted with Ci-3alkyl” is intended to encompass both unsubstituted CAscycloalkyl groups and Cs-scycloalkyl groups substituted with C1-3 alkyl, such

[0344] that, for example, both

[0345]

[0346] are encompassed. Further, if a structural moiety (for example, Z) is described as optionally substituted with one or more of a range of nonhydrogen substituents, e.g., (a) halo; (b) Ci-salkyl; or (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms, etc., the structural moiety (for example, Z), may be substituted with any of the non-hydrogen substituents more than once, and this may bemultiple substitutions of the same type (e.g. two methyl substitutions), or multiple substitutions of different type (e.g. a methyl and a halogen).

[0347] Any bivalent group disclosed herein, e.g. -C(=O)NH- discloses the group in either orientation, i.e. -C(=O)NH- and -NHC(=O)-. Preferably, a disclosure of a bivalent group, for example -C(=O)NH-, is to be read from left to right, such that, for instance, when L3 is -C(=O)NH- and L2 and L4 are present, the moiety -L2-C(=O)NH-L4- is described.

[0348] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features and advantages of the invention will be apparent from the description and drawings, and from the claims.

[0349] DESCRIPTION OF DRAWINGS

[0350] FIG. 1 shows the dose-response curves of Compounds 665-667, 678-681, 761-762 and 764-772 in a FKBP12F36V-nanoLuciferase reporter cell line. Increasing concentration of these compounds display increasing levels of degradation of FKBP12F36Vprotein. Some compounds show a phenomenon typical of PROTACs at high concentrations where degradation effects decrease due to what is referred to as a ‘hook effect’. This is a result of the compound saturating the binding site of either the target or the E3 ligase and forming binary complexes instead of ternary complexes that result in degradation.

[0351] FIGS. 2A-C show the degradation of the FKBP12F36V-GFP reporter by Compounds 665, 666, and 667 in HEK293T WT and FBX031 KO cells. In the absence of FBX031 expression in KO cells, the FKBP12F36V-GFP reporter levels are unaffected by treatment with Compounds 665, 666, and 667. The degradation is therefore rescued by the genetic deletion of FBX031 and dependent on the expression of the E3 ligase.

[0352] FIG. 3A shows the degradation of endogenous FKBP12 with increasing concentrations of either Compound 668 or Compound 669 in NCI-H1155 WT and FBX031 KO cells by Western blot while GAPDH levels remain constant. In the absence of FBX031 expression, FKBP12 levels are unaffected by treatment with either Compound 668 or 669. The degradation is therefore rescued by the genetic deletion of FBX031 and dependent on the expression of the E3 ligase.FIG. 3B shows that increasing concentrations of Compound 760 results in increasing levels of endogenous FKBP12 degradation in NCI-H1155 cells by Western blot, while GAPDH levels remain constant.

[0353] FIG. 3C shows the degradation of BRD4 by either Compound 670, 671 and 672, in HEK293T WT and FBXO31 KO cells by Western blot. In the absence of FBXO31 expression in KO cells, BRD4 levels are unaffected by treatment with Compounds 670, 671 and 672. The degradation is therefore rescued by the genetic deletion of FBXO31 and dependent on the expression of the E3 ligase. Degradation is also shown to be rescued by co-treatment with a Nedd8-activating enzyme (NAE) inhibitor, MLN4924. Neddylation of the Cullin protein is required for activity of Cullin-RING ligase complexes such as that of CRL1FBXO31.

[0354] FIG. 3D shows that increasing concentrations of Compound 671 results in increasing levels of endogenous BRD4 degradation, while GAPDH levels remain constant. At 10 pM, degradation effects are slightly attenuated due to the PROTAC hook effect as described in FIG. 1

[0355] FIG. 3E shows that increasing concentrations of Compound 20 results in increasing levels of endogenous MST1 (also known as STK4) degradation in NCI-H1155 cells that inducibly overexpress FBXO31, while GAPDH levels remain constant. The right side of the Western blot shows that under doxycycline pretreatment where FBXO31 overexpression is induced, degradation potency of Compound 20 is enhanced.

[0356] FIG. 3F shows the degradation of LRRC41 with increasing concentrations of Compound 215, in NCI-H1155 WT and FBXO31 KO cells by Western blot while GAPDH levels remain constant. In the absence of FBXO31 expression, LRRC41 levels are unaffected by treatment with Compound 215. The degradation is therefore rescued by the genetic deletion of FBXO31 and dependent on the expression of the E3 ligase. Degradation is also shown to be rescued by co-treatment with a Nedd8-activating enzyme (NAE) inhibitor, MLN4924, as described above in FIG. 3B.

[0357] FIG. 4 shows the dose-response curves of Compounds 670, 671 and 672 in a BRD4-HiBiT reporter cell line. Increasing concentration of these compounds displays increasing levels of degradation of BRD4 protein in a dose-dependent manner.

[0358] FIG. 5 shows the dose-response curve of Compound 20 in an FBXO31-MST1 nanoBRET engagement assay. Increasing concentration of Compound 20 displays increasing levels ofBRET between the Halotag-conjugated ligand fused to FBX031 and the Nanoluciferase fused to MST1, indicating dose-dependent compound-induced proximity of FBX031 and MST1.

[0359] FIG. 6 is a quantitative proteomics plot demonstrating the change in change in relative abundance of CLIP2 when Hl 155-iOE cells or Hl 155-KO cells are treated with Compound 215 at 10 pMfor 24 h.

[0360] FIG. 7 is a quantitative proteomics plot demonstrating the change in change in relative abundance of STK4 when Hl 155-iOE cells or Hl 155-KO cells are treated with Compound 20 at 10 pM for 24 h.

[0361] FIG. 8 is a quantitative proteomics plot demonstrating the change in change in relative abundance of SRSF4 and SRSF6 when Hl 155-iOE cells or Hl 155-KO cells are treated with Compound 59 at 10 pM for 24 h.

[0362] FIG. 9 illustrates relative mRNA expression of the indicated E3 ligase across tissues. The logio of the ratio between the ligase’s mRNA level in each tissue and its average expression across all tissues is shown.

[0363] DETAILED DESCRIPTION

[0364] Compounds that bind FBXO31

[0365] Compounds of Formula (I)

[0366] In an aspect, the invention relates to a compound of Formula (I):

[0367]

[0368] Formula (I)

[0369] or a pharmaceutically acceptable salt thereof;

[0370] wherein:

[0371] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[0372] L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl;NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); or

[0373] -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-salkyl)(Ci-salkyl); -Ci-salkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-salkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein said C3-scycloalkyl may be optionally substituted with -NH2, Ci-salkyl, Ci-salkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, or Cs-9heteroaryl which may be optionally substituted with halo or Ci-salkyl;

[0374] L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NCs-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NCi-salkyl-; (j) -O-;

[0375] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[0376] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-salkyl), or -N(Ci-salkyl)(Ci-salkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-salkyl-; or (w) -C3-6cycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-salkyl), or -N(Ci-3alkyl)(Ci-salkyl);

[0377] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-salkyl); or -N(Ci-3alkyl)(Ci-salkyl); -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -Cs-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-salkyl); or -N(Ci-salkyl)(Ci-salkyl);R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-shaloalkyl; or Ci-salkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[0378] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0379] R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0380] R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[0381] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0382] R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;

[0383] R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[0384] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[0385] R8fand R8gare each, independently H; or Ci-3alkyl;

[0386] m is 1-4;

[0387] n is 0, 1 or 2;

[0388] o is 1-8;

[0389] p is 1-5;

[0390] q is 1-5;

[0391] r is 0, 1 or 2;

[0392] t is 1-5;

[0393] Z is:

[0394] (I) halo;

[0395] (II) Ci-2oalkyl;

[0396] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[0397] (IV) -OCi-3alkyl;(V) Ci-shaloalkyl;

[0398] (VI) Cs-ncycloalkyl which may be optionally substituted with halo; -C(O)OCi-3alkyl; Ci-salkoxy; Ci-3haloalkyl; and / or Ci-salkyl-Cearyl;

[0399] (VII) Ci-3alkoxy;

[0400] (VIII) C6-15aryl which may be optionally substituted with (a) C1-6alkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) C1-5alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=0)NH2; (1) -C2-ealkylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (o) -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2-6alkynylene-C6aryl, wherein said C6aryl may be optionally substituted with halo; (q) -C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (s) -OC4-8alkylene-NH2; (t) -OC4-8alkylene-NHC(=O)R56; (u) -SO2NH2; (v) -OCearyl; (w) C3-8cycloalkyl; (x) -OCi-3alkyleneCi-3haloalkyl; (y) -SCi-3alkyl; (z) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (ai) Ci-4hydroxyalkyl; (bi) -SO2NHCi-3alkyl; (ci) -SChCi-salkyl; (di) -OC4-8alkylene-NHC(=O)R32; (ei) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms;

[0401] (fi) -OCearyl, wherein said Cearyl may be optionally substituted with halo; (gi) Cearyl, wherein said Cearyl may be optionally substituted with halo; (hi) -Ci-4alkyleneNHC(=O)OCi-ealkyl; (ii) -NHCearyl; (ji) -OCs-ecycloalkyl; (ki) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (li) -C5-9alkyleneNHC(=O)-B, wherein B is R56or R93; (mi) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ni) -C(=0)NHCi-5alkyl; (oi) -N(Ci-3alkyl)(Ci-3alkyl); and / or (pi) NO2;

[0402] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-3alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -C1-5alkyleneC3-8cycloalkyl; (g) -NHC(=0)Ci-3alkyl; (h) Ci-shaloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); and / or (m) oxo;(X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -Ci-salkyleneCearyl;

[0403] (b) -C(O)NHCi-4alkyl; (c) Ci-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)Ci-5alkyl;

[0404] (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-shaloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; and / or (1) -NHCi-3alkylene-Ci-3haloalkyl; or (XI) Ci5-i9cycloalkenyl which may be optionally substituted with oxo and / or Ci-3alkyl; R9is -Ci.3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[0405]

[0406]

[0407] Further description of compounds of Formula (I)

[0408] Z may be Ce-isaryl, which may be optionally substituted as defined herein. Z may be Cearyl, which may be optionally substituted as defined herein.

[0409] Li may be absent, -CH2-, or -C(=O)-.

[0410] L2 may be absent; -(CRlaRlb)m-; -C3-8cycloalkylene-; or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms; and wherein Rla, Rlband m are as defined herein.

[0411] Rlaand Rlbmay each be, independently for each occurrence, H; Ci-ioalkyl; Cishy droxy alkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH or Ci-3alkoxy; -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein said C3-scycloalkyl may be optionally substituted with Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, or -C(=O)C6aryl.

[0412] L2 may be absent, -(CRlaRlb)m-,

[0413]

[0414] wherein Rlaand Rlbare each, independently for each occurrence, H, Me, Et, Tr,.s-butyl, -CH2OH,

[0415]

[0416] or, Rlaand Rlb, together with the carbon atom to which they are attached, may form cyclopropyl, cyclobutyl, cyclopentyl,

[0417]

[0418] R80is H or Me;

[0419] R95aand R95bare each, independently H or Me;

[0420] R96is H or -C(=O)OfBu;

[0421] R97is H, Me, -C(=O)Me, -C(=O)OfBu, or -C(=O)Ph;

[0422] represents a bond to Li;

[0423] represents a bond to L3; and

[0424] m is as defined herein.

[0425] L3may be absent; -NHC(=O)NH-; -NHC(=O)NCi-5alkyl-; -NHC(=O)NC3. scycloalkyl-; -NH-; -NCi-3alkyl; -0-; -C(=O)NH-; -C(=O)NCi-3alkyl-; -NHC(=O)-; -NCi-3alkylC(=O)-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); -C(=O)-; -NHSO2-; -NHC(=O)O-; -SO2-; -OCi-5alkylene-; -NHSO2NH-; or -NHSO2NCi-3alkylene-.

[0426] L3may be absent; -NHC(=O)NR2-; -NR3-; -O-; -C(=O)NR22-; -NR29C(= -C(=O)-; -NHSO2-; -NHC(=O)O-; -SO2-; -O(CH2)2-, or -NHSO2NR86-; wherein

[0427]

[0428] Et or cyclohexyl; R3is H or Me; R22is H or Me; R29is H or Me; and R86is Me.

[0429] L4 may be, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -C3-6cycloalkylene-, wherein the cycloalkylene contains 3 to 6 ring atoms; and wherein R4a, R4b, o and q are as defined herein.

[0430] L4 may be, independently, for each occurrence, -(CR4aR4b)0-; -O-;

[0431]

[0432] ; wherein R4aand R4bare each, independently for each occurrence, H, Me, Et, CF3, or

[0433]

[0434] together with the carbon atom to which they are attached, formcyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, or tetrahydropyranyl; and wherein o is as defined herein.

[0435] In some embodiments, R7ais H; or Ci-3alkyl; R7bis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); R7cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9; R7dis H; or Ci-3alkyl; R8aand R8bare each, independently H; Ci-3alkyl; or Cearyl; R8cand R8dare each, independently H; or Ci-3alkyl; or one of R8Cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-; R8eis H; or Ci-3alkyl; or R8eand R8a, together with the carbon atoms to which they are attached, form C3-6cycloalkyl; R8fand R8gare each, independently H; or Ci-3alkyl; and n is 0 or 1.

[0436] R7amay be H or Me.

[0437] R713may be H, OH, Me or OMe.

[0438] R7Cmay be H, OH, Me, OMe, or -(OCH2CH2)P-R9, wherein R9is as defined herein. R7dmay be H or Me.

[0439] In some embodiments, R7ais H or Me; R7bis H, OH, Me or OMe; R7cis H, OH, Me, OMe, or -(OCH2CH2)P-R9; and R7dis H or Me, wherein R9is as defined herein.

[0440] In some embodiments, R8ais H, Me or Ph; R8bis H; R8cis H or Me; and R8dis H; or one of R8Cor R8d, and one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-.

[0441] In some embodiments, R8ais H, Me or Ph; and R8bis H.

[0442] In some embodiments, R8cis H or Me; and R8dis H; or one of R8cor R8d, and one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-.

[0443] R7a, R713, R7C, and R7dmay all be H.

[0444] R8a, R8b, R8C, R8dand R8emay all be H.

[0445] R8fand R8gmay both be H.

[0446] m may be 1 or 2.

[0447] n may be 1.

[0448] o may be 1, 2, 3, 4 or 6.

[0449] p may be 2.

[0450] q may be 3.

[0451]

[0452]

[0453]

[0454] C°1

[0455] R101•

[0456] R10is neopentyl;

[0457] RnisMe or Ph;

[0458] R12is neopentyl, 'Bu or Me;

[0459] R13aand R13bare each, independently H, Me, CF3, -NHC(=O)CH2CH3, NHCH2CF3, or

[0460]

[0461] R14aand R14bare each, independently, H or OMe;

[0462] R14cis H or Cl;

[0463] R15is H or Me;

[0464] R16isH or Me;

[0465] R17is H or OEt;R18aand R18care each, independently, H, F, Cl, CN, OH, OMe, OEt, C(=O)NHMe, Me, 'Pr, " Bu, CF3, or OCF3;

[0466] R18band R18dare each, independently, H, F, Cl, Br, Me, Et, OMe, CF3, OCF3, C(=O)OMe,

[0467]

[0468] R19is Ph (which may be optionally substituted with o-Cl or m-Cl), 4-pyridinyl, 3-pyridinyl, or 2-pyridinyl;

[0469] R20is 4-pyridinyl, 3-pyridinyl, 2-pyridinyl, or Ph (which may be optionally substituted once with o-Cl or m-Cl);

[0470] R21is Ph (which may be optionally substituted once with o-Cl or m-Cl), 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl;R22is H or Me;

[0471] R23is H, CF3, or Me;

[0472] R24is Me;

[0473] R25aand R25bare each, independently H or Me;

[0474] R26aand R26care each, independently, H or F

[0475] R27aand R27bare each, independently, H, F, OMe, CF3, or -CH2PI1;

[0476] R28is Me;

[0477] R29is H or Me;

[0478] R30is Me;

[0479] R31is Me;

[0480]

[0481] R33is 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, or Ph (which may be optionally substituted once with o-Cl or / 77-Cl );

[0482] R34isH orF;

[0483] R35aisH orF;

[0484] R35bis H orF;

[0485] R36ais Me;

[0486] R36bis cyclopropyl;

[0487] R37aand R37bare each, independently, H or Cl;

[0488] R38aand R38bare each, independently, H or F;

[0489] R39a, R39band R39care each, independently, H or F;R40ais H or Me;

[0490] R40bis H or Me;

[0491] R41ais H or Tr;

[0492] R41band R41care each, independently H or Me;

[0493] R42aand R42bare each, independently H or Me;

[0494] R43aand R43bare each, independently H or Me;

[0495] R44is H or Ph;

[0496] R45is Me;

[0497] R46is Me;

[0498] R47is -C(=O)OzBu;

[0499] R48is -C(=O)NHEt;

[0500] R49is F;

[0501] R50aand R50bare each, independently H or Me;

[0502] R51ais H or F;

[0503] R51bis F;

[0504] R52is H or Me;

[0505] R53is Cl

[0506] R54is -C(=O)'Pr, -CH₂Ph, 2-pyridinyl, or Et;

[0507] R55aand R55bare each, independently H or F;

[0508]

[0509] R57ais H or Me;

[0510] R57bis / 77-ClPh;

[0511] R58ais H or F;

[0512] R58bis H or Me;

[0513] R58Cis H or CH2O(CH2)2SiMe3;

[0514] R59ais H or Cl;

[0515] R59bis H or F;R60is Ph (which may be optionally substituted with p-F) or Me; R61is H or Cl;

[0516] R62ais H or Cl;

[0517] R62bis H or Me;

[0518] R63is Me;

[0519] R64ais H or Me;

[0520] R64bis H or Cl;

[0521] R65ais H or Cl;

[0522] R65band R65care each, independently H or Me;

[0523] R66is Me or -CH2Ph;

[0524] R67is Me;

[0525] R68is Me;

[0526] R69is Cl;

[0527] R70is -NHC(=O)-R56or -NH2;

[0528] R71is Et;

[0529] R72is F;

[0530] R73ais H or Cl;

[0531] R73bis H or F;

[0532] R74is 'Pr, -CHF2or o-MePh;

[0533] R75ais H or Me;

[0534]

[0535] R76is -CH2Ph;

[0536] R77is -CH2Ph or Ph;

[0537] R78ais H, Me, F or Cl;

[0538] °- N

[0539] R78bis H, Me, or

[0540] R78cis H, or ‘-O;

[0541] R79is -CO2Me;

[0542] R80is H or Me;

[0543] R81ais H or Cl;R81bis H, F, Cl, or Me;

[0544] R81cis H, OMe, CF3;

[0545] R82aand R82care each, independently H, Me, Tr, or Ph;

[0546] R82band R82dare each, independently H or Me;

[0547] R82eand R82fare each, independently H, Me, OMe, CF3, / ?-ClPh, or

[0548]

[0549] R83aand R83care each, independently H or Ph;

[0550] R83band R83dare each, independently H, Me, F or Cl;

[0551] R84aand R84bare each, independently H or Me;

[0552] R84cis Me;

[0553] R85is Me;

[0554] R86is Me;

[0555] R87isH or Me;

[0556] R88is 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, m-CIPh, o-CIPh, or Ph;

[0557] R89ais H or Me;

[0558] R89bis H or -NHC(=O)Me;

[0559] R90is Ph, o-CIPh, m-CIPh, 2-pyridinyl, 4-pyridinyl, or 3-pyridinyl;

[0560] R91is Me;

[0561] R92is Me;

[0562]

[0563] R94aand R94bare each, independently H or Me;

[0564] R95aand R95bare each, independently H or Me;

[0565] R96is H or -C(=O)OfBu;

[0566] R97is H, Me, -C(=O)Me, -C(=O)OfBu, or -C(=O)Ph;

[0567] R98is H or Cl;

[0568] R99is Me or Cl;

[0569] R100is H or OMe;

[0570] R101is -CH2PI1; and

[0571] R102is H or Cl.In another aspect, the invention provides a pharmaceutical composition that includes a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0572] In the invention, the compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof may be for use in therapy. Thus, the invention provides in another aspect, a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition to a subject in need thereof. The disease or condition may be one associated with elevated levels of a target protein.

[0573] In another aspect, the invention provides a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in a method of degrading a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition to a subject in need thereof. Preferably, the target protein is degraded using FBXO31.

[0574] In another aspect, the invention provides a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in a method of decreasing the level of a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein level is decreased using FBX031.

[0575] In another aspect, the invention provides a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in a method of ubiquitinating a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein is ubiquitinated using FBX031.

[0576] In another aspect, the invention a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula(I) or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition by degrading a target protein associated with said disease or condition, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition to a subject in need thereof. Preferably, the target protein is degraded using FBX031.

[0577] In another aspect, the invention provides a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition, comprising (a) administering said compound or pharmaceutically acceptable salt thereof to a subject in need thereof; (b) forming a ternary complex with FBX031 and a target protein associated with said disease or condition; and (c) reducing the level of said target protein.

[0578] In another aspect, the invention provides a ternary complex comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, FBX031 and a target protein.

[0579] In another aspect, the invention provides a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treating a disease or condition wherein dysregulated protein activity is responsible for said disease or condition, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition to a subject in need thereof.

[0580] In another aspect, the invention provides a method of degrading a target protein ex vivo, comprising contacting said target protein with a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof.

[0581] In another aspect, the invention provides a method of decreasing the level of a target protein ex vivo, comprising contacting said target protein with a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof.

[0582] In another aspect, the invention provides a method of ubiquitinating a target protein ex vivo, comprising contacting said target protein with a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof.

[0583] In another aspect, the invention provides the use of a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising thecompound of Formula (I) or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.

[0584] In another aspect, the invention provides the use of a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the manufacture ofaPROTAC.

[0585] In another aspect, the invention provides the use of a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof, for the manufacture of a molecular glue degrader.

[0586] In another aspect, the invention provides a method of treating a disease or condition associated with elevated levels of a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0587] In another aspect, the invention provides a method of degrading a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031.

[0588] In another aspect, the invention provides a method of decreasing the level of a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the level of the target protein is decreased using FBX031.

[0589] In another aspect, the invention provides a method of ubiquitinating a target protein, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein is ubiquitinated using FBX031.

[0590] In another aspect, the invention provides a method of treating a disease or condition by degrading a target protein associated with said disease or condition, comprisingadministering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBXO31.

[0591] In another aspect, the invention provides a method of treating a disease or condition, comprising (a) administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof; (b) forming a ternary complex with FBXO31 and a target protein associated with said disease or condition; and (c) reducing the level of said target protein.

[0592] In another aspect, the invention provides method of treating a disease or condition wherein dysregulated protein activity is responsible for said disease or condition, comprising administering a compound of Formula (I), pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0593] In another aspect, the invention provides a compound of Formula (I) or pharmaceutically acceptable salt thereof, or pharmaceutical composition comprising the compound of Formula (I) or pharmaceutically acceptable salt thereof, in the manufacture of a medicament.

[0594] Further compounds that bind FBXO31

[0595] The compound or pharmaceutically acceptable salt thereof may be of Formula (1-1):

[0596]

[0597] or a pharmaceutically acceptable salt thereof; wherein:

[0598] Li is absent, -CH2-, or -C(=O)-;

[0599] L2 is absent,

[0600]

[0601] Rlaand Rlbare each, independently for each occurrence, H, Me, Et, Tr,.s-butyl, -CH2OH,

[0602]

[0603] or, Rlaand Rlb, together with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl, cyclopentyl,

[0604]

[0605]

[0606] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -O-;

[0607]

[0608] R2is H, Me, Et or cyclohexyl;

[0609] R3is H or Me;

[0610] R4aand R4bare each, independently for each occurrence,

[0611]

[0612] R4aand R4btogether with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl, or tetrahydropyranyl;

[0613] R5is H, Et, 'Bu or m-CIPh;R6is H, neopentyl

[0614]

[0615] R7ais H or Me;

[0616] R7bis H, OH, Me or OMe;

[0617] R7Cis H, OH, Me, OMe, or -(OCH2CH2)P-R9;

[0618] R7dis H or Me;

[0619] R8ais H, Me or Ph;

[0620] R8bis H;

[0621] R8Cis H or Me; or R8cand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[0622] R8dis H;

[0623] R8eis H or Me; or R8aand R8e, together with the carbon atoms to which they are attached, form cyclopropyl;

[0624] R8fand R8gare each, independently H or Me;

[0625] R9is -NH2or -NHC(NH)NH2;

[0626] m is 1 or 2;

[0627] n is 0 or 1;

[0628] o is 1, 2, 3, 4 or 6;

[0629] p is 2

[0630] q is 3;

[0631] r is 0, 1 or 2;

[0632] represents a bond to Li;

[0633] represents a bond to L3;

[0634] Z is F; Cl; Me; Et; Tr; " Pr; "butyl; 'Bu; "decyl; "dodecyl; cyclopropyl; cyclopentyl; NH2;

[0635]

[0636]

[0637]

[0638]

[0639] R10is neopentyl;

[0640] R11is Me or Ph;

[0641] R12is neopentyl, 'Bu or Me;

[0642] R13aand R13bare each, independently H, Me, CF3, -NHC(=O)CH2CH3, NHCH2CF3, or

[0643]

[0644] R14aand R14bare each, independently, H or OMe;

[0645] R14cis H or Cl;

[0646] R15is H or Me;

[0647] R16is H or Me;

[0648] R17is H or OEt;

[0649] R18aand R18care each, independently, H, F, Cl, CN, OH, OMe, OEt, C(=O)NHMe, Me, 'Pr, " Bu, CF3, or OCF3;

[0650] R18band R18dare each, independently, H, F, Cl, Br, Me, Et, OMe, CF3, OCF3, C(=O)OMe,

[0651]

[0652]

[0653] R19is Ph (which may be optionally substituted with o-Cl or m-Cl), 4-pyridinyl, 3-pyridinyl, or 2-pyridinyl;

[0654] R20is 4-pyridinyl, 3-pyridinyl, 2-pyridinyl, or Ph (which may be optionally substituted once with o-Cl or m-Cl);

[0655] R21is Ph (which may be optionally substituted once with o-Cl or m-Cl), 2-pyridinyl, 3- pyridinyl, or 4-pyridinyl;

[0656] R22is H or Me;

[0657] R23is H, CF3, or Me;

[0658] R24isMe;

[0659] R25aand R25bare each, independently H or Me;

[0660] R26aand R26care each, independently, H or FR27aand R27bare each, independently, H, F, OMe, CF3, or -CH2PI1;

[0661] R28is Me;

[0662] R29is H or Me;

[0663] R30is Me;

[0664]

[0665] R33is 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, or Ph (which may be optionally substituted once with o-Cl or m-Cl);

[0666] R34isH orF;

[0667] R35aisH orF;

[0668] R35bis H orF;

[0669] R36ais Me;

[0670] R36bis cyclopropyl;

[0671] R37aand R37bare each, independently, H or Cl;

[0672] R38aand R38bare each, independently, H or F;

[0673] R39a, R39band R39care each, independently, H or F;

[0674] R40ais H or Me;

[0675] R40bisH orMe;

[0676] R41ais H or Tr;

[0677] R41band R41care each, independently H or Me;

[0678] R42aand R42bare each, independently H or Me;R43aand R43bare each, independently H or Me;

[0679] R44isH or Ph;

[0680] R45is Me;

[0681] R46is Me;

[0682] R47is -C(=O)OzBu;

[0683] R48is -C(=O)NHEt;

[0684] R49is F;

[0685] R50aand R50bare each, independently H or Me;

[0686] R51ais H or F;

[0687] R51bis F;

[0688] R52is H or Me;

[0689] R53is Cl

[0690] R54is -C(=O)Tr, -CH₂Ph, 2-pyridinyl, orEt;

[0691] R55aand R55bare each, independently H or F;

[0692]

[0693] R57aisH or Me;

[0694] R57bis m-CIPh;

[0695] R58ais H or F;

[0696] R58bis H or Me;

[0697] R58Cis H or CH2O(CH2)2SiMe3;

[0698] R59aisH or Cl;

[0699] R59bis H or F;

[0700] R60is Ph (which may be optionally substituted with j?-F) or Me; R61is H or Cl;

[0701] R62ais H or Cl;

[0702] R62bisH orMe;

[0703] R63is Me;R64ais H or Me;

[0704] R64bis H or Cl;

[0705] R65ais H or Cl;

[0706] R65band R65care each, independently H or Me;

[0707] R66is Me or -CH2Ph;

[0708] R67is Me;

[0709] R68is Me;

[0710] R69is Cl;

[0711]

[0712] R76is -CH2Ph;

[0713] R77is -CH2Ph or Ph;

[0714] R78ais H, Me, F or Cl;

[0715] o

[0716] N

[0717] R78bis H, Me, orW;

[0718]

[0719] R80is H or Me;

[0720] R81ais H or Cl;

[0721] R81bis H, F, Cl, or Me;

[0722] R81cis H, OMe, CF3;

[0723] R82aand R82care each, independently H, Me, Tr, or Ph; R82band R82dare each, independently H or Me;R82eand R82fare each, independently H,

[0724]

[0725] R83aand R83care each, independently H or Ph;

[0726] R83band R83dare each, independently H, Me, F or Cl;

[0727] R84aand R84bare each, independently H or Me;

[0728] R84cis Me;

[0729] R85is Me;

[0730] R86is Me;

[0731] R87is H or Me;

[0732] R88is 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, m-CIPh, o-CIPh, or Ph;

[0733] R89ais H or Me;

[0734] R89bis H or -NHC(=O)Me;

[0735] R90is Ph, o-CIPh, / 77-ClPh, 2-pyridinyl, 4-pyridinyl, or 3-pyridinyl;

[0736] R91is Me;

[0737] R92is Me;

[0738]

[0739] R94aand R94bare each, independently H or Me;

[0740] R95aand R95bare each, independently H or Me;

[0741] R96is H or -C(=O)OfBu;

[0742] R97is H, Me, -C(=O)Me, -C(=O)OfBu, or -C(=O)Ph;

[0743] R98is H or Cl;

[0744] R99is Me or Cl;

[0745] R100is H or OMe;

[0746] R101is -CIbPh; and

[0747] R102is H or Cl.

[0748] The compound or pharmaceutically acceptable salt thereof may be of Formula (lai):

[0749]

[0750] Formula (lai)

[0751] or a pharmaceutically acceptable salt thereof;

[0752] wherein:

[0753] R7a, R7b, R7c, and R7dare as defined herein;

[0754] L4is absent, -O-, -NHC(=O)-, -C(=O)NH-, or -NH-;

[0755] Z is phenyl, wherein the phenyl may be optionally substituted with halo, Ci-shaloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-3alkyl, or C(=0)NH2; heteroaryl, wherein the heteroaryl contains 5 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)3, -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl), or Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl); heterocycloalkyl, wherein the heterocycloalkyl contains 7 to 10 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with oxo; or Ce-naryl; and

[0756] o is 0-8.

[0757] The compound or pharmaceutically acceptable salt thereof may be of Formula (laii):

[0758]

[0759] Formula (laii)

[0760] or a pharmaceutically acceptable salt thereof.

[0761] In some embodiments, R7a, R7b, R7cand R7dare as defined herein; and(i) L4 is absent, and Z is Ph; o-CIPh; m-CIPh; / ?-ClPh; 2-pyridyl; 3-pyridyl; 4-pyridyl;

[0762]

[0763] wherein R58aand R58bare H and R58cis -CH2O(CH2)2SiMe3, or wherein R58a,

[0764]

[0765] (ii) L4 is -O- and Z is Ph;

[0766] (iii) L4 is -NHC(=O)- and Z is Ph;

[0767] (iv) L4 is -C(=O)NH- and Z is Ph; or

[0768] (v) L4 is -NH- and Z is Ph.

[0769] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ibi):

[0770]

[0771] Formula (Ibi)

[0772] or a pharmaceutically acceptable salt thereof;

[0773] wherein:

[0774] R7ap7b j^7cancj j^7dare asdefined herein;

[0775] R18a, R18C, R18dand R18eare each, independently, (a) Ci-ealkyl; (b) -OH; (c) -CN;

[0776] (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-shaloalkyl; (h) -OCi-shaloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; or (k) -C(=O)NH2;

[0777] R18bis (a) -C2-6alkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (b) -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (c) -C2-ealkenylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (d)

[0778] -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (e) -C2-ealkynylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (f) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (g) -OC4-8alkylene-NHC(=O)R56; or (h) -C5-9alkyleneNHC(=O)-B, wherein B is R56or R93; wherein R56is

[0779]

[0780] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ibii):

[0781]

[0782] Formula (Ibii)

[0783] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7dand R18dare as defined herein.

[0784] R18dmay be (i)

[0785]

[0786] wherein R19is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or

[0787] 4-pyridyl;

[0788]

[0789] wherein R21is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

[0790] (iii)

[0791]

[0792] wherein R88is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

[0793]

[0794]

[0795] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ibiii):

[0796]

[0797] Formula (Ibiii)

[0798] or a pharmaceutically acceptable salt thereof;

[0799] wherein:

[0800] R7ap7b j^7cancj j^7dare asdefined herein;R18a, R18b, R18Cand R18dare each, independently, (a) Ci-ealkyl; (b) -OH; (c) -CN;

[0801] (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-shaloalkyl; (h) -OCi-shaloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; or (k) -C(=O)NH2; and

[0802] R18eis (a) -C2-6alkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (b) -C2-ealkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (c) -C2-ealkenylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (d)

[0803] -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (e) -C2-ealkynylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (f) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (g) -OC4-8alkylene-NHC(=O)R56; or (h) -C5-9alkyleneNHC(=O)-B, wherein B is R56or R93; wherein R56is

[0804]

[0805] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ibiv):

[0806]

[0807] Formula (Ibiv)

[0808] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7dand R18eare as defined herein.

[0809] R18emay be (i)

[0810]

[0811] ; wherein R20is 4-pyridinyl, 3-pyridinyl, 2-pyridinyl, or Ph (which may be optionally substituted once with o-Cl or m-Cl;

[0812]

[0813] wherein R33is 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, or Ph (which may be optionally substituted once with o-Cl or m-Cl);

[0814] ; wherein R90is Ph, o-CIPh, m-CIPh, 2-pyridinyl, 4-pyridinyl, or 3-

[0815]

[0816] rein R90is Ph, o-CIPh, m-CIPh, 2-pyridinyl, 4-pyridinyl, or 3-pyridinyl;

[0817]

[0818] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ici):

[0819]

[0820] or a pharmaceutically acceptable salt thereof;

[0821] wherein:

[0822] R7a, R7b, R7c, and R7dare as defined herein;

[0823] R18a, R18b, R18C, R18dand R18eare each, independently, (a) Ci-ealkyl; (b) -OH; (c) -CN;

[0824] (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-shaloalkyl; (h) -OCi-shaloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; or (k) -C(=O)NH2;

[0825] Rlaand Rlbare each, independently, H, Ci-ioalkyl, Ci-shydroxyalkyl, -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH or Ci-3alkoxy; -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 8 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein the Cs-scycloalkyl may be optionally substituted with Ci-3alkyl; or (b) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, or -C(=O)C6aryl; and

[0826] m is 1-4.

[0827] The compound or pharmaceutically acceptable salt thereof may be of Formula (Icii):

[0828]

[0829] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7d, Rla, Rlband m are as defined herein.In some embodiments, Rlais H; and Rlbis Me, Et, 'Pr,.s-butyl, -CH2OH, -CH2PI1, -CH2- / 1-

[0830]

[0831] or, Rlaand Rlb, together with the carbon atom to

[0832] which they are attached, form cyclopropyl, cyclobutyl, cyclopentyl,

[0833]

[0834] ,

[0835]

[0836] (ii) Rlaand Rlbare both Me;

[0837] wherein R80is H or Me; one of R95aand R95bis H and the other is Me; R96is H or -C(=O)OfBu; R97is H, Me, -C(=O)Me, -C(=O)OfBu, or -C(=O)Ph; and m is 1.

[0838] The compound or pharmaceutically acceptable salt thereof may be of Formula (Idi):

[0839]

[0840] Formula (Idi)

[0841] or a pharmaceutically acceptable salt thereof;

[0842] wherein:

[0843] R7a, R7b, R7Cand R7dare as defined herein;

[0844] R18a, R18b, R18Cand R18dare each, independently, (a) Ci-ealkyl; (b) -OH; (c) -CN;

[0845] (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-shaloalkyl; (h) -OCi-shaloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; or (k) -C(=O)NH2; and

[0846] R18eis -C2-6alkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; -C2-ealkenylene-Cearyl, wherein the Cearyl may be optionally substituted with halo;

[0847] -C2-ealkenylene heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; -C2-ealkynylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; or

[0848] -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms.

[0849] The compound or pharmaceutically acceptable salt thereof may be of Formula (Idii):

[0850]

[0851] Formula (Idii)

[0852] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7d, and R18eare as defined herein.

[0853] In some embodiments, R18eis (i)

[0854]

[0855] and R20is Ph, o-CIPh, m-CIPh, 2-pyridyl,

[0856] 3-pyridyl, or 4-pyridyl

[0857]

[0858] wherein R33is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl;

[0859] ; wherein R90is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl,

[0860]

[0861] wherein R90is Ph, o-ClPh, m-ClPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl.

[0862] The compound or pharmaceutically acceptable salt thereof may be of Formula (lei):

[0863]

[0864] Formula (lei)

[0865] or a pharmaceutically acceptable salt thereof;

[0866] wherein:

[0867] Rla, R7a, R7b, R7C, R7d, R8a, R8b, R8Cand R8d, are as defined herein; and

[0868] R18a, R18b, R18C, R18d, and R18eare each, independently, (a) Ci-ealkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-shaloalkyl; (h) -OCi-shaloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; or (k) -C(=O)NH2.The compound or pharmaceutically acceptable salt thereof may be of Formula (leii):

[0869]

[0870] Formula (leii)

[0871] or a pharmaceutically acceptable salt thereof;

[0872] wherein:

[0873] RlaisH;

[0874] R8aand R8bare each, independently, H, Ci-salkyl or Ph; and

[0875] R8Cand R8dare each, independently, H or Ci-salkyl; or R8cand Rla, together with the carbon atoms to which they are attached, form pyrrolidone.

[0876] In some embodiments, R8ais H, Me or Ph; R8bis H; R8cis H or Me; or R8cand Rla, together with the carbon atoms to which they are attached, form pyrrolidone; and

[0877] R8dis H.

[0878] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ig):

[0879]

[0880] Formula (Ig)

[0881] or a pharmaceutically acceptable salt thereof;

[0882] wherein:

[0883] R7a, R7b, R7Cand R7dare as defined herein; and

[0884] R18bis C2-6alkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; -C2-ealkynylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; or

[0885] -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms.In some embodiments, R18bis (i)

[0886]

[0887] ; wherein R19is Ph, o-CIPh, m-CIPh, 2-

[0888] pyridyl, 3-pyridyl, or 4-pyridyl

[0889]

[0890] wherein R21is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl.

[0891] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ih):

[0892]

[0893] Formula (Ih)

[0894] or a pharmaceutically acceptable salt thereof;

[0895] wherein:

[0896] R7a, R7b, R7Cand R7dare as defined herein; and

[0897] R18eis -C2-6alkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; -C2-ealkynylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; or

[0898] -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms.

[0899] In some embodiments, R18eis (i)

[0900]

[0901] ; wherein R20is Ph, o-CIPh, m-CIPh, 2-

[0902] pyridyl, 3-pyridyl, or 4-pyridyl

[0903]

[0904] wherein R33is Ph, o-CIPh, m-CIPh, 2-pyridyl, 3-pyridyl, or 4-pyridyl.

[0905] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ii):

[0906]

[0907] Formula (Ii)or a pharmaceutically acceptable salt thereof;

[0908] wherein:

[0909] R7a, R7b, R7Cand R7dare as defined herein;

[0910] Rlaand Rlb, are both H; or Rlaand Rlb, together with the carbon atom to which they are attached, form Cs-scycloalkyl, wherein Cs-scycloalkyl may be optionally substituted with Cisalkyl; and

[0911] Z is heteroaryl, wherein the heteroaryl contains 7 to 11 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) C1-5alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-salkyl; (f) -C1-5alkyleneC3-8cycloalkyl; (g) -NHC(=0)Ci-3alkyl; (h) Ci-shaloalkyl; (i) C1-5alkoxy; (j) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)3; (k) -Ci-salkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl); (1) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl); and / or (m) oxo.

[0912] In some embodiments, Z is heteroaryl, wherein the heteroaryl contains 7 to 11 ring atoms, and wherein said heteroaryl may be optionally substituted with halo.

[0913] In some embodiments, (i) Rlaand Rlbare both H; and

[0914]

[0915] wherein R15is Me and R61is H or Cl; or

[0916] (ii) Rlaand Rlb, together with the carbon atom to which they are attached, form cyclopropyl, cyclobutyl, cyclopentyl; and

[0917]

[0918] ; wherein R61is H, halo, Ci-salkyl, Ci-shaloalkyl, or Ci-salkoxy.

[0919] R61may be H or Cl.The compound or pharmaceutically acceptable salt thereof may be of Formula (Ij):

[0920]

[0921] or a pharmaceutically acceptable salt thereof;

[0922] wherein:

[0923] R7a, R7b, R7c, and R7dare as defined herein;

[0924] Rlais H or Ci-3alkyl;

[0925] Rlbis H or Ci-3alkyl;

[0926] R18aand R18bare each, independently, H, Ci-shaloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-salkyl, -C(=0)NH2, or halogen; and

[0927] R29isH or Ci-3alkyl.

[0928] In some embodiments, Rlais H or Me;

[0929] Rlbis H or Me;

[0930] R18ais H or Cl;

[0931] R18bis H or Cl, provided that R18aand R18bare not both Cl; and

[0932] R29is H or Me.

[0933] The compound or pharmaceutically acceptable salt thereof may be of Formula (Iki):

[0934]

[0935] Formula (Iki)

[0936] or a pharmaceutically acceptable salt thereof;

[0937] wherein:

[0938] R7a, R7b, R7Cand R7dare as defined herein;

[0939] R18a, R18C, R18dand R18eare each, independently, (a) Ci-ealkyl; (b) -OH; (c) -CN;

[0940] (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; or (k) -C(=O)NH2;

[0941] R18bis -(OCH2CH2)P-R9; andR9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2.

[0942] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ikii):

[0943]

[0944] Formula (Ikii)

[0945] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7dand R18bare as defined herein.

[0946] In some embodiments, R7bis H, OH or Me;

[0947] R7Cis H, OH, Me, OMe, or -(OCH2CH2)P-R9;

[0948] R18bis -(OCH2CH2)p-R9; provided that at least one of R7band R7cis H; and

[0949] R9is -NH2or -NHC(NH)NH2.

[0950] The compound or pharmaceutically acceptable salt thereof may be of Formula (Hi):

[0951]

[0952] Formula (Ili)

[0953] or a pharmaceutically acceptable salt thereof;

[0954] wherein:

[0955] R7a, R7b, R7Cand R7dare as defined herein;

[0956] L2 is -(CRlaRlb)m-, or -Cs-ecycloalkylene-;

[0957] Rlaand Rlb, are each, independently for each occurrence, Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlbtogether with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein C3-scycloalkyl may be optionally substituted with Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may beoptionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, or Cs-9heteroaryl which may be optionally substituted with halo; and

[0958] Z is defined according to (II), (VIII) or (IX).

[0959] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ilii):

[0960]

[0961] Formula (Ilii)

[0962] or a pharmaceutically acceptable salt thereof;

[0963] wherein R7a, R7b, R7cand R7dare as defined herein;

[0964] R18ais H, Ci-shaloalkyl or halogen;

[0965] R18bis H, Ci-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or halogen; and

[0966] R18eisH, CN, halogen, Ci-3haloalkyl, -NHC(=O)OCi-8alkyl, -C(=O)OCi-3alkyl, -SO2NHC1-3alkyl, or -SO2Ci-3alkyl.

[0967] In some embodiments, L2is -(CRlaRlb)m-, or -C3-6cycloalkylene-; wherein

[0968] Rlaand Rlb, are each, independently for each occurrence, H or Me; or Rlaand Rlbtogether with the carbon atom to which they are attached, form C3.8cycloalkyl, wherein C3.8cycloalkyl may be optionally substituted with Ci-3alkyl.

[0969] In some embodiments,

[0970]

[0971] wherein Rlaand Rlb, together with the carbon atom to which they are attached, form cyclopropyl, or cyclobutyl;

[0972] R18ais H or Cl;

[0973] R18bis H or Cl; and

[0974] R18eisH or Cl.The compound or pharmaceutically acceptable salt thereof may be of Formula (Im):

[0975]

[0976] Formula (Im)

[0977] or a pharmaceutically acceptable salt thereof;

[0978] wherein:

[0979] R7a, R7b, R7c, R7dand are as defined herein;

[0980] L4 is -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H, or Cisalkyl; or R4aand R4b, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;

[0981] o is 1-8; and

[0982] r is 0, 1 or 2.

[0983] In some embodiments, L4 is -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H, or Ci-salkyl; or R4aand R4b, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and

[0984] Z is (a) Ci-salkyl; (b) Cs-iocycloalkyl which may be optionally substituted with halo, -C(O)OCi-3alkyl, Ci-3alkoxy, and / or Ci-3haloalkyl; or (c) heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms.

[0985] In some embodiments, L4 is -CH2-; or L4 is -(CR4aR4b)-, wherein R4aand R4btogether with the carbon atom to which they are attached, form tetrahydropyranyl;

[0986]

[0987] R27ais H or CF3

[0988] R27bis H;

[0989] R72is F;

[0990] R100is H or OMe; and

[0991] r is 0, 1 or 2.The compound or pharmaceutically acceptable salt thereof may be of Formula (In):

[0992]

[0993] Formula (In)

[0994] or a pharmaceutically acceptable salt thereof;

[0995] wherein:

[0996] R7a, R7b, R7cand R7dare as defined herein;

[0997] R18ais H, Ci-shaloalkyl or halogen;

[0998]

[0999] In some embodiments, R18ais H or Cl;

[1000] R18Cis H or Cl; and

[1001]

[1002] The compound or pharmaceutically acceptable salt thereof may be of Formula (Io):

[1003]

[1004] or a pharmaceutically acceptable salt thereof;

[1005] wherein R7a, R7b, R7c, R7d, L4, r, Z, and R2are as defined herein.

[1006] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ip):

[1007]

[1008] Formula (Ip)

[1009] or a pharmaceutically acceptable salt thereof;

[1010] wherein:

[1011]

[1012] defined herein.In some embodiments, when L4 is

[1013] -CH2- and r is 1, Z cannot

[1014]

[1015] The compound or pharmaceutically acceptable salt thereof may be of Formula (Iq):

[1016]

[1017] Formula (Iq)

[1018] or a pharmaceutically acceptable salt thereof;

[1019] wherein R7a, R7b, R7c, R7d, L4, r, and Z are as defined herein.

[1020] The compound or pharmaceutically acceptable salt thereof may be of Formula (Ir):

[1021]

[1022] Formula (Ir)

[1023] or a pharmaceutically acceptable salt thereof;

[1024] wherein R7a, R7b, R7c, and R7dare as defined herein;

[1025] L4is -(CR4aR4b)-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms; or -Cs-ecycloalkylene-;

[1026] R4aand R4b, together with the carbon atom to which they are attached, form CL-iocycloalkyl; r is 0 or 1; and

[1027] Z is Ci-salkyl; Cs-iocycloalkyl which may be optionally substituted with halo, -C(O)OCi-salkyl, Ci-3alkoxy, Ci-3haloalkyl, and / or Ci-salkyl-Cearyl; heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; heteroaryl, wherein the heteroaryl contains 5 to 7 ring atoms; Cearyl which may be optionally substituted with halogen; or Ci5-i9cycloalkenyl which may be optionally substituted with oxo and / or Ci-3alkyl;

[1028] with the proviso that when r is 0, Z is Cs-iocycloalkyl which may be optionally substituted with halo, -C(O)OCi-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, and / or Ci-salkyl-Cearyl.The compound or pharmaceutically acceptable salt thereof may be of Formula (Is):

[1029]

[1030] Formula (Is)

[1031] or a pharmaceutically acceptable salt thereof;

[1032] wherein R7a, R7b, R7c, and R7dare as defined herein; and

[1033] Z is C4or Ce-scycloalkyl; heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; heteroaryl, wherein the heteroaryl contains 4 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl, oxo, or halogen; Cs-naryl which may be optionally substituted with halogen or -OCi-shaloalkyl.

[1034] In some embodiments, Z is Cecycloalkyl; heterocycloalkyl, wherein the heterocycloalkyl contains 6 ring atoms; heteroaryl, wherein the heteroaryl contains 5 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with Me, oxo, or F; or Ce-ioaryl which may be optionally substituted with halogen or -OCF3.

[1035] The compound or pharmaceutically acceptable salt thereof may be of Formula (It):

[1036]

[1037] Formula (It)

[1038] or a pharmaceutically acceptable salt thereof;

[1039] wherein R7a, R7b, R7c, and R7dare as defined herein; and

[1040] Z is (i) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, wherein said heteroaryl may be optionally substituted with (a) heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms; (b) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms; or (c) Cearyl, wherein said Cearyl may be optionally substituted with halogen or -O-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms; or(ii) Cearyl which may be optionally substituted with (a) halogen, (b) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (c) -Cearyl, wherein said -Cearyl may be optionally substituted with halogen; or (d) -OCearyl, wherein said -OCearyl may be optionally substituted with -C(=O)OCi-3alkyl.

[1041] In some embodiments, Z is (i) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) heterocycloalkyl, wherein the heterocycloalkyl contains 6 ring atoms; (b) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 4 ring atoms; or (c) Cearyl, wherein said Cearyl may be optionally substituted with F, Cl or -O-heterocycloalkyl, wherein the heterocycloalkyl contains 4 ring atoms; or

[1042] (ii) Cearyl which may be optionally substituted with (a) F; (b) -CFF-heterocycloalkyl, wherein the heterocycloalkyl contains 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Me; (c) -Cearyl, wherein said -Cearyl may be optionally substituted with Cl; or (d) -OCearyl, wherein said -OCearyl may be optionally substituted with -C(=O)OMe.

[1043] The compound or pharmaceutically acceptable salt thereof may be of Formula (lu):

[1044]

[1045] Formula (lu)

[1046] or a pharmaceutically acceptable salt thereof;

[1047] wherein R7a, R7b, R7c, and R7dare as defined herein; and

[1048] Z is Cs-7cycloalkyl optionally substituted with Ci-3alkyl; heteroaryl, wherein the heteroaryl contains 4 to 12 ring atoms, and wherein said heteroaryl may be substituted with Ci-3alkyl or halogen; Cearyl optionally substituted with halogen, Ci-3alkoxy or Ci-3haloalkyl; or heterocycloalkyl, wherein the heterocycloalkyl contains 6 to 10 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -OC2-salkyl.

[1049]

[1050]

[1051] wherein R17is OEt; R18ais H or OMe; R18bis H or Cl; R18cis H or Cl; R18dis H or CF3; R34is F; R37ais Cl; R37bis H; R43ais Me; R43bis Me; R78ais F; R78bis H; R78cis H; R81ais H; R81bis Me; R81cis H; R83ais H; R83bis Me; R83cis H; and R83dis H.

[1052] The compound or pharmaceutically acceptable salt thereof may be of Formula (Iv):

[1053]

[1054] Formula (Iv)

[1055] or a pharmaceutically acceptable salt thereof;

[1056] wherein R7a, R7b, R7c, and R7dare as defined herein;

[1057] L3is -C(=O)NCi-3alkylene- or -C(=O)NH-, wherein Z is bound to L3via the nitrogen atom of L3; and

[1058] Z is heteroaryl, wherein the heteroaryl contains 5 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with halogen, and / or Ci-3alkyl; heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 12 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -C(O)NHCi-4alkyl; (b) -NHCi-3alkylene-Ci-3haloalkyl; (c) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (d) Ci-salkyl and / or (e) -OCi-4alkyl; C3-7cycloalkyl which may be optionally substituted with Ci-3haloalkyl and / or Ci-3alkoxy; or Cearyl which may be optionally substituted with halogen.In some embodiments, Z is heteroaryl, wherein the heteroaryl contains 5 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with halogen, and / or Ci-3alkyl; C3-7cycloalkyl which may be optionally substituted with Ci-3haloalkyl and / or Ci-3alkoxy; or Cearyl which may be optionally substituted with halogen.

[1059] In some embodiments, (i) L3 is -C(=O)NH-, wherein Z is bound to L3 via the nitrogen atom of L3; and

[1060]

[1061] is -C(=O)NHEt; R50ais Me; R50bis Me; R55ais H or F; R55bis F or Cl; R59ais H or Cl; R59bis H or F; R63is Me; R64ais Me; R64bis Me; R65ais H or Cl; R65bis H or Me; R65cis H or Me; R69is Cl; R73ais Cl; R73bis F; R84ais Me; R84bis Me; and R84cis Me; or(ii) L3 is -C(=O)NMe-, wherein Z is bound to L3 via the nitrogen atom of L3; and

[1062]

[1063] The compound or pharmaceutically acceptable salt thereof may be of Formula (Iw):

[1064]

[1065] Formula (Iw)

[1066] or a pharmaceutically acceptable salt thereof;

[1067] wherein R7a, R7b, R7c, and R7dare as defined herein;

[1068] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[1069] L2 is absent or -(CRlaRlb)m-; wherein Rlaand Rlbare each, independently for each occurrence, H; Ci-3alkyl; or Ci-3hydroxyalkyl;

[1070] L3is absent; -C(=O)NH-; -C(=O)NCi-3alkyl-; -NHC(=O)-; or -O-;

[1071] L4 is absent or -(CR4aR4b)0-; wherein R4aand R4bare each, independently for each occurrence, H; Ci-3alkyl; or Ci-3haloalkyl;

[1072] Z is Cearyl which may be optionally substituted with halo; Ci-ealkyl; -NH2; -OH; -CN; Ci-salkoxy; Ci-3haloalkyl; -OCi-3haloalkyl -C(=0)NH2; -C(=O)NHCi-5alkyl; or -NHC(=O)OCi-8alkyl;

[1073] m is 1-3; and

[1074] o is 1-3.

[1075] In some embodiments, Li is absent or -C(=O)-;L2 is absent or -(CRlaRlb)m-; wherein Rlaand Rlbare each, independently for each occurrence, H; wherein m is 1;

[1076] L3 is absent or -O-;

[1077] L4 is absent or -(CR4aR4b)0-; wherein R4aand R4bare each, independently for each occurrence, H; wherein o is 1;

[1078] Z is Cearyl which may be optionally substituted with Cl; -NH2; -C(=O)NHMe; or -NHC(=O)OtBu.

[1079] In some embodiments, the compound or pharmaceutically acceptable salt thereof is not a compound of Formula (Iw) or a pharmaceutically acceptable salt thereof.

[1080] Further compounds that bind FBXO31

[1081] The compound may be of Formula (I):

[1082]

[1083] Formula (I)

[1084] or a pharmaceutically acceptable salt thereof;

[1085] wherein:

[1086] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[1087] L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), or -C(=O)OCi-6alkyl;

[1088] Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -CN; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb,together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (i) -Ci-3alkyl, (ii) -Ci-salkylene-Cearyl wherein said Cearyl may be optionally substituted with -Ci-3alkoxy, (iii) -C(=O)OCi-6alkyl, (iv) -C(=O)Ci-3alkyl, (v) -C(=O)C3-8cycloalkyl, (vi) -C(=O)NH-C3-8cycloalkyl, (vii) -C(=O)C3-8heterocycloalkyl wherein said heterocyclocalkyl may be optionally substituted with -C(=O)OC1-6alkyl, (viii) -C(=O)OCi-4alkylene-C3-8heterocycloalkyl, (ix) -C(=O)C6aryl wherein said C6aryl may be optionally substituted with halo, (x) -C(=O)Ci-3alkylene-Cearyl, (xi) -C(=O)OC6aryl, (xii) -C(=O)OCi-4alkylene-Cearyl, (xiii) -C(=O)NH-Cearyl, (xiv) -C(=O)-N(Ci-3alkyl)-Cearyl, (xv) -C(=O)NHCi-4alkylene-Cearyl, (xvi) -SO2-Cearyl, (xvii) -C(=O)C5-9heteroaryl, or (xviii) C5-gheteroaryl which may be optionally substituted with halo or Ci-3alkyl;

[1089] L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;

[1090] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[1091] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; (w) -Cs-ecycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); (x) -NHC(=O)N(Ci-4alkylene-C6aryl)-; or (y) -N(Cearyl)-;

[1092] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci.3alkyl)(Ci.3alkyl), or -C(=O)NH2; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; -SO2-; or -C3-6cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);

[1093] R4aand R4bare each, independently for each occurrence, H; OH; C1-5alkyl; C1-3haloalkyl; or C1-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[1094] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1095] R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1096] R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[1097] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1098] R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;

[1099] R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[1100] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[1101] R8fand R8gare each, independently H; or Ci-3alkyl;

[1102] m is 1-4;

[1103] n is 0, 1 or 2;

[1104] o is 1-8;

[1105] p is 1-5;

[1106] q is 1-5;

[1107] r is 0, 1 or 2;

[1108] t is 1-5;

[1109] Z is:

[1110] (I) halo;

[1111] (II) Ci-2oalkyl;

[1112] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1113] (IV) -OCi-3alkyl;

[1114] (V) C1-5haloalkyl;(VI) C3-11cycloalkyl which may be optionally substituted with halo; -C(O)OCi-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; and / or Ci-salkyl-Cearyl;

[1115] (VII) Ci-3alkoxy;

[1116] (VIII) C6-15aryl which may be optionally substituted with (a) C1-6alkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) C1-5alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-4alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (o)

[1117] -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2. ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4.8alkylene-NH2; (t) -OC4.8alkylene-NHC(=O)R56; (u) -SO2NH2; (V) -OCearyl; (w) C3-8cycloalkyl; (x) -OCi-3alkyleneCi-3haloalkyl; (y) -SCi-3alkyl; (z) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (ai) Ci-4hydroxyalkyl; (bi) -SO2NHCi-3alkyl; (ci) -SO2Ci-3alkyl; (di) -OC4.

[1118] 8alkylene-NHC(=O)R32; (ei) -O -heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (fi) -OCearyl, wherein said Cearyl may be optionally substituted with halo; (gi) Cearyl, wherein said Cearyl may be optionally substituted with halo; (hi) -C1-4alkyleneNHC(=O)OC1-6alkyl; (ii) -NHCearyl; (ji) -OCs-ecycloalkyl; (ki) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with C1-3 alkyl; (li) -C5-9alkyleneNHC(=O)-B, wherein B is -OCi-4alkyl, R56, or R93; (mi) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ni) -C(=O)NHCi-5alkyl; (oi) -N(Ci-3alkyl)(Ci-3alkyl); (pi) NO2; (qi) -C(=O)OH; (ri) -C1-3alkylene-N(C1-3alkyl)(C1-3alkyl); (si) -OC1-5alkylene-C6aryl; (ti) -C4.8alkylene-NH2; (ui) -OC4.8alkylene-NHC(=O)OCi-4alkyl; (vi) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-4alkyl; (wi) -C2.4hydroxyalkynyl; (xi) heterocycloalkenyl, wherein the heterocycloalkenyl contains 4 to 6 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl; and / or (yi) heterocycloalkyl which may be optionally substituted with -Ci-4alkylene-heterocycloalkyl or -Ci-4alkylene-heterocycloalkylene-C(=O)OCi-4alkyl wherein said heterocycloalkyls and heterocycloalkylene contain 4 to 6 ring atoms;

[1119] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) C1-5alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O- heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -C1-5alkyleneC3-8cycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-5alkoxy; (j) -Ci- 3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)3; (k) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci- 3alkyl)2(Ci-3alkyl); (1) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci- 3alkyl); (m) oxo; (n) -C(=O)OCi-4alkyl; (o) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (p) -Ci-salkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (q) -O-Cearyl; (r) -Ci-3alkyl optionally substituted with OH; (s) -C(=O)Cearyl; (t) C4-8cycloalkyl; (u) -C4-8alkyl optionally substituted with NH2; (v) -C(=O)NH-C6aryl, wherein the C6aryl may be optionally substituted with halo; (w) -C5-9alkylene-NHC(=O)OC1-4alkyl; (x) C1-4hydroxyalkyl; (y) -C2-4hydroxyalkynyl; (z) -C1-4alkylene-O-C1-3alkyl; and / or (ai) -C1-4alkylene-O-C1-3haloalkyl;

[1120] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -C1-5alkyleneC6aryl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; (1)

[1121] -NHC1-3alkylene-C1-3haloalkyl; (m) C6aryl optionally substituted with halo; (n) -C(=O)-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and / or (o) -SO2C1-3alkyl;

[1122] (XI) C15-19cycloalkenyl which may be optionally substituted with oxo and / or C1-3alkyl; or

[1123] (XII) -C(=O)OH;

[1124] R9is -C1-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[1125]

[1126] The compound may be of Formula (I):

[1127]

[1128] Formula (1)

[1129] or a pharmaceutically acceptable salt thereof;

[1130] wherein:

[1131] Li is -C(=O)-;

[1132] L2 is absent; -(CR1aR1b)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, NH(C1-3alkyl), or -N(C1-3alkyl)(C1-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, NH(C1-3alkyl), and / or -N(C1-3alkyl)(C1-3alkyl);

[1133] Rlaand Rlbare each, independently for each occurrence, H; Ci-3alkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)OC6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci-3alkyleneC6aryl, -C(=O)NH-Cearyl, -NHC(=O)-C6aryl, -C(=O)C4-8cycloalkyl, -C(=O)NH-Ci-3alkylene-C6aryl, -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substitutedwith halo or Ci-3alkyl, wherein any of said Cearyl may be optionally substituted with halo and / or C 1-3 alkoxy;

[1134] L3is absent; (a) -NHC(=O)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;

[1135] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[1136] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -Cs-ecycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1137] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -C3-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo;

[1138] R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-3haloalkyl; or Ci-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[1139] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1140] R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1141] R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[1142] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;

[1143] m is 1-4;

[1144] n is 0 or 1;

[1145] o is 1-8;

[1146] p is 1-5;

[1147] q is 1-5;

[1148] r is 0, 1 or 2;

[1149] t is 1-5;

[1150] Z is:

[1151] (I) halo;

[1152] (II) Ci-2oalkyl;

[1153] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1154] (IV) -OCi-3alkyl;

[1155] (V) Ci-shaloalkyl;

[1156] (VI) C3-12cycloalkyl which may be optionally substituted with halo; -C(O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;

[1157] (VII) Ci-3alkoxy;

[1158] (VIII) C6-15aryl which may be optionally substituted with (a) C1-10alkyl which may be optionally substituted with OH and / or NH2; (b) -OH; (c) -CN; (d) -NH2; (e) halo on 1, 3 or 4 atoms of each ring; (f) C1-5alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) - C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2.6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene- heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene- Cearyl, wherein said Cearyl may be optionally substituted with halo; (o) -C2. ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2. ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) - C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) - (OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OC6aryl; (v) C3. scycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl, oxo, -C(=O)OCi-8alkyl, and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2C1-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-9alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-6cycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (ji) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ki) -C(=O)NHC1-5alkyl; (li) -N(Ci-3alkyl)(Ci-3alkyl); (mi) NO2; (ni) C2-5alkynyl which may be optionally substituted with OH and / or NH2; (oi) C2-5alkenyl which may be optionally substituted with OH and / or NH2; or (pi) -C3-9alkylene-NH2;

[1159] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo; (f) -C1-5alkyleneC3-8cycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); (m) oxo; (n) -OCi-salkyleneCearyl; (o) OH; (p) Ci-3hydroxyalkyl; (q) -OCearyl; (r) -Ci-3alkylene-Cearyl; (s) -Ci-3alkylene-O-Ci-3alkyl; or (t) Ci-4haloalkoxy;

[1160] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -Ci-salkyleneCearyl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-6alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; (1) -NHCi-3alkylene-Ci-3haloalkyl; (m) oxo; (n) -OCearyl; (o) -Cs-9alkylene-NH2; (p) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms; (q) C5-7cycloalkyl; (r) -Ci-3alkylene-O-Ci-3alkyl; (s) Ci-4haloalkoxy; and / or (t) Cearyl;

[1161] (XI) C15-19cycloalkenyl which may be optionally substituted with oxo and / or C1-3alkyl; or

[1162] (XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9; and

[1163] R9is NH2, -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[1164] wherein when L1 is -C(=O)-, L2is -(CR1aR1b)m- and m is 1, then:

[1165] (i) L3, if present, cannot be -NH(C=O)-; (ii) L4 cannot be -NHC(=O)- if L3is absent; and (iii) Z cannot be NH2if L3and L4 are absent.

[1166] In some embodiments, L1 is -C(=O)-;

[1167] L2is absent; -(CR1aR1b)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1168] R1aand R1bare each, independently for each occurrence, H; C1-5hydroxyalkyl;

[1169] -C1-3alkylene-C6aryl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, C1-3alkyl, C1-3alkoxy, NH(C1-3alkyl), -N(C1-3alkyl)(C1-3alkyl), -C(=O)NH2, -C(=O)NHC1-3alkyl, -C(=O)N(C1-3alkyl)(C1-3alkyl), NHC(=O)C1-3alkyl, and / or N(C1-3alkyl)C(=O)C1-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C1-3alkyl, -C(=O)OC1-6alkyl, -C(=O)C1-3alkyl, -C(=O)C6aryl, and / or C5-9heteroaryl which may be optionally substituted with halo and / or C1-3alkyl;

[1170] L3is absent; (a) -NHC(=O)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NCi-3alkyl-; (j) -O-;

[1171] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[1172] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-salkyl), and / or -N(Ci-3alkyl)(Ci-salkyl);

[1173] (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -Cs-ecycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1174] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -Cs-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1175] R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-3haloalkyl; or Ci-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[1176] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1177] R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1178] R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[1179] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1180] R8aand R8bare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or C6aryl;

[1181] m is 1-4;

[1182] n is 1;

[1183] o is 1-8;

[1184] p is 1-5;

[1185] q is 1-5;

[1186] r is 0, 1 or 2;

[1187] t is 1-5;

[1188] Z is:(I) halo;

[1189] (II) Ci-2oalkyl;

[1190] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1191] (IV) -OCi-3alkyl;

[1192] (V) Ci-shaloalkyl;

[1193] (VI) C3-12cycloalkyl which may be optionally substituted with halo; -C(O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;

[1194] (VII) Ci-3alkoxy;

[1195] (VIII) Ce-isaryl which may be optionally substituted with (a) Ci-ealkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo on 1, 3 or 4 atoms of each ring; (f) Ci-salkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-6alkenylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (o) -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2-6alkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (s) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OCearyl; (v) C3-8cycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2Ci-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-4alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-ecycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (ji) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ki) -C(=O)NHCi-5alkyl; (li) -N(Ci-3alkyl)(Ci-3alkyl); and / or (mi) NO2;

[1196] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-3alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearylwhich may be optionally substituted with halo; (f) -C1-5alkyleneC3-8cycloalkyl; (g) - NHC(=0)Ci-3alkyl; (h) Ci-shaloalkyl; (i) C1-5alkoxy; (j) -Ci-3alkylene-O-Ci-3alkylene- Si(Ci-3alkyl)3; (k) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl); and / or (1) - Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl);

[1197] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -C1-5alkyleneC6aryl; (b) -C(0)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) - C(=O)Ci-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=0)Ci-4alkyl; and / or (1) - NHCi-3alkylene-Ci-3haloalkyl;

[1198] (XI) Ci5-i9cycloalkenyl which may be optionally substituted with oxo and / or Ci- 3alkyl; or

[1199] (XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9;

[1200] R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; and

[1201] wherein when Li is -C(=O)-, L2 is -(CRlaRlb)m- and m is 1, then:

[1202] (i) L3, if present, cannot be -NH(C=O)-; (ii) L4 cannot be -NHC(=O)- if L3 is absent; and (iii) Z cannot be NH2 if L3 and L4 are absent.

[1203] FBOX31-recruiting PROTACs

[1204] Since their introduction in the early 2000s, Proteolysis targeting chimeras (PROTACs) have been extensively described in the scientific literature and are now widely understood by the skilled person in the fields of chemical biology, medicinal chemistry, and drug discovery. PROTACs are heterobifunctional molecules that consist of a ligand for a protein of interest (POI), an E3 -ligase ligand and a linker covalently bonding these two ligands together. PROTACs recruit the POI and E3 -ligase into an artificially induced proteinprotein interaction and ternary complex. Ubiquitin is transferred from an E2 ubiquitin-conjugating enzyme recruited by the E3 -ligase to the POI, leading to subsequent poly-ubiquitination of the POI and to its ‘tagging’ for degradation by the proteasome.

[1205] E3 ligases have been successfully harnessed in PROTAC design, for example cereblon (Pavan, A. R., Smalley, J. P., Patel, U., Pytel, W. A., dos Santos, J. L.,Cowley, S. M., Schwabe, J. W. R., & Hodgkinson, J. T. (2024). Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3. Chemical Communications, 60(94), 13879-13882), and ligands for a wide range of target proteins are already known.

[1206] For PROTACs that recruit cereblon as the E3 ligase, it is well known that glutarimide is the key structural feature of the warhead required for binding to cereblon. The inventors discovered that tetrahydroisoquinoline amide (THIQ-A) or an analogue thereof as described herein is a key structural feature for recruiting the E3 ligase FBXO31, providing the skilled person with the structural blueprint for the development of FBXO31 -recruiting degraders. As shown in FIG. 9, FBXO31 is broadly expressed across all tissue types similarly to cereblon and thus has the potential to degrade therapeutics targets of interest in a range of tissues relevant to diverse disease indications.

[1207] While the discovery that THIQ-A as the essential structural element for binding FBXO31 is unexpected, after consulting the present application the skilled person could substitute, within a PROTAC scaffold, a known warhead for an FBXO31 -recruiting warhead to arrive at PROTACs according to the invention. Once ligands for different E3 ligases are known, exchanging such ligands in an otherwise analogous bifunctional construct involves standard synthetic chemistry. Indeed, this modularity is a defining feature of PROTAC technology. The design paradigm treats the POI-binding ligand, linker, and E3 ligase-binding ligand as interchangeable components, allowing systematic variation and optimisation.

[1208] PROTACs can be prepared using conventional organic synthetic chemistry, typically involving the functionalisation of known ligands and their coupling via a linker. Such methods are standard and reproducible, and even rudimentary alkyl or PEG linkers can be used. For instance, the FKBP12-targeting PROTACs described in Example 5 (compounds 665-667) were synthesised using a known FKBP12 ligand (Clackson, T. Redesigning an FKBP -ligand interface to generate chemical dimerisers with novel specificity. PNAS, 1998, 95(18), 10437-10442), an FBXO31 recruiting warhead as described herein, and a basic, alkyl linker. Similarly, the BRD4-targeting PROTACs discussed in Example 7 (Compounds 670-672) were synthesised using a known BRD4 ligand (JQ1), an FBXO31 recruiting warhead as described herein and a basic, alkyl linker.

[1209] Screening of varying linker lengths and functionality can be conducted to establish the linker requirements for a degrader of a specific target protein: once a PROTAC is synthesised, its ability to induce degradation of a target protein can be readily assessed using well-established cellular and biochemical assays. These include, for example, Westernblotting (e.g. as described in Example 6) proteomics-based approaches (e.g. as described in Example 9), and reporter assays. Thus, the evaluation of degradation (e.g., DCso, Dmax) can be directly and positively verified by tests or procedures described in Example 6 or 9, or known to the skilled person, and which do not require undue experimentation.

[1210] Therefore, in view of the present invention, the skilled person is able to identify a suitable POI ligand, FBX031 -recruiting warhead, and linker, and to assemble and test a PROTAC capable of degrading a target protein according to the claimed invention using methods known in the art.

[1211] Compounds of Formula (II) or pharmaceutically acceptable salts thereof, as described below, recruit FBX031 as the E3 -ligase.

[1212] Compounds of Formula (II)

[1213] In an aspect, the invention provides a compound of Formula (Ila):

[1214]

[1215] or a pharmaceutically acceptable salt thereof; wherein:

[1216] R7a, R7b, R7C, R7d, R8a, R8b, R8C, R8d, R8e, R8f, R8g, and n are as defined herein;

[1217] L is a linker; and

[1218] Lig is a moiety that binds to a target protein.

[1219] Compounds of Formula (Ila) are also PROTACs of Formula (V), where W is

[1220]

[1221] and “Bm” is “Lig”, i.e. a moiety that binds to a target protein.

[1222] In compounds of Formula (Ila), R8emay be H.The compound of Formula (Ila) may be a compound of Formula (Ilai):

[1223]

[1224] Formula (Ilai)

[1225] or a pharmaceutically acceptable salt thereof.

[1226] Compounds of Formula (Ilai) can have the (R) or (S) configuration at the chiral center at position 3 of the tetrahydroisoquinoline depending on the nature of R8a, R8b, and R8e, so long as the compound has the configuration shown above. For example, R8emay be H and the chiral center at position 3 of the tetrahydroisoquinoline may be, therefore, in the (S) configuration.

[1227] The compound or pharmaceutically acceptable salt thereof may be of Formula (lib):

[1228]

[1229] Formula (lib)

[1230] or a pharmaceutically acceptable salt thereof;

[1231] wherein R7a, R7b, R7c, R7d, R8a, R8b, R8c, R8d, R8e, R8f, R8g, n, Li, L2, L3, L4, r and Lig are as defined herein;

[1232] Ls is, independently for each occurrence, (a) -Cs-ncycloalkylene- which may be optionally substituted with Ra; (b) -Ce- narylene- which may be optionally substituted with Ra;

[1233] (c) -heterocycloalkylene-, wherein said heterocycloalkylene contains 4 to 12 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with Ra;

[1234] (d) -heteroarylene-, wherein said heteroarylene contains 5 to 12 ring atoms, and wherein said heteroarylene may be optionally substituted with 1-3 Ra; (e) -Ci-salkylene- which may beoptionally substituted with Rc; (f) -C2-ioalkenylene- which may be optionally substituted with Rc; (g) -C2-ioalkynylene- which may be optionally substituted with Rc;

[1235] (h) -(OCH2CH2)W-; (i) -(OCH2CH2CH2)X-; 0) -C(=O), (k) -C(=O)O-, (1) -O-, (m) -N(Rb)-, (n) -S-, (o) -C(=S)-, (p) -C(=S)O-, (q) -SO2-, (r) -SO2NH-, (s) -C(=O)N(Rb)-, (t) -C=N-, (u) -OC(=O)N(Rb)-, (v) -OC(=O)O-; (w) -N(Rb)C(=O)-; or (x) -NH-;

[1236] Rais, independently for each occurrence, (a) oxo; (b) halo; (c) -NO2; (d) CN; (e) C1-6 alkyl; (f) C2-ealkenyl; (g) C2-ealkynyl; (h) Cs-iscycloalkyl, (i) Ci-shaloalkyl; (j) Ce-naryl; (k) heteroaryl, wherein said heteroaryl contains 5 to 12 ring atoms; (1) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 12 ring atoms; (m) -O-Rb; (n) -C(=O)-Rb; (o) -C(=O)O-Rb; (p) -C(=O)N(Rb)(Rb); (q) -N(Rb)(Rb); (r) -N(Rb)C(=O)Rb; (s) -N(Rb)C(=O)ORb;

[1237] (t) -N(Rb)C(=O)N(Rb)(Rb); (u) -N(Rb)SO2(Rb); (v) -NRbSO2N(Rb)(Rb);

[1238] (w) -N(Rb)SO2O(Rb); (x) -OC(=O)Rb; (y) -OC(=O)N(Rb)(Rb), (z) -Si(Rb)3, (ai)

[1239] -SRb, (bi) -S(=O)Rb, (ci) -S(=O)NHRb, (di) -SO2Rbor (ei) -SO2N(Rb)(Rb); wherein any of said Ci-ealkyl, C2-ealkenyl, C2-ealkynyl, Cs-iscycloalkyl, Ci-shaloalkyl, Ce-naryl, heteroaryl, wherein said heteroaryl contains 5 to 12 ring atoms, or heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 12 ring atoms may be optionally substituted with Rc;

[1240] Rbis, independently for each occurrence, hydrogen or Ci-ealkyl;

[1241] Rcis, independently for each occurrence, (a) halo; (b) oxo; (c) -CN; (d) -OH; (e) Ci-ealkyl optionally substituted with halo; (f) C3-8 cycloalkyl; or (g) -OCi-ealkyl optionally substituted with halo;

[1242] v is 0-8;

[1243] w is 1-6; and

[1244] x is 1-6.

[1245] Lig may be a compound that binds to any of FKBP12, BRD4, MST1 or LRRC41. Lig may be sirolimus, tacrolimus, echinomycin, JQ1, orZL0580.The compound of Formula (lib) may be a compound of Formula (Ilbi):

[1246]

[1247] Formula (I Ibi)

[1248] or a pharmaceutically acceptable salt thereof.

[1249] Compounds of Formula (Ilbi) can have the (R) or (S) configuration at the chiral center at position 3 of the tetrahydroisoquinoline depending on the nature of R8a, R8b, and R8e, so long as the compound has the configuration shown above. For example, R8emay be H and the chiral center at position 3 of the tetrahydroisoquinoline may be, therefore, in the (S) configuration.

[1250] In the compound of Formula (Ila), (Ilai), (lib) or (Ilbi), or a pharmaceutically acceptable salt thereof, the -Li-L2-L3-(L4)r-(Ls)v- linkage may be defined as above. Alternatively, the -Li-L2-L3-(L4)r-(Ls)v- linkage may comprise:

[1251] (i) -(OCH2CH2)W, wherein w is 1-6;

[1252] (ii) -(OCH2CH2CH2)X, wherein x is 1-6;

[1253] (iii) -Ci-salkylene- which may be optionally substituted with Rc;

[1254] (iv) -heteroarylene-, wherein said heteroarylene contains 5 ring atoms, and wherein said heteroarylene may be optionally substituted with 1-3 Ra;

[1255] (v) -NHC(=O)-;

[1256] (vi) -C(=O)NH-;

[1257] (vii) -heterocycloalkylene-, wherein said heterocycloalkylene contains 4 to 11 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with Ra; (viii) -Cearylene- which may be optionally substituted with Ra; and / or

[1258] (ix) -Cs-scycloalkylene- which may be optionally substituted with Ra.

[1259] For example, in the compound of Formula (Ila), (Ilai), (lib) or (Ilbi), or a pharmaceutically acceptable salt thereof, the -Li-L2-L3-(L4)r-(Ls)v- linkage may comprise:

[1260]

[1261] The compound or pharmaceutically acceptable salt thereof may be of Formula (lie):

[1262]

[1263] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7d, R8a, R8b, R8c, R8d, R8e, R8f, R8g, n, L5, v and Lig are as defined herein.The compound of Formula (lie) may be a compound of Formula (Ilci):

[1264]

[1265] or a pharmaceutically acceptable salt thereof.

[1266] Compounds of Formula (Ilci) can have the (R) or (S) configuration at the chiral center at position 3 of the tetrahydroisoquinoline depending on the nature of R8a, R8b, and R8e, so long as the compound has the configuration shown above. For example, R8emay be H and the chiral center at position 3 of the tetrahydroisoquinoline may be, therefore, in the (S) configuration.

[1267] The compound or pharmaceutically acceptable salt thereof may be of Formula (lid):

[1268]

[1269] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7d, R8a, R8b, R8c, R8d, R8e, R8f, R8g, n, L5, v and Lig are as defined herein.The compound of Formula (lid) may be a compound of Formula (Ildi):

[1270]

[1271] Formula (Udi)

[1272] Compounds of Formula (Ildi) can have the (R) or (S) configuration at the chiral center at position 3 of the tetrahydroisoquinoline depending on the nature of R8a, R8b, and R8e, so long as the compound has the configuration shown above. For example, R8emay be H and the chiral center at position 3 of the tetrahydroisoquinoline may be, therefore, in the (S) configuration.

[1273] The compounds of the invention may not comprise groups known to be unstable in the art. For example, the compounds of the invention may not comprise -O-O-, -N-O-, -O-N-, -N-N-, or -N-halogen bonds. For example, when L3 is -O-, L4 may not be a group that results in L3 and L4 forming a -O-O- or -0-N- bond. Similarly, when L3 is -NHC(=0)NH-; -NHC(=O)NCi-5alkylene-; -NHC(=O)NC3-8cycloalkylene-; -NH-; -NCi-3alkylene-; -C(=0)NH-; or -C(=O)NCi-3alkylene-, L4 may not be a group that results in L3 and L4 forming a -N-0- or -N-N- bond.

[1274] In some embodiments, the compounds of the invention do not comprise a sequence of three or more amino acids.

[1275] In some embodiments, the compounds of the invention do not comprise a sequence of three amino acids, wherein the C-terminal amino acid is selected from the group consisting of isoleucine, leucine, valine, phenylalanine, asparagine, tyrosine, serine, threonine, alanine, tryptophan and methionine. The amino acids are contiguous.

[1276] In some embodiments, the compounds of the invention do not comprise a sequence of three amino acids.

[1277] In some embodiments, when Li is -C(=0)-, L2 is -(CRlaRlb)m- and m is 1, then:

[1278] (i) L3, if present, cannot be -NH(C=0)-; (ii) L4 cannot be -NHC(=0)- if L3 is absent; and (iii) Z cannot be NH2 if L3 and L4 are absent.

[1279] In some embodiments, when Li is -C(=0)-, L2 is -(CRlaRlb)m- and m is 1, then:(i) L3, if present, cannot be -NH(C=O)- or -NCi-3alkylC(=O)-; (ii) L4 cannot be -NHC(=O)- if L3 is absent; and (iii) Z cannot be NH2 if L3 and L4 are absent.

[1280] In some embodiments, when Li is -C(=O)-, L2 is -(CRlaRlb)m- and m is 1, then L3, L4, and Z are not arranged such that the group adjacent to L2 is an amide or NH2.

[1281] The total molecular weight of the compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (Ii), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1 A, or a pharmaceutically acceptable salt thereof, may be less than 500, less than 750, less than 1,000, less than 1,250, less than 1,500, less than 1,750, less than 2,000, less than 2,250, or less than 2,500 Daltons; wherein the molecular weight is expressed by the molecular weight of the compound.

[1282] In the compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (Ii), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid), (Ildi), or (III), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof, R8c, R8d, R8e, R8fand R8gmay all be H. Alternatively, or in addition, Rlaand Rlbmay be independently for each occurrence, H; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, orN(Ci- 3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, or Cs-gheteroaryl which may be optionally substituted with halo or Ci-3alkyl. In the compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (Ii), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Ilbi), (lie), (Ilci), (lid), (Ildi), or (III), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof, R8c, R8d, R8e, R8fand R8gmay all be H and Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH or Ci-3alkoxy; -Ci-3alkylene-heteroaryl,wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, or -C(=O)C6aryl.

[1283] The compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid), or (Ildi), or a compound of Table 1 A, or a pharmaceutically acceptable salt thereof, may have an ECso of less than 10 pM in a HTRF peptide displacement assay. The HTRF peptide displacement assay may be as described in example 2.

[1284] The compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid), or (Ildi), or a compound of Table 1 A, or a pharmaceutically acceptable salt thereof, may have an ECso of less than 10 pM in a PROTAC displacement assay. The PROTAC displacement assay may be as described in example 3.

[1285] Further FBXO31 -recruiting PROTACs

[1286] The PROTAC may be of Formula (V):

[1287] W-L-Bm

[1288] Formula (V);

[1289] or a pharmaceutically acceptable salt thereof, wherein:

[1290] W is a warhead of Formula (W-l):

[1291]

[1292] Formula (W-l)

[1293] wherein:Ring A is phenyl; or a 5-6 membered heteroaryl ring, wherein 1-4 ring atoms are each independently selected from N, O or S; wherein said phenyl or 5-6 membered heteroaryl ring may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl) and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1294] n is 0 or 1;

[1295] R8aand R8bare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), or Cearyl;

[1296] R8Cand R8dare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);

[1297] R8eis H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or

[1298] -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[1299] R8fand R8gare each, independently H; or Ci-3alkyl;

[1300] L is a linker; and

[1301] Bm is a moiety that binds to a target protein.

[1302] The warhead may be of Formula (W-l-i):

[1303]

[1304] The warhead may be of Formula (W-2):

[1305]

[1306] Formula (W-2)

[1307] The warhead may be of Formula (W-2-i):

[1308]

[1309] Formula (W-2-i)

[1310] The warhead may be of Formula (W-3):

[1311]

[1312] Formula (W-3)The warhead may be Formula (W-3-i):

[1313]

[1314] Formula (W-3-i)

[1315] The warhead may be of Formula (W-4):

[1316]

[1317] Formula (W-4)

[1318] wherein L2is absent; -(CRlaRlb)m-; -Cs-scycloalkylene- optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -NH(Ci-3alkyl); and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1319] Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl optionally substituted with NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / orN(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or Cs-gheteroaryl optionally substituted with halo and / or Ci-3alkyl; and

[1320] m is 1-4.

[1321] The warhead may be Formula (W-4-i):

[1322]

[1323] Formula (W-4-i)

[1324] The PROTAC may be of Formula (V):

[1325] W-L-Bm

[1326] Formula (V);

[1327] or a pharmaceutically acceptable salt thereof;

[1328] wherein W is a warhead of Formula (W-5):

[1329]

[1330] wherein:

[1331] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[1332] L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); and / or -heterocycloalkylene-, wherein theheterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=O)OCi-6alkyl;

[1333] Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -CN; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (i) -Ci-3alkyl, (ii) -Ci-salkylene-Cearyl wherein said Cearyl may be optionally substituted with -Ci-3alkoxy, (iii) -C(=O)OC1-6alkyl, (iv) -C(=O)Ci-3alkyl, (v) -C(=O)C3-8cycloalkyl, (vi) -C(=O)NH-C3-8cycloalkyl, (vii) -C(=O)C3-8heterocycloalkyl wherein said heterocycloalkyl may be optionally substituted with -C(=O)OC1-6alkyl, (viii) -C(=O)OCi-4alkylene-C3-8heterocycloalkyl, (ix) -C(=O)C6aryl wherein said C6aryl may be optionally substituted with halo, (x) -C(=O)Ci-3alkylene-Cearyl, (xi) -C(=O)OC6aryl, (xii) -C(=O)OCi-4alkylene-Cearyl, (xiii) -C(=O)NH-Cearyl, (xiv) -C(=O)-N(Ci-3alkyl)-Cearyl, (xv) -C(=O)NHCi-4alkylene-Cearyl, (xvi) -SO2-Cearyl, (xvii) -C(=O)C5-9heteroaryl, and / or (xviii) Cs-9heteroaryl which may be optionally substituted with halo and / or Ci-3alkyl;

[1334] L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;

[1335] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[1336] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; (w) -C3-6cycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (x) -NHC(=O)N(Ci-4alkylene-C6aryl)-; and / or (y) -N(Cearyl)-;L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=0)NH2; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; -SO2-; or -C3-6cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); R4aand R4bare each, independently for each occurrence, H; OH; Ci-salkyl; Ci-3haloalkyl; or Ci -3 alkyl -heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[1337] R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1338] R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1339] R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;

[1340] R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1341] R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;

[1342] R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[1343] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[1344] R8fand R8gare each, independently H; or Ci-3alkyl;

[1345] m is 1-4;

[1346] n is 0, 1 or 2;

[1347] o is 1-8;

[1348] p is 1-5;

[1349] q is 1-5;r is 0, 1 or 2;

[1350] t is 1-5;

[1351] Z is H or:

[1352] (I) halo;

[1353] (II) Ci-2oalkyl;

[1354] (III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1355] (IV) -OCi-3alkyl;

[1356] (V) Ci-shaloalkyl;

[1357] (VI) C3-12cycloalkyl which may be optionally substituted with halo; -C(O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;

[1358] (VII) Ci-3alkoxy;

[1359] (VIII) Ce-isaryl which may be optionally substituted with (a) Ci-ealkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) Ci-salkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-4alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2.6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene- heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene- Cearyl, wherein said Cearyl may be optionally substituted with halo; (o)

[1360] -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2. ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t)

[1361] -SO2NH2; (U) -OCearyl; (v) C3-8cycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2Ci-3alkyl; (ci) -O- heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo or Ci-3alkoxy; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -Ci-4alkyleneNHC(=O)OCi- ealkyl; (gi) -NHC6aryl; (hi) -OC3-ecycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3 alkyl; (ji) -C5-9alkyleneNHC(=O)OCi-4alkyl; (ki) -Ci-3alkylene- heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (li) - C(=O)NHCi-5alkyl; (mi) -N(Ci-3alkyl)(Ci-3alkyl); (ni) NO2; (oi) -C(=O)OH; (pi) -Ci-3alkylene-N(Ci-3alkyl) (Ci-3alkyl); (qi) -OC1-3alkylene-C6aryl; (ri) -C4-8alkylene-NH2; (si) -OC4-8alkylene-NHC(=O)OC1-4alkyl; (ti) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-4alkyl; (ui) -C2-4hydroxyalkynyl; (vi) heterocycloalkenyl, wherein the heterocycloalkenyl contains 4 to 6 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl; and / or (wi) heterocycloalkyl which may be optionally substituted with -Ci-4alkylene-heterocycloalkyl and / or -Ci-4alkylene-heterocycloalkylene-C(=O)OCi-4alkyl wherein any of said heterocycloalkyl or heterocycloalkylene contain 4 to 6 ring atoms;

[1362] (IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -Ci-3alkyleneC3-scycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); (m) oxo; (n) -C(=O)OCi-4alkyl; (o) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (p) -C1-5alkylene-C6aryl, wherein the C6aryl may be optionally substituted with halo; (q) -O-C6aryl; (r) -C1-3alkyl optionally substituted with OH; (s) -C(=O)C6aryl; (t) C4-8cycloalkyl; (u) -C4-8alkyl optionally substituted with NH2; (v) -C(=O)NH-C6aryl, wherein the C6 aryl may be optionally substituted with halo; (w) -C5-9alkylene-NHC(=O)OC1-4alkyl; (x) Ci-4hydroxyalkyl; (y) -C2-4hydroxyalkynyl; (z) -Ci-4alkylene-O-Ci-3alkyl; and / or (ai) -Ci-4alkylene-O-Ci-shaloalkyl;

[1363] (X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -Ci-salkyleneCearyl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; (1)

[1364] -NHCi-3alkylene-Ci-3haloalkyl; (m) Ce aryl optionally substituted with halo; (n)-C(=O)-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and / or (o) -SO2Ci-3alkyl;

[1365] (XI) Ci5-i9cycloalkenyl which may be optionally substituted with oxo and / or Ci- salkyl;

[1366] (XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9;

[1367] (XIII) -C(=O)OH; or

[1368] R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;

[1369] L is a linker; and

[1370] Bm is a moiety that binds to a target protein.

[1371] The warhead may be Formula (W-6):

[1372]

[1373] Formula (W-6)

[1374] or a pharmaceutically acceptable salt thereof; wherein Z is Cearyl which may be optionally substituted with halo; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-3alkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl.

[1375] Z may

[1376]

[1377] wherein R18a, R18c, R18dand R18eare each, independently, (a) H; (b) Ci-ealkyl; (c) -OH; (d) -CN; (e) -NH2; (f) halo; (g) Ci-salkoxy; (h) Ci-3haloalkyl; (i) -OCi-3haloalkyl; (j) -C(=O)OCi-3alkyl; (k) -NHC(=O)OCi-8alkyl; (1) -C(=O)NH2; or (m) -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; and

[1378] p is 1-5.

[1379] Z may

[1380]

[1381] wherein R119, R120and R121are each, independently H, Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-5alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9; or R119and R120together with the carbon atoms to which they are attached, join to form Cearyl which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9;

[1382] R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; and

[1383] p is 1-5.

[1384]

[1385] The warhead may be of Formula (W-7):

[1386]

[1387] Formula (W-7)

[1388] wherein:

[1389] R7a, R7b, R7Cand R7dare each, independently, H, OH, Ci-3alkyl or Ci-3alkoxy;

[1390] L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3.

[1391] 8cycloalkyl, wherein said C3.8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl,Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-3alkyleneC6aryl, -C(=O)NH-Cearyl, and / or -NHC(=O)-Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;

[1392] L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;

[1393] L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; -C3-6cycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;

[1394] Z is -NH2; Ci-salkyl; Ci-3haloalkyl; Ci-3alkoxy; Cearyl optionally substituted with (i) OH, (ii) halo, (iii) -C2-6alkylene-Cearyl, (iv) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (v) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (vi) -Cs-9alkylene-NH2, and / or (vii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-3alkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; heteroaryl wherein the heteroaryl contains 5 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-3alkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; Ce-iocycloalkyl optionally substituted with halo; or heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-3alkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl,wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-salkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-6alkyl;

[1395] m is 1-2;

[1396] n is 0 or 1;

[1397] o is 1-8; and

[1398] r is 0-2.

[1399] L2 may be -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form C3-4cycloalkyl, azetidinyl or piperidinyl, wherein said azetidinyl or piperidinyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-4alkyl, -C(=O)Me, -C(=O)Cearyl, -C(=O)CH2Cearyl, -CFhCearyl, -C(=O)NHCearyl, and / or -NHC(=O)Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or -OMe.

[1400] Z may be phenyl, 5-10 membered heteroaryl or 5-6 membered heterocycloalkyl; wherein said phenyl may be optionally substituted with (i) halo, (ii) -Cs-salkylene-Cearyl, (iii) -Ce 8alkyleneNHC(=O)OCi-4alkyl, (iv) 6-membered heterocycloalkyl, (v) -Ce-salkylene-NFh, and / or (vi) 5-6-membered heteroaryl which may be optionally substituted with Ci-3alkyl, -OCFhCearyl, and / or 6-membered heterocycloalkyl which may be optionally substituted with Ci-3alkyl; wherein said 5-10 membered heteroaryl or 5-6 membered heterocycloalkyl may be optionally substituted with (i) OH, (ii) halo, (iii) Ci-3alkyl, (iv) -CH2OH, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -C^Cearyl, (ix) -Ce-8alkylene-NH2, (x) pyridinyl, (xi) 5-6-membered heterocycloalkyl, (xii) cyclohexyl, (xiii) -(CH2)2OMe, and / or (xiv) -(CH2)2CF3.

[1401] The warhead may be Formula (W-8):

[1402]

[1403] Formula (W-8)or a pharmaceutically acceptable salt thereof; wherein:

[1404] L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Cisalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-salkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-salkoxy;

[1405] L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;

[1406] L4 is absent, or -C 1-3 alkylene-;

[1407] Z is Ce-ioaryl which may be optionally substituted with halo, Ci-salkyl, and / or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-salkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;

[1408] n is 0 or 1; and

[1409] m is 1-2.

[1410] L2 may be -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form azetidinyl, tetrahydropyranyl or pyrrolidinyl, wherein said azetidinyl may be optionally substituted with -C(=O)OCi-4alkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)CH2C6aryl, -CH2C6aryl, -C(=O)NHC6aryl, -C(=O)NHCH2C6aryl, -NHC(=O)C6aryl, -C(=O)C5-ecycloalkyl, -C(=O)-pyridinyl, and / or -C(=O)OCH2-tetrahydropyranyl; wherein any of said Cearyl may be optionally substituted with halo or -OMe, and any of said tetrahydropyranyl or pyrrolidinyl may be optionally substituted with -C(=O)Me.

[1411] Z may be phenyl, napthyl, 6-10-membered heteroaryl, or 5-6-membered heterocycloalkyl; wherein said phenyl or napthyl may be optionally substituted with halo, Ci-3alkyl and / or pyrrolyl; wherein said 6-10-membered heteroaryl may be optionally substituted with Cisalkyl, oxo, Cearyl and / or -CftCearyl; and wherein said 5-6-membered heterocycloalkenyl may be optionally substituted with oxo, Cearyl and / or -CftCearyl.The warhead may be Formula (W-9):

[1412]

[1413] Formula (W-9)

[1414] or a pharmaceutically acceptable salt thereof; wherein:

[1415] L2 is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci- 3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Cisalkyl;

[1416] L3is absent, -NHC(=O)- or -C(=O)NH-;

[1417] Z is (i) Ce-ioaryl which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, and / or -C(=0)NH2; (ii) heteroaryl, wherein said heteroaryl contains 5 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with halo, Ci-salkyl, and / or oxo; (iii) heterocycloalkyl, wherein said heterocycloalkyl contains 5 to 10 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with halo, Ci-ialkyl, and / or oxo; or (iv) heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 10 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with halo, Ci-salkyl, and / or oxo; m is 1-3; and

[1418] n is 0 or 1.

[1419] Rlaand Rlbmay come together with the carbon atom to which they are attached to form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Cisalkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci.3alkyl)(Ci.3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl,-C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-3alkyl.

[1420] L2 may be -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl.

[1421] The warhead may be of Formula (W-10):

[1422]

[1423] Formula (W-10)

[1424] or a pharmaceutically acceptable salt thereof; wherein:

[1425] Z is phenyl or 6-10 membered heteroaryl, wherein said phenyl or 6-10 membered heteroaryl may be optionally substituted with halo, phenyl, -[O(CH2)2]u-NH2, Ci-ioalkyl which may be optionally substituted with OH and / or NH2, C2-salkynyl which may be optionally substituted with OH and / or NH2, C2-salkenyl which may be optionally substituted with OH and / or NH2, 5-7 membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl, wherein said 5-7 membered heterocycloalkyl or 5-7 membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-8alkyl and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl;

[1426] o is 0-3; and

[1427] u is 1-5.

[1428] Z may be phenyl, pyridinyl, or indolyl, wherein said phenyl or pyridinyl may be optionally substituted with halo, phenyl, -[O(CH2)2]2-NH2, Ci-7alkyl which may be optionally substituted with OH and / or NH2, C2-4alkynyl which may be optionally substituted with OH, 6-membered heterocycloalkyl, or 6-membered heterocycloalkenyl, wherein said 6-membered heterocycloalkyl or 6-membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl and / or -CH2-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-4alkyl; and

[1429] o is 0-3.

[1430] The linker may be attached to the warhead through any of Z, L4, L3, L2, Li, or the isoquinoline amine.

[1431] The PROTAC may be of Formula (Ilb-ii):

[1432]

[1433] Formula (Ilb-ii)

[1434] or a pharmaceutically acceptable salt thereof, wherein:

[1435] L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;

[1436] L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); or

[1437] -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-salkyl); -Ci-salkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-salkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein said C3-scycloalkyl may be optionally substituted with -NH2, Ci-salkyl, Ci-salkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may beoptionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, or Cs-9heteroaryl which may be optionally substituted with halo or Ci-3alkyl;

[1438] L3is absent; (a) -NHC(=O)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=0)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;

[1439] (k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;

[1440] (o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -C3-6cycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);

[1441] L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci.3alkyl)(Ci.3alkyl); -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -Cs-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);

[1442] R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-shaloalkyl; or Ci-salkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form Cs-iocycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;

[1443] R7ais H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); or -N(C1-3alkyl)(C1-3alkyl);

[1444] R7bis H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); or -N(C1-3alkyl)(C1-3alkyl);

[1445] R7Cis H; OH; CN; NH2; halo; Ci-salkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or -(OCH2CH2)p-R9;

[1446] R7dis H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); or -N(C1-3alkyl)(C1-3alkyl);

[1447] R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-salkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;R8cand R8dare each, independently, H; OH; CN; NH2; halo; Ci-salkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;

[1448] R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;

[1449] R8fand R8gare each, independently H; or Ci-3alkyl;

[1450] L5 is, independently for each occurrence, (a) -Cs-ncycloalkylene- which may be optionally substituted with Ra; (b) -Ce- narylene- which may be optionally substituted with Ra;

[1451] (c) -heterocycloalkylene-, wherein said heterocycloalkylene contains 4 to 12 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with Ra;

[1452] (d) -heteroarylene-, wherein said heteroarylene contains 5 to 12 ring atoms, and wherein said heteroarylene may be optionally substituted with 1-3 Ra; (e) -Ci-salkylene- which may be optionally substituted with Rc; (f) -C2-ioalkenylene- which may be optionally substituted with Rc; (g) -C2-ioalkynylene- which may be optionally substituted with Rc;

[1453] (h) -(OCH2CH2)W-; (i) -(OCH2CH2CH2)X-; 0) -C(=O), (k) -C(=O)O-, (1) -O-, (m) -N(Rb)-, (n) -S-, (o) -C(=S)-, (p) -C(=S)O-, (q) -SO2-, (r) -SO2NH-, (s) -C(=O)N(Rb)-, (t) -C=N-, (u) -OC(=O)N(Rb)-, (v) -OC(=O)O-; (w) -N(Rb)C(=O)-; or (x) -NH-;

[1454] Rais, independently for each occurrence, (a) oxo; (b) halo; (c) -NO2; (d) CN; (e) C1-6 alkyl; (f) C2-ealkenyl; (g) C2-ealkynyl; (h) Cs-iscycloalkyl, (i) Ci-shaloalkyl; (j) Ce-naryl; (k) heteroaryl, wherein said heteroaryl contains 5 to 12 ring atoms; (1) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 12 ring atoms; (m) -O-Rb; (n) -C(=O)-Rb; (o) -C(=O)O-Rb; (p) -C(=O)N(Rb)(Rb); (q) -N(Rb)(Rb); (r) -N(Rb)C(=O)Rb; (s) -N(Rb)C(=O)ORb;

[1455] (t) -N(Rb)C(=O)N(Rb)(Rb); (u) -N(Rb)SO2(Rb); (v) -NRbSO2N(Rb)(Rb);

[1456] (w) -N(Rb)SO2O(Rb); (x) -OC(=O)Rb; (y) -OC(=O)N(Rb)(Rb), (z) -Si(Rb)3, (ai)

[1457] -SRb, (bi) -S(=O)Rb, (ci) -S(=O)NHRb, (di) -SO2Rbor (ei) -SO2N(Rb)(Rb); wherein any of said Ci-ealkyl, C2-ealkenyl, C2-ealkynyl, Cs-iscycloalkyl, Ci-shaloalkyl, Ce-naryl, heteroaryl, wherein said heteroaryl contains 5 to 12 ring atoms, or heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 12 ring atoms may be optionally substituted with Rc;

[1458] Rbis, independently for each occurrence, hydrogen or Ci-ealkyl;

[1459] Rcis, independently for each occurrence, (a) halo; (b) oxo; (c) -CN; (d) -OH; (e) Ci-ealkyl optionally substituted with halo; (f) C3-8 cycloalkyl; or (g) -OCi-ealkyl optionally substituted with halo;Bm is a moiety that binds to a target protein;

[1460] n is 0, 1 or 2;

[1461] r is 0, 1 or 2;

[1462] v is 0-8;

[1463] w is 1-6; and

[1464] x is 1-6.

[1465] The PROTAC may be of Formula (Ild-i):

[1466]

[1467] or a pharmaceutically acceptable salt thereof.

[1468] Linkers

[1469] The linkers described herein attach the FBXO31 -recruiting warhead to the ligand that binds to a protein of interest.

[1470] L may comprise LA, wherein LA comprises at least one of Li, L2, L3, L4 or Z as defined herein.

[1471] L may consist of LA and / or LB, wherein LB is absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR-, -SiR2-, -Si(OH)R-, -Si(OH)2- -P(O)OR-, - P(O)R- -P(O)NR2-, -S-, -OC(O)-, -

[1472]

[1473] each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-7 membered saturated or partially unsaturatedcarbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroaryl enyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

[1474] each R is independently hydrogen, or an optionally substituted group selected from C1-6aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or;

[1475] two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur, and;

[1476] each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[1477] wherein at least one of LA or LB is present.

[1478] LB may be absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-20 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR-, -SiR.2-, -Si(OH)R-, -Si(OH)2-, -P(O)OR-, -P(O)R-, -P(O)NR2-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2-, -

[1479]

[1480] each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur

[1481] each R is independently hydrogen, or an optionally substituted group selected from C1-6aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

[1482] two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur, and; each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[1483] L may be:

[1484] -LG-LH-LJ-LK-wherein:

[1485] LGis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLG-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;

[1486] LHis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLH-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;

[1487] LJis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLJ-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;LKis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLK-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;

[1488] wherein each R is independently H, or an optionally substituted group selected from C1-6aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from N, O and S, and a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from N, O and S; or two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from N, O and S; and

[1489] each of -CyLG-, -CyLH-, -CyLJ-, and -CyLK- is independently -Cyx-;.

[1490] wherein -Cyx- is an optionally substituted ring selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclylenyl or heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-9 membered monocyclic or bicyclic heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

[1491] LGmay be -CyLG-, wherein -CyLG- is phenyl or pyridinyl, wherein said phenyl may be optionally substituted with halo, CN, C1-4 alkyl, C1-4alkoxy, C1-4haloalkyl, C1-4haloalkoxy, and wherein said pyridinyl may be optionally substituted with halo, Ci-4haloalkyl, or Ci-4haloalkoxy.

[1492] -CyLG- may be:

[1493] R112

[1494]

[1495] 114

[1496]

[1497]

[1498] R113

[1499] wherein R111, R112, R113and R114are each independently selected from H, halo, CN, C1-4 alkyl, Ci-4alkoxy, Ci-4haloalkyl, Ci-4haloalkoxy.

[1500] R111and R112may each independently be selected from H, halo, CN, C1-4 alkyl, Ci-4alkoxy, Ci-4haloalkyl, or Ci-4haloalkoxy; and R113and R114may each independently be selected from H, halo, Ci-3alkyl, or Ci-3haloalkyl.

[1501] LHmay be -CyLH-, wherein -CyLH- is a 4 to 12 membered monocyclic, bridged, bicyclic, or bridged bicyclic heterocyclylenyl containing one or two nitrogen ring atoms; or a C3-7carbocyclylenyl; wherein said heterocyclylenyl may be optionally substituted with halo, C1-3 alkyl or oxo.

[1502] -CyLH- may be:

[1503]

[1504] wherein R115, R116, R117and R118are each independently selected from H, halo, C1-3alkyl and oxo.

[1505] i-salkyl or oxo.

[1506]

[1507] wherein Rlaand Rlbare each independently H, halo, C1-3alkyl, C1-3alkoxy, or C1-3haloalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, join to form

[1508] cyclopropyl or cyclobutyl; and wherein

[1509]

[1510] is the point of attachment to the warhead.

[1511] LKmay comprise:

[1512]

[1513] wherein Rlaand Rlbare each independently H, halo, C1-3alkyl, C1-3alkoxy, or C1-3haloalkyl;or Rlaand Rlb, together with the carbon atom to which they are attached, join to form

[1514] cyclopropyl or cyclobutyl; and wherein is the point of attachment to the warhead.

[1515] Rlaand Rlbmay both be H.

[1516]

[1517] is the point of attachment to the moiety that binds to a target protein.

[1518] L may comprise:

[1519]

[1520] wherein

[1521] is the point of attachment to the moiety that binds to a target protein and

[1522]

[1523] is the point of attachment to the warhead.

[1524]

[1525] wherein R111, R112, R113and R114are each independently selected from H, halo, CN, C1-4 alkyl, Ci-4alkoxy, Ci-4haloalkyl, Ci-4haloalkoxy;

[1526] R115, R116, R117and R118are each independently selected from H, halo, C1-3alkyl and oxo; xs and ys are independently 0-4;LHand LJare each independently absent or a bivalent, saturated or partially unsaturated, straight or branched C1-6hydrocarbon chain, wherein 1-3 methylene units are optionally and independently replaced by -phenylene-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, - C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or - NRC(O)O-; wherein each R is independently H, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from N, O and S, or a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from N, O and S; and

[1527] wherein the point of attachment to the warhead.

[1528] L may be absent and at least one of Li, L2, L3, L4 and Z are present. Li may be present. Li, L2, L3, L4 and Z may be present.

[1529] The linker may be attached to the warhead through Z, if Z is present. The linker may be attached to the warhead through L4, if L4 is present. The linker may be attached to the warhead through L3, if L3 is present. The linker may be attached to the warhead through L2, if L2is present. The linker may be attached to the warhead through Li, if Li is present. The linker may be attached to the warhead through the isoquinoline amine. LGmay be attached to the warhead through Z, if Z is present. LGmay be attached to the warhead through L4, if L4 is present. LGmay be attached to the warhead through L3, if L3 is present. LGmay be attached to the warhead through L2, if L2is present. LGmay be attached to the warhead through Li, if Li is present. LGmay be attached to the warhead through the isoquinoline amine.

[1530] Li, L2, L3, and L4 may be absent and Z may be H or absent.

[1531] At least one of Li, L2, L3, L4 and Z may form part of the linker. Li, L2, L3, L4 and Z may form part of the linker. Thus, in any subformulae where one or more of Li, L2, L3, L4 or Z have been specified, these groups form part of the linker, L, and may not be specified again in the linker, L.

[1532] Linker length can be used to predict the degradation activity of the PROTACs described herein, using either of the calculation methods described below. Preferably, the “linker length” is defined according to Method 2.

[1533] Linker length calculation - Method 1

[1534] In the PROTACs as described herein “linker length” may be defined as the distance between the centroid of the warhead and the centroid of the ligand that binds to a protein ofinterest. That is, the linker length may be the distance between the two centroids highlighted below (exemplified in the context of THIQ-A, but equivalent in warheads where Ring A is not phenyl):

[1535]

[1536] To predict the activity of compounds described herein in ternary complex formation assays, the following computational approach can be applied based on the distance between the centroid of the warhead and the centroid of the ligand that binds to a protein of interest: Three-dimensional conformers of compounds is generated using Omega v5.1.0.0 (OpenEye Scientific Software) with the following parameters: energy window of 10 kcal / mol, RMS threshold of 1.0 A for conformer clustering, hydrogen sampling enabled, enumeration of all nitrogen configurations, ring conformer enumeration enabled, bond flipper activated, strict stereochemistry enforcement, Guba torsion library, and MMFF94S force field for energy calculations. The warhead is used as a static reference structure during conformer generation. Conformers exhibiting steric clashes of >1.0 A of the van der Waals radius between heavy atoms with the E3 ligase structure are excluded from the analysis. For each retained conformer, geometric centroid coordinates are calculated for predefined substructures within each warhead, and the Euclidean distance between the warhead and ligand that binds to a protein of interest is computed using standard three-dimensional coordinate geometry.

[1537] Bifunctional compounds with a range of linker lengths are synthesised and screened for degradation activity, for instance using a degradation assay as described herein. PROTACs are classified as active when exhibiting Dmax of >20%, and a median warhead-POI ligand distance of such PROTACs is calculated across all conformers. Linker length can be calculated in accordance with methods known in the art. Thus, for any given target protein, appropriate linker lengths can be determined.

[1538] Accordingly, in the invention, the median linker length may be 5-50 A, preferably 10-30 A. The median linker length may be 5-50 A, 10-30 A or 15-25 A across all conformers, when calculated according to the method described above.

[1539] Linker length calculation - Method 2

[1540] “Linker length” may be defined as the lowest number of chemical bonds between the THIQ-A amine (or analogue thereof, i.e. when Ring A is not phenyl) and the ligand thatbinds to a protein of interest. For instance, the linker length may be the shortest path between the two fragments highlighted below:

[1541]

[1542] the point of attachment to the linker.

[1543] To predict the activity of compounds described herein in ternary complex formation assays, the following computational approach may be applied based on the lowest number of bonds between the THIQ-A amine (or analogue thereof, i.e. when Ring A is not phenyl) and the ligand that binds to a protein of interest: for each compound, a molecular connectivity graph is generated using the “GetDistanceMatrix” in the cheminformatics suite RDKit v2024.03.2, and the shortest path between predefined substructures within the warhead and the ligand that binds to a protein of interest, is computed. Bifunctional compounds are synthesised and screened for degradation activity, for instance using a degradation assay as described herein. PROTACs are classified as active when exhibiting Dmax of >20%. For the active PROTACs, the average number of bonds between the warhead and the ligand that binds to the protein of interest is calculated for a given target protein.

[1544] Accordingly, in the invention, the linker length i.e., the lowest number of chemical bonds between the THIQ-A amine or analogue thereof and the ligand that binds to a protein of interest may be 3-40 bonds, 8-30 bonds, or 13-25 bonds.

[1545] The linker length calculated according to Method 2 may be 3-40 bonds, 8-30 bonds, or 13-25 bonds.

[1546] The linker length i.e., the lowest number of chemical bonds between the THIQ-A amine or analogue thereof and the ligand that binds to a protein of interest, optionally calculated according to Method 2, may be 3-40 bonds, 8-30 bonds, or 13-25 bonds, and the median linker length, optionally calculated according to Method 1, may be 5-50 A, 10-30 A or 15-25 A.

[1547] Moieties that Bind to a Target Protein

[1548] In the invention, the ligand that binds to a protein of interest (e.g. “Lig” or “Bm”) may not be a STAT6-binding moiety (SBM), i.e. a moiety that binds to the STAT6 protein. The ligand that binds to a protein of interest may not be a STAT6-binding moiety with an IC50 of less than 50 pM, less than about 1 pM, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.Synthetic Intermediates

[1549] In an aspect, the invention provides a synthetic intermediate of Formula (W-6-Int):

[1550]

[1551] Formula (W-6-Int)

[1552] or a pharmaceutically acceptable salt thereof; wherein Li, L2, L3, L4 and n are as defined herein; and

[1553] Z is Cearyl; 6-10 membered heteroaryl; 6-10 membered heteroaryl-Cearyl; 6-10 membered heteroaryl-Ci-salkyleneCearyl; 5-6 membered heterocycloalkyl, 5-6 membered heterocycloalkenyl-Cearyl; or 5-6 membered heterocycloalkenyl-Ci-salkyleneCearyl; wherein any of said Cearyl, 6-10 membered heteroaryl, 6-10 membered heteroaryl-Cearyl, 6-10 membered heteroaryl-Ci-salkyleneCearyl, 5-6 membered heterocycloalkenyl, 5-6 membered heterocycloalkenyl-Cearyl, or 5-6 membered heterocycloalkenyl-Ci-salkyleneCearyl may be optionally substituted with Ci-3alkyl, oxo, and / or a reactive group, for example -NH2, -CN, -C(=O)OH, - C(=0)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2;

[1554] n is 0 or 1; and

[1555] u is 1-5.

[1556] The reactive group may be -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2.

[1557]

[1558] which may be optionally substituted with Ci-3alkyl, oxo, -NH2, -CN, -C(=O)OH, - C(=0)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2.In an aspect, the invention provides a synthetic intermediate of Formula (W-7-Int):

[1559]

[1560] Formula (W-7-Int)

[1561] or pharmaceutically acceptable salt thereof, wherein:

[1562] R7aR7bR7CancjR7dare each, in(iepen(ienly3H, OH, Ci-3alkyl or Ci-3alkoxy;

[1563] L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci.3alkyl)C(=O)Ci.3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl,

[1564] -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci- salkyleneCearyl, -C(=O)NH-Cearyl, and / or -NHC(=O)-Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;

[1565] L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;

[1566] L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; -Cs-ecycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;

[1567] Z is -NH2; Ci-salkyl; Ci-3haloalkyl; Ci-3alkoxy; Cearyl optionally substituted with (i) OH, (ii) halo, (iii) -C2-ealkylene-Cearyl, (iv) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (v) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (vi) -Cs-9alkylene-NH2, and / or (vii)heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-salkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; heteroaryl wherein the heteroaryl contains 5 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-shydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; Ce-iocycloalkyl optionally substituted with halo; or heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl;

[1568] and wherein, for Z, any of said aryl, alkylene, alkyl, heterocycloalkyl, heteroaryl, heterocycloalkyl, hydroxyalkyl, cycloalkyl or haloalkoxy may be optionally substituted with a reactive group, for example -NH2, -CN, -C(=O)OH, - C(=0)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;

[1569] m is 1-2;

[1570] n is 0 or 1;

[1571] o is 1-8;

[1572] r is 0-2; and

[1573] u is 1-5.

[1574] The reactive group may be -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2.In an aspect, the invention provides a synthetic intermediate of Formula (W-8-Int):

[1575]

[1576] Formula (W-8-Int)

[1577] or a pharmaceutically acceptable salt thereof; wherein:

[1578] L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Cisalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-salkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-salkoxy;

[1579] L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;

[1580] L4 is absent, or -C 1-3 alkylene-;

[1581] Z is Ce-ioaryl which may be optionally substituted with halo, Ci-salkyl, and / or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-salkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;

[1582] and wherein, for Z, any of said aryl, alkyl, heteroaryl, alkylene or heterocycloalkenyl may be optionally substituted with a reactive group, for example, -NH2, -CN, -C(=O)OH, -C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;

[1583] n is 0 or 1;

[1584] m is 1-2; and

[1585] u is 1-5.The reactive group may be -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2.

[1586] In an aspect, the invention provides a synthetic intermediate of Formula (W-9-Int):

[1587]

[1588] Formula (W-9-Int)

[1589] or a pharmaceutically acceptable salt thereof, wherein:

[1590] L2is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-6cycloalkyl, wherein said C3-6cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-3alkyl;

[1591] L3is absent, -NHC(=O)- or -C(=O)NH-;

[1592] Z is Ce-ioaryl, heteroaryl, wherein said heteroaryl contains 5 to 10 ring atoms, heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 10 ring atoms, or heterocycloalkenyl, wherein said heterocycloalkenyl contains 4 to 10 ring atoms wherein said Ce-ioaryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl may be optionally substituted with oxo, phenyl, and / or a reactive group, for example, -NH2, Ci-9alkylene-NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]U-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2;

[1593] m is 1-3;

[1594] n is 0 or 1; andu is 1-5.

[1595] The reactive group may be oxo, -NH2, C1-9alkylene-NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, -[O(CH2)2]U-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, -C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]u-NH2.

[1596] In an aspect, the invention provides a synthetic intermediate of Formula (W-10-Int):

[1597]

[1598] Formula (W-10-Int)

[1599] or a pharmaceutically acceptable salt thereof, wherein:

[1600] Z is phenyl, 6-10 membered heteroaryl, C1-10alkyl, C2-5alkynyl, C2-5alkenyl, 5-7 membered heterocycloalkyl, 5-7 membered heterocycloalkenyl, 5-7 membered heterocycloalkyl-Ci-3alkylene-6-membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl-Ci-3alkylene-6-membered heterocycloalkyl;

[1601] wherein said phenyl, 6-10 membered heteroaryl, C1-10alkyl, C2-5alkynyl, C2-5alkenyl,

[1602] 5-7 membered heterocycloalkyl, 5-7 membered heterocycloalkenyl, 5-7 membered heterocycloalkyl-Ci-3alkylene-6-membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl-Ci-3alkylene-6-membered heterocycloalkyl may be optionally substituted with a reactive group, for example, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]u-NH2, or Ci- walkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2;

[1603] o is 0-3; and

[1604] u is 1-5.The reactive group may be -NH2, -CN, -C(=O)OH, - C(=0)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]u-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=0)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2.

[1605] Further Embodiments

[1606] In the invention, the ligand that binds to a protein of interest (e.g. “Lig” or “Bm”) may not be a STAT6-binding moiety (SBM), i.e. a moiety that binds to the STAT6 protein; and / or a PROTAC or pharmaceutically acceptable salt thereof as described herein may be provided in a pharmaceutical composition including said PROTAC, or a pharmaceutically acceptable salt thereof (e.g., a therapeutically effective amount of the PROTAC or salt), and a pharmaceutically acceptable excipient, optionally wherein the pharmaceutical composition comprises from 0.1 mg to 300 mg or 1-100 mg of the PROTAC or a pharmaceutically acceptable salt thereof; and / or a PROTAC or pharmaceutically acceptable salt thereof as described herein may be provided in a dosage form as a pill, tablet or capsule. The dosage form may be a pill. The dosage form may be a tablet. The dosage form may be a capsule.

[1607] In an aspect, the invention provides a molecular glue degrader comprising a compound as described herein, or a pharmaceutically acceptable salt thereof.

[1608] In some embodiments, when Li is -CH2- and L2, L3, and L4are absent, Z may not be phenyl or CO2H; when L2is -CH2- and LbL3and L4are absent, Z may not be phenyl or CO2H; when L4is -CH2- and LbL2, and L3are absent, Z may not be phenyl or CO2H; when Li is -CH(Me)- and L2, L3, and L4are absent, Z may not be Me; when L2is -CH(Me)- and LbL3and L4are absent, Z may not be Me; and when L4is -CH(Me)- and LbL2, and L3are absent, Z may not be Me. In some embodiments, the first group of the linker attached to the warhead is not wherein is the point of

[1609]

[1610]

[1611] attachment to the warhead.

[1612] Exemplary Compounds

[1613] In one aspect, the invention provides a compound of Table 1 A or a pharmaceutically acceptable salt thereof.Table 1A.

[1614]

[1615]

[1616]

[1617]

[1618]

[1619]

[1620]

[1621]

[1622]

[1623]

[1624]

[1625]

[1626]

[1627]

[1628]

[1629]

[1630]

[1631]

[1632]

[1633]

[1634]

[1635]

[1636]

[1637]

[1638]

[1639]

[1640]

[1641]

[1642]

[1643]

[1644]

[1645]

[1646]

[1647]

[1648]

[1649]

[1650]

[1651]

[1652] In another aspect, the invention provides a compound of Table IB, or a pharmaceutically acceptable salt thereof.

[1653] Table IB.

[1654]

[1655]

[1656]

[1657]

[1658]

[1659]

[1660]

[1661]

[1662]

[1663]

[1664]

[1665]

[1666]

[1667]

[1668]

[1669] 7

[1670]

[1671]

[1672]

[1673]

[1674]

[1675]

[1676]

[1677]

[1678]

[1679]

[1680]

[1681] In another aspect, the invention provides a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof.

[1682] Pharmaceutical Compositions & Dosage Forms

[1683] In another aspect, the invention provides a pharmaceutical composition that includes any one of the compounds described herein, or a pharmaceutically acceptable salt thereof (e.g., a therapeutically effective amount of the compound or salt), and a pharmaceutically acceptable excipient. The pharmaceutical composition may comprise a filler, binder and / or disintegrant. For example, the pharmaceutical composition may comprise a filler, a binder, and a disintegrant. The pharmaceutical composition may comprise from 0.001 mg to 500 mg of the compound as defined herein, or pharmaceutically acceptable salt thereof. The pharmaceuticalcomposition may comprise from 0.1 mg to 300 mg or 1-100 mg of the compound (e.g. a PROTAC) as defined herein, or pharmaceutically acceptable salt thereof.

[1684] The pharmaceutical compositions provided herein can be administered by a variety of routes including, but not limited to, oral (enteral) administration, parenteral (by injection) administration, rectal administration, transdermal administration, intradermal administration, intrathecal administration, subcutaneous (SC) administration, intravenous (IV) administration, intramuscular (IM) administration, and intranasal administration. Details of such formulations and processing thereof are set forth in Part 8 of Remington’s Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, which is incorporated herein by reference.

[1685] In an aspect, the invention provides a dosage form comprising any one of the compounds described herein, or a pharmaceutically acceptable salt thereof (e.g., a therapeutically effective amount of the compound or salt), or a pharmaceutical composition as defined herein. The dosage form may be a solid or a liquid dosage form. The dosage form may have a total mass of less than 1 g.

[1686] The dosage form may be a pill, tablet or capsule.

[1687] Solid Forms

[1688] Any PROTAC, compound, molecular glue degrader, or pharmaceutically acceptable salt thereof as defined herein may be provided in crystalline or amorphous form. For example, a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi) may be provided in crystalline or amorphous form.

[1689] Methods of Use

[1690] The invention also provides the use of a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament.In the invention, the compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof may be for use in therapy. Thus, the invention provides in another aspect, a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The disease or condition may be one associated with elevated levels of a target protein. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof for use in therapy. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table IB, or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The disease or condition may be one associated with elevated levels of a target protein.

[1691] In another aspect, the invention provides a compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof for use in a method of degrading a target protein, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1 A or IB, or a pharmaceutically acceptable salt thereof for use in a method of degrading a target protein, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031.In another aspect, the invention provides a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Hbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof for use in a method of decreasing the level of a target protein, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein level is decreased using FBXO31. The invention also provides the use of aPROTAC of Formula (II), (Ila), (Ilai), (Hb), (Hbi), (Hb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof for use in a method of decreasing the level of a target protein, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition.

[1692] In another aspect, the invention provides a compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Hbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof for use in a method of ubiquitinating a target protein, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein is ubiquitinated using FBXO31. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Hbi), (Hb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof for use in a method of ubiquitinating a target protein, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein is ubiquitinated using FBXO31.

[1693] In another aspect, the invention provides a compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Hbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition by degrading a target protein associated with said disease or condition. Preferably, the target protein isdegraded using FBX031. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition by degrading a target protein associated with said disease or condition. Preferably, the target protein is degraded using FBX031.

[1694] In another aspect, the invention provides a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition, comprising (a) administering said compound or pharmaceutically acceptable salt thereof to a subject in need thereof; (b) forming a ternary complex with FBX031 and a target protein associated with said disease or condition; and (c) reducing the level of said target protein. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1 A or IB, or a pharmaceutically acceptable salt thereof for use in a method of treating a disease or condition, comprising (a) administering said compound or pharmaceutically acceptable salt thereof to a subject in need thereof; (b) forming a ternary complex with FBX031 and a target protein associated with said disease or condition; and (c) reducing the level of said target protein.

[1695] In another aspect, the invention provides a ternary complex comprising a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof, FBX031 and a target protein. The invention also provides a ternary complex comprising a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Hb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof FBX031 and a target protein.

[1696] In another aspect, the invention provides a compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceuticallyacceptable salt thereof for use in treating a disease or condition wherein dysregulated protein activity is responsible for said disease or condition, comprising administering the compound or pharmaceutically acceptable salt thereof to a subject in need thereof. The invention also provides the use of aPROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1 A or IB, or a pharmaceutically acceptable salt thereof for use in treating a disease or condition wherein dysregulated protein activity is responsible for said disease or condition, comprising administering the PROTAC or pharmaceutically acceptable salt thereof to a subject in need thereof.

[1697] In another aspect, the invention provides a method of degrading a target protein ex vivo, comprising contacting said target protein with a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof. The invention also provides a method of degrading a target protein ex vivo, comprising contacting said target protein with a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof.

[1698] In another aspect, the invention provides a method of decreasing the level of a target protein ex vivo, comprising contacting said target protein with a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof. The invention provides a method of decreasing the level of a target protein ex vivo, comprising contacting said target protein with a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof.

[1699] In another aspect, the invention provides a method of ubiquitinating a target protein ex vivo, comprising contacting said target protein with a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceuticallyacceptable salt thereof. The invention also provides a method of ubiquitinating a target protein ex vivo, comprising contacting said target protein with a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof.

[1700] In another aspect, the invention provides the use of a compound of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof, for the manufacture of a medicament. The invention also provides the use of a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1 A or IB, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.

[1701] In another aspect, the invention provides the use of a compound of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof, for the manufacture of a PROTAC.

[1702] In another aspect, the invention provides the use of a compound of Formula (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof, for the manufacture of a molecular glue degrader.

[1703] In another aspect, the invention provides a method of treating a disease or condition associated with elevated levels of a target protein, comprising administering a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (Hb), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof to a subject in need thereof. The invention also provides a method of treating a disease or condition associated with elevated levels of a target protein comprising administering a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof.In another aspect, the invention provides a method of degrading a target protein, comprising administering a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031. the invention provides a method of degrading a target protein, comprising administering a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031.

[1704] In another aspect, the invention provides a method of decreasing the level of a target protein, comprising administering a compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein level is decreased using FBX031. The invention also provides a method of decreasing the level of a target protein, comprising administering a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Ilbi), (Hb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein level is decreased using FBX031.

[1705] In another aspect, the invention provides a method of ubiquitinating a target protein, comprising administering a compound of any of Formulas (I), (I- 1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein is ubiquitinated using FBX031. The invention also provides a method of ubiquitinating a target protein, comprising administering a PROTAC of Formula (II), (Ila), (Ilai), (Hb), (Ilbi), (Hb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or apharmaceutically acceptable salt thereof to a subject in need thereof. The target protein may be associated with a disease or condition. Preferably, the target protein is ubiquitinated using FBX031.

[1706] In another aspect, the invention provides a method of treating a disease or condition by degrading a target protein associated with said disease or condition, comprising administering a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or a pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031. The invention also provides a method of treating a disease or condition by degrading a target protein associated with said disease or condition, comprising administering a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof to a subject in need thereof. Preferably, the target protein is degraded using FBX031.

[1707] In another aspect, the invention provides a method of treating a disease or condition, comprising (a) administering a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof to a subject in need thereof; (b) forming a ternary complex with FBX031 and a target protein associated with said disease or condition; and (c) reducing the level of said target protein. The invention also provides a method of treating a disease or condition comprising (a) administering a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof to a subject in need thereof.; (b) forming a ternary complex with FBX031 and a target protein associated with said disease or condition; and (c) reducing the level of said target protein.

[1708] In another aspect, the invention provides a ternary complex comprising a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof, FBX031 and a target protein. The inventionprovides a ternary complex comprising a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (Hd), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof, FBXO31 and a target protein.

[1709] In another aspect, the invention provides method of treating a disease or condition wherein dysregulated protein activity is responsible for said disease or condition, comprising administering a compound of any of Formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof to a subject in need thereof. The invention provides method of treating a disease or condition wherein dysregulated protein activity is responsible for said disease or condition, comprising administering a PROTAC of Formula (II), (Ila), (Ilai), (lib), (Ilbi), (Ilb-ii), (lie), (Ilci), (lid), (Ildi), (Ild-ii), (Ile-i), (Ilf-i), (V), (V-i), (V-ii), (V-iii), (V-iv), (V-v), or (V-vi), or a compound of Table 1A or IB, or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[1710] The disease or condition may be a neurodegenerative disease, autoimmune disease, cardiovascular disease, or cancer, or a combination thereof. The disease or condition may be a neurodegenerative disease. The disease or condition may be an autoimmune disease. The disease or condition may be a cardiovascular disease. The disease or condition may be cancer.

[1711] Processes

[1712] In one aspect, the invention provides a method for making a molecular glue degrader or a PROTAC by reacting a compound of Formula (III) or a pharmaceutically acceptable salt thereof with a reactive chemical moiety, wherein the compound of Formula (III) is:

[1713]

[1714] Formula (III)

[1715] or a pharmaceutically acceptable salt thereof; wherein R7a, R7b, R7c, R7d, R8a, R8b, R8c, R8d, R8e, R8f, R8gand n are as defined herein; and A forms a reactive group with N that is capable of forming a linkage with said reactive chemical moiety, n may be 0 or 1.The reaction between the compound of Formula (III) or a pharmaceutically acceptable salt thereof with a reactive chemical moiety may be an amide forming reaction, nucleophilic substitution reaction, or reductive amination reaction. The reaction between the compound of Formula (III) or a pharmaceutically acceptable salt thereof with a reactive chemical moiety may be a cross-coupling reaction.

[1716] The compound of Formula (III) or a pharmaceutically acceptable salt thereof may be an amine, and the reactive chemical moiety may be a carboxylic acid, acyl halide (e.g., an acyl chloride), acid anhydride, ester (e.g., activated esters such those formed from a reaction between HATU and a carboxylic acid), or an isocyanate. The compound of Formula (III) or a pharmaceutically acceptable salt thereof may be an amine, and the reactive chemical moiety may be an alkyl halide (e.g., MeCl), epoxide, aziridine, or aldehyde, or a ketone, or nitrile.

[1717] The method may further comprise reacting the product of the compound of Formula (III) or a pharmaceutically acceptable salt thereof and any of the reactive chemical moieties defined herein with an additional reactive chemical moiety, such as any of those as defined herein.

[1718] The method may form a compound of any of formulas (I), (1-1), (lai), (laii), (Ibi), (Ibii), (Ibiii), (Ibiv), (Ici), (Icii), (Idi), (Idii), (lei), (leii), (Ig), (Ih), (li), (Ij), (Iki), (Ikii), (Hi), (Ilii), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is), (It), (lu), (Iv), (Iw), (Ila), (Ilai), (lib), (Ilbi), (lie), (Ilci), (lid) or (Ildi), or a compound of Table 1A, or pharmaceutically acceptable salt thereof.

[1719] In an aspect, the invention provides the use of a compound of Formula (III), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament.

[1720] In another aspect, the invention provides the use of a compound of Formula (III), or a pharmaceutically acceptable salt thereof, for the manufacture of a PROTAC.

[1721] In another aspect, the invention provides the use of a compound of Formula (III), or a pharmaceutically acceptable salt thereof, for the manufacture of a molecular glue degrader.Further Processes

[1722] In an aspect, the invention provides a method of making a PROTAC comprising reacting a warhead of Formula (W-l-ii):

[1723]

[1724] Formula (W-l-ii)

[1725] or a pharmaceutically acceptable salt thereof with a linker and a moiety that binds to a target protein;

[1726] wherein Ring A is phenyl; or a 5-6 membered heteroaryl ring, wherein 1-4 ring atoms are each independently selected from N, O or S; wherein said phenyl or 5-6 membered heteroaryl ring may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, NH(Ci-3alkyl) and / or -N(Ci-3alkyl)(Ci-3alkyl);

[1727] n is 0 or 1;

[1728] R8aand R8bare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(C1-3alkyl), -N(C1-3alkyl)(C1-3alkyl), or C6aryl;

[1729] R8cand R8dare ea...

Claims

CLAIMS1. A PROTAC of Formula (V):W-L-BmFormula (V);or a pharmaceutically acceptable salt thereof, wherein:W is a warhead of Formula (W-l):Formula (W-l)wherein:Ring A is phenyl; or a 5-6 membered heteroaryl ring, wherein 1-4 ring atoms are each independently selected from N, O or S; wherein said phenyl or 5-6 membered heteroaryl ring may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl) and / or -N(Ci-3alkyl)(Ci-3alkyl);n is 0 or 1;R8aand R8bare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), or Cearyl;R8Cand R8dare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);R8eis H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;R8fand R8gare each, independently H or Ci-3alkyl;L is a linker; andBm is a moiety that binds to a target protein.

2. The PROTAC or pharmaceutically acceptable salt thereof of claim 1, wherein the warhead is of Formula (W-l-i):Formula (W-l-i)3. The PROTAC or pharmaceutically acceptable salt thereof of claim 1, wherein the warhead is of Formula (W-2):Formula (W-2)4. The PROTAC or pharmaceutically acceptable salt thereof of claim 3, wherein the warhead is of Formula (W-2-i):Formula (W-2-i)5. The PROTAC or pharmaceutically acceptable salt thereof of claim 1, wherein the warhead is of Formula (W-3):

6. The PROTAC or pharmaceutically acceptable salt thereof of claim 5, wherein the warhead is of Formula (W-3-i):Formula (W-3-i)7. The PROTAC or pharmaceutically acceptable salt thereof of claim 1, wherein the warhead is of Formula (W-4):Formula (W-4)wherein L2is absent; -(CRlaRlb)m-; -Cs-scycloalkylene- optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -NH(Ci-3alkyl); and / or -N(Ci-3alkyl)(Ci-3alkyl);Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl optionally substituted with NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Cisalkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or Cs-gheteroaryl optionally substituted with halo and / or Ci-salkyl; andm is 1-4.

8. The PROTAC or pharmaceutically acceptable salt thereof of claim 7, wherein the warhead is of Formula (W-4-i):Formula (W-4-i)9. A PROTAC of Formula (V):W-L-BmFormula (V);or a pharmaceutically acceptable salt thereof;wherein W is a warhead of Formula (W-5):Formula (W-5)wherein:L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); and / or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=O)OCi-6alkyl;Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -CN; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (i) -Ci-3alkyl, (ii) -Ci-salkylene-Cearyl wherein said Cearyl may be optionally substituted with -Ci-3alkoxy, (iii) -C(=O)OC1-6alkyl, (iv) -C(=O)Ci-3alkyl, (v) -C(=O)C3-8cycloalkyl, (vi) -C(=O)NH-C3-8cycloalkyl, (vii) -C(=O)C3-8heterocycloalkyl wherein said heterocycloalkyl may be optionally substituted with -C(=O)OC1-6alkyl, (viii) -C(=O)OCi-4alkylene-C3-8heterocycloalkyl, (ix) -C(=O)C6aryl wherein said C6aryl may be optionally substituted with halo, (x) -C(=O)Ci-3alkylene-Cearyl, (xi) -C(=O)OC6aryl, (xii) -C(=O)OCi-4alkylene-Cearyl, (xiii) -C(=O)NH-Cearyl, (xiv) -C(=O)-N(Ci-3alkyl)-Cearyl, (xv)-C(=O)NHCi-4alkylene-C6aryl, (xvi) -SO2-Cearyl, (xvii) -C(=O)C5-9heteroaryl, and / or (xviii) Cs-9heteroaryl which may be optionally substituted with halo and / or Ci-3alkyl;L3is absent; (a) -NHC(=O)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=0)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NCi-3alkyl-; (j) -O-;(k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;(o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; (w) -C3-6cycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (x) -NHC(=O)N(Ci-4alkylene-C6aryl)-; and / or (y) -N(Cearyl)-;L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=0)NH2; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; -SO2-; or -C3-6cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); R4aand R4bare each, independently for each occurrence, H; OH; C1-5alkyl; C1-3haloalkyl; or C1-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-iocycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-salkoxy; Ci-shaloalkyl; OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or C6aryl;R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;R8fand R8gare each, independently, H or Ci-3alkyl;m is 1-4;n is 0, 1 or 2;o is 1-8;p is 1-5;q is 1-5;r is 0, 1 or 2;t is 1-5;Z is H or:(I) halo;(II) Ci-2oalkyl;(III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);(IV) -OCi-3alkyl;(V) Ci-shaloalkyl;(VI) Cs-ncycloalkyl which may be optionally substituted with halo; -C(O)OCi-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; and / or Ci-salkyl-Cearyl;(VII) Ci-3alkoxy;(VIII) C6-15aryl which may be optionally substituted with (a) C1-6alkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) C1-5alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-4alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene- heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-6alkenylene-C6aryl, wherein said C6aryl may be optionally substituted with halo; (o)-C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2- ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q)-C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t)-SO2NH2; (u) -OCearyl; (v) Cs-scycloalkyl; (w) -OCi-salkyleneCi-shaloalkyl; (x) -SCi-salkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxyalkyl; (ai) -SO2NHC1-3alkyl; (bi) -SO2C1-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo or Ci-3alkoxy; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-4alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-6cycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with C1-3 alkyl; (ji) -C5-9alkyleneNHC(=O)OC1-4alkyl; (ki) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (li) -C(=O)NHCi-5alkyl; (mi) -N(Ci-3alkyl)(Ci-3alkyl); (ni) NO2; (oi) -C(=O)OH; (pi) -Ci- 3alkylene-N(Ci-3alkyl) (Ci-3alkyl); (qi) -OC1-3alkylene-C6aryl; (ri) -C4-8alkylene-NH2; (si) -OC4-8alkylene-NHC(=O)OC1-4alkyl; (ti) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-4alkyl; (ui) -C2-4hydroxyalkynyl; (vi) heterocycloalkenyl, wherein the heterocycloalkenyl contains 4 to 6 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl; and / or (wi) heterocycloalkyl which may be optionally substituted with -Ci-4alkylene-heterocycloalkyl and / or -Ci-4alkylene-heterocycloalkylene-C(=O)OCi-4alkyl wherein any of said heterocycloalkyl or heterocycloalkylene contain 4 to 6 ring atoms;(IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -Ci-3alkyleneC3-scycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); (m) oxo; (n) -C(=O)OCi-4alkyl; (o) heteroaryl, wherein the heteroarylcontains 5 or 6 ring atoms; (p) -Ci-salkylene-Cearyl, wherein the Cearyl may be optionally substituted with halo; (q) -O-Cearyl; (r) -Ci-3alkyl optionally substituted with OH; (s) -C(=O)Cearyl; (t) C4-8cycloalkyl; (u) -C4-8alkyl optionally substituted with NH2; (v) -C(=O)NH-C6aryl, wherein the C6aryl may be optionally substituted with halo; (w) -C5-9alkylene-NHC(=O)OC1-4alkyl; (x) C1-4hydroxyalkyl; (y) -C2-4hydroxyalkynyl; (z) -C1-4alkylene-O-C1-3alkyl; and / or (ai) -C1-4alkylene-O-C1-3haloalkyl;(X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -C1-5alkyleneC6aryl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; (1)-NHC1-3alkylene-C1-3haloalkyl; (m) C6aryl optionally substituted with halo; (n) -C(=O)-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and / or (o) -SO2C1-3alkyl;(XI) C15-19cycloalkenyl which may be optionally substituted with oxo and / or C1-3alkyl;(XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9;(XIII) -C(=O)OH; orR9is -C1-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;L is a linker; andBm is a moiety that binds to a target protein.

10. The PROTAC or pharmaceutically acceptable salt thereof of claim 9, wherein the warhead is of Formula (W-6):Formula (W-6)or a pharmaceutically acceptable salt thereof; wherein Z is Cearyl which may be optionally substituted with halo; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-3alkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl.

11. The PROTAC or pharmaceutically acceptable salt thereof of claim 9 or 10, wherein Zwherein R18a, R18c, R18dand R18eare each, independently, (a) H; (b) Ci-ealkyl; (c) -OH; (d) -CN; (e) -NH2; (f) halo; (g) Ci-salkoxy; (h) Ci-3haloalkyl; (i) -OCi-3haloalkyl; (j) -C(=O)OCi-3alkyl; (k) -NHC(=O)OCi-8alkyl; (1) -C(=O)NH2; or (m) -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andp is 1-5.

12. The PROTAC or pharmaceutically acceptable salt thereof of claim 9 or 10, wherein Zwherein R119, R120and R121are each, independently H, Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-5alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9; or R119and R120together with the carbon atoms to which they are attached, join to form Cearyl which may be optionally substituted with Ci-ealkyl,-OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andp is 1-5.

13. The PROTAC or pharmaceutically acceptable salt thereof of claim 12, wherein Z is14. The PROTAC or pharmaceutically acceptable salt thereof of claim 9, wherein the warhead is of Formula (W-7):Formula (W-7)wherein:R7a, R7b, R7cand R7dare each, independently, H, OH, C1-3alkyl or C1-3alkoxy;L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, and / or -NHC(=O)-Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or C 1-3 alkoxy;L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; -Cs-ecycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;Z is -NH2; Ci-salkyl; Ci-3haloalkyl; Ci-3alkoxy; Cearyl optionally substituted with (i) OH, (ii) halo, (iii) -C2-ealkylene-Cearyl, (iv) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (v) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (vi) -Cs-9alkylene-NH2, and / or (vii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-salkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; heteroaryl wherein the heteroaryl contains 5 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-3alkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; Ce-iocycloalkyl optionally substituted with halo; or heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-3alkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl;m is 1-2;n is 0 or 1;o is 1-8; andr is 0-2.

15. The PROTAC or pharmaceutically acceptable salt thereof of claim 14, wherein L2 is -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form C3-4cycloalkyl, azetidinyl or piperidinyl, wherein said azetidinyl or piperidinyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-4alkyl, -C(=O)Me, -C(=O)Cearyl, -C(=O)CH2Cearyl, -CPfcCearyl, -C(=O)NHCearyl, and / or -NHC(=O)Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or -OMe.

16. The PROTAC or pharmaceutically acceptable salt thereof of claim 14 or 15, wherein Z is phenyl, 5-10 membered heteroaryl or 5-6 membered heterocycloalkyl; wherein said phenyl may be optionally substituted with (i) halo, (ii) -Cs-salkylene-Cearyl, (iii) -Ce 8alkyleneNHC(=O)OCi-4alkyl, (iv) 6-membered heterocycloalkyl, (v) -Ce-salkylene-NTfc, and / or (vi) 5-6-membered heteroaryl which may be optionally substituted with Ci-3alkyl, -OCTfcCearyl, and / or 6-membered heterocycloalkyl which may be optionally substituted with Ci-3alkyl; wherein said 5-10 membered heteroaryl or 5-6 membered heterocycloalkyl may be optionally substituted with (i) OH, (ii) halo, (iii) Ci-3alkyl, (iv) -CH2OH, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -C^Cearyl, (ix) -Ce-salkylene-NTH, (x) pyridinyl, (xi) 5-6-membered heterocycloalkyl, (xii) cyclohexyl, (xiii) -(CH2)2OMe, and / or (xiv) -(CH2)2CF3.

17. The PROTAC or pharmaceutically acceptable salt thereof of claim 9, wherein the warhead is of Formula (W-8):Formula (W-8)or a pharmaceutically acceptable salt thereof; wherein:L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Cisalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-salkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;L4 is absent, or -C 1-3 alkylene-;Z is Ce-ioaryl which may be optionally substituted with halo, Ci-3alkyl, and / or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-salkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;n is 0 or 1; andm is 1-2.

18. The PROTAC or pharmaceutically acceptable salt thereof of claim 17, wherein L2 is -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form azetidinyl, tetrahydropyranyl or pyrrolidinyl, wherein said azetidinyl may be optionally substituted with -C(=O)OCi-4alkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)CH2C6aryl, -CH2C6aryl, -C(=O)NHC6aryl, -C(=O)NHCH2C6aryl, -NHC(=O)C6aryl, -C(=O)C5-ecycloalkyl, -C(=O)-pyridinyl, and / or -C(=O)OCH2-tetrahydropyranyl; wherein any of said Cearyl may be optionally substituted with halo or -OMe, and any of said tetrahydropyranyl or pyrrolidinyl may be optionally substituted with -C(=O)Me.

19. The PROTAC or pharmaceutically acceptable salt thereof of claim 17 or 18, wherein Z is phenyl, napthyl, 6-10-membered heteroaryl, or 5-6-membered heterocycloalkyl; wherein said phenyl or napthyl may be optionally substituted with halo, Ci-3alkyl and / or pyrrolyl; wherein said 6-10-membered heteroaryl may be optionally substituted with Ci-3alkyl, oxo, Cearyl and / or -CFfcCearyl; and wherein said 5-6-membered heterocycloalkenyl may be optionally substituted with oxo, Cearyl and / or -CFfcCearyl.

20. The PROTAC or pharmaceutically acceptable salt thereof of claim 9, wherein the warhead is of Formula (W-9):Formula (W-9)or a pharmaceutically acceptable salt thereof; wherein:L2 is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci- 3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Cisalkyl;L3is absent, -NHC(=O)- or -C(=O)NH-;Z is (i) Ce-ioaryl which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, and / or -C(=0)NH2; (ii) heteroaryl, wherein said heteroaryl contains 5 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with halo, Ci-salkyl, and / or oxo; (iii) heterocycloalkyl, wherein said heterocycloalkyl contains 5 to 10 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with halo, Ci-ialkyl, and / or oxo; or (iv) heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 10 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with halo, Ci-salkyl, and / or oxo; m is 1-3; andn is 0 or 1.

21. The PROTAC or pharmaceutically acceptable salt thereof of claim 20, wherein Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci.3alkyl)(Ci.3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=0)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-3alkyl.

22. The PROTAC or pharmaceutically acceptable salt thereof of claim 20 or 21, wherein L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-salkyl.

23. The PROTAC or pharmaceutically acceptable salt thereof of claim 9, wherein the warhead is of Formula (W-10):or a pharmaceutically acceptable salt thereof; wherein:Z is phenyl or 6-10 membered heteroaryl, wherein said phenyl or 6-10 membered heteroaryl may be optionally substituted with halo, phenyl, -[O(CH2)2]u-NH2, Ci-ioalkyl which may be optionally substituted with OH and / or NH2, C2-salkynyl which may be optionally substituted with OH and / or NH2, C2-salkenyl which may be optionally substituted with OH and / or NH2, 5-7 membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl, wherein said 5-7 membered heterocycloalkyl or 5-7 membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-8alkyl and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl;o is 0-3; andu is 1-5.

24. The PROTAC or pharmaceutically acceptable salt thereof of claim 23, wherein Z is phenyl, pyridinyl, or indolyl, wherein said phenyl or pyridinyl may be optionally substituted with halo, phenyl, -[O(CH2)2]2-NH2, Ci-?alkyl which may be optionallysubstituted with OH and / or NH2, C2-4alkynyl which may be optionally substituted with OH, 6-membered heterocycloalkyl, or 6-membered heterocycloalkenyl, wherein said 6-membered heterocycloalkyl or 6-membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl and / or -CH2-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-4alkyl; ando is 0-3.

25. The PROTAC or pharmaceutically acceptable salt thereof of any of claims 9-24, wherein the linker is attached to the warhead through any of Z, L4, L3, L2, Li, or the isoquinoline amine.

26. The PROTAC or pharmaceutically acceptable salt thereof of claim 1, wherein the PROTAC is of Formula (Ilb-ii):or a pharmaceutically acceptable salt thereof, wherein:L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); or-heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-salkyl, Ci-salkoxy; Ci-shaloalkyl, OCi-shaloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-salkyl); -Ci-salkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-salkyl; or Rlaand Rlb, togetherwith the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, or Cs-9heteroaryl which may be optionally substituted with halo or Ci-3alkyl;L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;(k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;(o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -Cs-ecycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl); -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -Cs-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-3haloalkyl; or Ci-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;R8Cand R8dare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of R1aor R1b, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;R8fand R8gare each, independently H; or Ci-3alkyl;L5 is, independently for each occurrence, (a) -Cs-ncycloalkylene- which may be optionally substituted with Ra; (b) -Ce- narylene- which may be optionally substituted with Ra;(c) -heterocycloalkylene-, wherein said heterocycloalkylene contains 4 to 12 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with Ra;(d) -heteroarylene-, wherein said heteroarylene contains 5 to 12 ring atoms, and wherein said heteroarylene may be optionally substituted with 1-3 Ra; (e) -Ci-salkylene- which may be optionally substituted with Rc; (f) -C2-ioalkenylene- which may be optionally substituted with Rc; (g) -C2-ioalkynylene- which may be optionally substituted with Rc;(h) -(OCH2CH2)W-; (i) -(OCH2CH2CH2)X-; 0) -C(=O), (k) -C(=O)O-, (1) -O-, (m) -N(Rb)-, (n) -S-, (o) -C(=S)-, (p) -C(=S)O-, (q) -SO2-, (r) -SO2NH-, (s) -C(=O)N(Rb)-, (t) -C=N-, (u) -OC(=O)N(Rb)-, (v) -OC(=O)O-; (w) -N(Rb)C(=O)-; or (x) -NH-;Rais, independently for each occurrence, (a) oxo; (b) halo; (c) -NO2; (d) CN; (e) C1-6 alkyl; (f) C2-ealkenyl; (g) C2-ealkynyl; (h) Cs-iscycloalkyl, (i) Ci-shaloalkyl; (j) Ce-naryl; (k) heteroaryl, wherein said heteroaryl contains 5 to 12 ring atoms; (1) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 12 ring atoms; (m) -O-Rb; (n) -C(=O)-Rb; (o) -C(=O)O-Rb; (p) -C(=O)N(Rb)(Rb); (q) -N(Rb)(Rb); (r) -N(Rb)C(=O)Rb; (s) -N(Rb)C(=O)ORb;(t) -N(Rb)C(=O)N(Rb)(Rb); (u) -N(Rb)SO2(Rb); (v) -NRbSO2N(Rb)(Rb);(w) -N(Rb)SO2O(Rb); (x) -OC(=O)Rb; (y) -OC(=O)N(Rb)(Rb), (z) -Si(Rb)3, (ai)-SRb, (bi) -S(=O)Rb, (ci) -S(=O)NHRb, (di) -SO2Rbor (ei) -SO2N(Rb)(Rb); wherein any of said Ci-ealkyl, C2-ealkenyl, C2-ealkynyl, Cs-iscycloalkyl, Ci-shaloalkyl, Ce-naryl, heteroaryl,wherein said heteroaryl contains 5 to 12 ring atoms, or heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 12 ring atoms may be optionally substituted with Rc;Rbis, independently for each occurrence, hydrogen or Ci-ealkyl;Rcis, independently for each occurrence, (a) halo; (b) oxo; (c) -CN; (d) -OH; (e) Ci-ealkyl optionally substituted with halo; (f) C3-8 cycloalkyl; or (g) -OCi-ealkyl optionally substituted with halo;Bm is a moiety that binds to a target protein;n is 0, 1 or 2;r is 0, 1 or 2;v is 0-8;w is 1-6; andx is 1-6.

27. The PROTAC or pharmaceutically acceptable salt thereof of claim 26, wherein the PROTAC is of Formula (Ild-ii):Formula (Ild-ii)or a pharmaceutically acceptable salt thereof.

28. A compound of Formula (1):Formula (1)or a pharmaceutically acceptable salt thereof;wherein:Li is -C(=O)-;L2 is absent; -(CR1aR1b)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, NH(C1-3alkyl), or -N(C1-3alkyl)(C1-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy, C1-3haloalkyl, -OC1-3haloalkyl, NH(C1-3alkyl), and / or -N(C1-3alkyl)(C1-3alkyl);Rlaand Rlbare each, independently for each occurrence, H; Ci-3alkyl; Ci-shydroxyalkyl; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)OC6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci-3alkyleneC6aryl, -C(=O)NH-Cearyl, -NHC(=O)-C6aryl, -C(=O)C4-8cycloalkyl, -C(=O)NH-Ci-3alkylene-C6aryl, -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo or Ci-3alkyl, wherein any of said Cearyl may be optionally substituted with halo and / or C 1-3 alkoxy;L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NCi-salkyl-; (j) -O-;(k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;(o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; or (w) -Cs-ecycloalkylene- which may be optionallysubstituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -C3-ecycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, and / or oxo;R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-3haloalkyl; or Ci-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;R8fand R8gare each, independently H or Ci-3alkyl;m is 1-4;n is 1;o is 1-8;p is 1-5;q is 1-5;r is 0, 1 or 2;t is 1-5;Z is:(I) halo;(II) Ci-2oalkyl;(III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);(IV) -OCi-3alkyl;(V) Ci-shaloalkyl;(VI) C3-12cycloalkyl which may be optionally substituted with halo; -C(O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;(VII) Ci-3alkoxy;(VIII) C6-15aryl which may be optionally substituted with (a) C1-10alkyl which may be optionally substituted with OH and / or NH2; (b) -OH; (c) -CN; (d) -NH2; (e) halo on 1, 3 or 4 atoms of each ring; (f) C1-5alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2.6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (o) -C2. ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2. ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-ealkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OC6aryl; (v) C3. scycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl, oxo, -C(=O)OCi-8alkyl, and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2Ci-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-9alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-ecycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (ji) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ki) -C(=O)NHC1-5alkyl; (li) -N(Ci-3alkyl)(Ci-3alkyl); (mi) NO2; (ni) C2-salkynyl which may be optionally substituted with OH and / or NH2; (oi) C2-salkenyl which may be optionally substituted with OH and / or NH2; or (pi) -Cs-9alkylene-NH2;(IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O- heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo; (f) -C1-5alkyleneC3-8cycloalkyl; (g) - NHC(=O)Ci-3alkyl; (h) Ci-shaloalkyl; (i) C1-5alkoxy; (j) -Ci-3alkylene-O-Ci-3alkylene- Si(Ci-3alkyl)3; (k) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl); (1) -Ci- 3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl); (m) oxo; (n) -OCi- salkyleneCearyl; (o) OH; (p) Ci-3hydroxyalkyl; (q) -OCearyl; (r) -Ci-salkylene-Cearyl; (s) -Ci-3alkylene-O-Ci-3alkyl; or (t) Ci-4haloalkoxy;(X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -C1-5alkyleneC6aryl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) - C(=O)Ci-6alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; (1) -NHCi- 3alkylene-Ci-3haloalkyl; (m) oxo; (n) -OCearyl; (o) -Cs-9alkylene-NH2; (p) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms; (q) Cs- 7cycloalkyl; (r) -Ci-3alkylene-O-Ci-3alkyl; (s) Ci-4haloalkoxy; and / or (t) Cearyl;(XI) C15-19cycloalkenyl which may be optionally substituted with oxo and / or C1-3alkyl; or(XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9; andR9is NH2, -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=0)NH2;wherein when Li is -C(=O)-, L2 is -(CRlaRlb)m- and m is 1, then:(i) L3, if present, cannot be -NH(C=O)-; (ii) L4 cannot be -NHC(=O)- if L3 is absent; and (iii) Z cannot be NH2 if L3 and L4 are absent.

29. The compound or pharmaceutically acceptable salt thereof of claim 28, wherein: Li is -C(=O)-;L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl,NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);Rlaand Rlbare each, independently for each occurrence, H; Ci-shydroxyalkyl;-Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy; Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-salkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or Cs-gheteroaryl which may be optionally substituted with halo and / or Cisalkyl;L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NCs-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NCi-salkyl-; (j) -O-;(k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;(o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-salkyl), and / or -N(Ci-salkyl)(Ci-salkyl);(p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-salkyl-; or (w) -Cs-ecycloalkylene- which may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, NH(Ci-salkyl), and / or -N(Ci-salkyl)(Ci-salkyl);L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, NH(Ci-salkyl), and / or -N(Ci-salkyl)(Ci-salkyl); -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; or -Cs-ecycloalkylene-, wherein thecycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl);R4aand R4bare each, independently for each occurrence, H; Ci-salkyl; Ci-3haloalkyl; or Ci-3alkyl-heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form Cs-iocycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;R8fand R8gare each, independently H;m is 1-4;n is 1;o is 1-8;p is 1-5;q is 1-5;r is 0, 1 or 2;t is 1-5;Z is:(I) halo;(II) Ci-2oalkyl;(III) -NH2; -NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);(IV) -OCi-3alkyl;(V) Ci-shaloalkyl;(VI) Cs-ncycloalkyl which may be optionally substituted with halo; -C(O)OCi-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; and / or Ci-salkyl-Cearyl;(VII) Ci-3alkoxy;(VIII) Ce-isaryl which may be optionally substituted with (a) Ci-ealkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo on 1, 3 or 4 atoms of each ring; (f) Ci-salkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-3alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-6alkylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-ealkenylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (o) -C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2-6alkynylene-C6aryl, wherein said C6aryl may be optionally substituted with halo; (q) -C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (s) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OCearyl; (v) C3-8cycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxyalkyl; (ai) -SO2NHCi-3alkyl; (bi) -SO2C1-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -C1-4alkyleneNHC(=O)OC1-6alkyl; (gi) -NHC6aryl; (hi) -OC3-ecycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (ji) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (ki) -C(=O)NHCi-5alkyl; (li) -N(Ci-3alkyl)(Ci-3alkyl); and / or (mi) NO2;(IX) heteroaryl, wherein the heteroaryl contains 4 to 15 ring atoms, and wherein said heteroaryl may be optionally substituted with (a) halo; (b) Ci-3alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo; (f) -Ci-3alkyleneC3-5cycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-5alkoxy; (j) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)3; (k) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)2(Ci-3alkyl); and / or (1) -Ci-3alkylene-O-Ci-3alkylene-Si(Ci-3alkyl)(Ci-3alkyl)(Ci-3alkyl);(X) heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 15 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (a) -Ci-3alkyleneCearyl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h)-C(=O)OC1-6alkyl; (i) Ci-shaloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; and / or (1) - NHCi-3alkylene-Ci-3haloalkyl;(XI) C15-19cycloalkenyl which may be optionally substituted with oxo and / or C1-3alkyl; or(XII) heterocycloalkenyl containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or - (OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andwherein when Li is -C(=O)-, L2 is -(CRlaRlb)m- and m is 1, then:(i) L3, if present, cannot be -NH(C=O)-; (ii) L4 cannot be -NHC(=O)- if L3 is absent; and (iii) Z cannot be NH2 if L3 and L4 are absent.

30. The compound or pharmaceutically acceptable salt thereof of claim 28 or 29, wherein the compound is of Formula (W-6):Formula (W-6)or a pharmaceutically acceptable salt thereof; wherein Z is Cearyl which may be optionally substituted with halo; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-salkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-salkyleneCearyl.

31. The compound or pharmaceutically acceptable salt thereof of claim 30, wherein Z iswherein R18a, R18c, R18dand R18eare each, independently, (a) H; (b) Ci-ealkyl; (c) -OH; (d) -CN; (e) -NH2; (f) halo; (g) Ci-salkoxy; (h) Ci-3haloalkyl; (i) -OCi-3haloalkyl; (j) -C(=O)OCi-3alkyl; (k) -NHC(=O)OCi-8alkyl; (1) -C(=O)NH2; or (m) -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andp is 1-5.

32. The compound or pharmaceutically acceptable salt thereof of claim 30, wherein Z iswherein R119, R120and R121are each, independently H, Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-5alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9; or R119and R120together with the carbon atoms to which they are attached, join to form Cearyl which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andp is 1-5.

33. The compound or pharmaceutically acceptable salt thereof of claim 32, wherein Z is34. The compound or pharmaceutically acceptable salt thereof of claim 28 or 29, wherein the compound is of Formula (W-7):Formula (W-7)or pharmaceutically acceptable salt thereof, wherein:R7aR7bR7CancjR7dare each, in(iepen(ienly3H, OH, Ci-3alkyl or Ci-3alkoxy;L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci.3alkyl)C(=O)Ci.3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl,-C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci- salkyleneCearyl, -C(=O)NH-Cearyl, and / or -NHC(=O)-Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; -Cs-ecycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;Z is -NH2; Ci-salkyl; Ci-3haloalkyl; Ci-3alkoxy; Cearyl optionally substituted with (i) OH, (ii) halo, (iii) -C2-ealkylene-Cearyl, (iv) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (v) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (vi) -Cs-9alkylene-NH2, and / or (vii)heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-salkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; heteroaryl wherein the heteroaryl contains 5 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-shydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; Ce-iocycloalkyl optionally substituted with halo; heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl;m is 1-2;n is 0 or 1;o is 1-8; andr is 0-2.

35. The compound or pharmaceutically acceptable salt thereof of any of claims 28-34, wherein L2 is -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form C3-4cycloalkyl, azetidinyl or piperidinyl, wherein said azetidinyl or piperidinyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-4alkyl, -C(=O)Me, -C(=O)Cearyl, -C(=O)CH2Cearyl, -C^Cearyl, -C(=O)NHCearyl, and / or -NHC(=O)Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or -OMe.

36. The compound or pharmaceutically acceptable salt thereof of any of claims 28-35, wherein Z is phenyl, 5-10 membered heteroaryl or 5-6 membered heterocycloalkyl; wherein said phenyl may be optionally substituted with (i) halo, (ii) -Cs-salkylene-Cearyl, (iii) -Ce 8alkyleneNHC(=O)OCi-4alkyl, (iv) 6-membered heterocycloalkyl, (v) -Ce-salkylene-Nkfc, and / or (vi) 5-6-membered heteroaryl which may be optionally substituted with Ci-3alkyl, -OCthCearyl, and / or 6-membered heterocycloalkyl which may be optionally substituted with Ci-3alkyl; wherein said 5-10 membered heteroaryl or 5-6 membered heterocycloalkyl may be optionally substituted with (i) OH, (ii) halo, (iii) Ci-3alkyl, (iv) -CH2OH, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -C^Cearyl, (ix) -Ce-8alkylene-NH2, (x) pyridinyl, (xi) 5-6-membered heterocycloalkyl, (xii) cyclohexyl, (xiii) -(CH2)2OMe, and / or (xiv) -(CH2)2CF3.

37. The compound or pharmaceutically acceptable salt thereof of claim 28 or 29, wherein the compound is of Formula (W-8):Formula (W-8)or a pharmaceutically acceptable salt thereof, wherein:L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Cisalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-salkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-salkoxy;L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;L4 is absent, or -C 1-3 alkylene-;Z is Ce-ioaryl which may be optionally substituted with halo, Ci-3alkyl, or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-salkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;n is 0 or 1; andm is 1-2.

38. The compound or pharmaceutically acceptable salt thereof of any of claims 28-37, wherein L2 is -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form azetidinyl, tetrahydropyranyl or pyrrolidinyl, wherein said azetidinyl may be optionally substituted with -C(=O)OCi-4alkyl, -C(=O)Cearyl, -C(=O)OC6aryl, -C(=O)CH2C6aryl, -CH2C6aryl, -C(=O)NHC6aryl, -C(=O)NHCH2C6aryl, -NHC(=O)Cearyl, -C(=O)C5-ecycloalkyl, -C(=O)-pyridinyl, and / or -C(=O)OCH2-tetrahydropyranyl; wherein any of said Cearyl may be optionally substituted with halo or -OMe, and any of said tetrahydropyranyl or pyrrolidinyl may be optionally substituted with -C(=O)Me.

39. The compound or pharmaceutically acceptable salt thereof of any of claims 28-38, wherein Z is phenyl, napthyl, 6-10-membered heteroaryl, or 5-6-membered heterocycloalkyl; wherein said phenyl or napthyl may be optionally substituted with halo, Ci-3alkyl and / or pyrrolyl; wherein said 6-10-membered heteroaryl may be optionally substituted with Cisalkyl, oxo, Cearyl and / or -CFhCearyl; and wherein said 5-6-membered heterocycloalkenyl may be optionally substituted with oxo, Cearyl and / or -CJbCearyl.

40. The compound or pharmaceutically acceptable salt thereof of claim 28 or 29, wherein the compound is of Formula (W-9):Formula (W-9)or a pharmaceutically acceptable salt thereof, wherein:L2 is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci- 3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Cisalkyl;L3is absent, -NHC(=O)- or -C(=O)NH-;Z is (i) Ce-ioaryl which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-shaloalkyl, -OCi-shaloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, and / or -C(=O)NH2;(ii) heteroaryl, wherein said heteroaryl contains 5 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with halo, Ci-salkyl, and / or oxo; (iii) heterocycloalkyl, wherein said heterocycloalkyl contains 5 to 10 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with halo, Ci-ialkyl, and / or oxo; or (iv) heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 10 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with halo, Ci-salkyl, and / or oxo; m is 1-3; andn is 0 or 1.

41. The compound or pharmaceutically acceptable salt thereof of any of claims 28-40, wherein Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci.3alkyl)(Ci.3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci.3alkyl)C(=O)Ci.3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-3alkyl.

42. The compound or pharmaceutically acceptable salt thereof of any of claims 28-41, wherein L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-salkyl.

43. The compound or pharmaceutically acceptable salt thereof of claim 28 or 29, wherein the compound is of Formula (W-10):Formula (W-10)or a pharmaceutically acceptable salt thereof, wherein:Z is phenyl or 6-10 membered heteroaryl, wherein said phenyl or 6-10 membered heteroaryl may be optionally substituted with halo, phenyl, -[O(CH2)2]u-NH2, Ci-ioalkyl which may be optionally substituted with OH and / or NH2, C2-salkynyl which may be optionally substituted with OH and / or NH2, C2-salkenyl which may be optionally substituted with OH and / or NH2, 5-7 membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl, wherein said 5-7 membered heterocycloalkyl or 5-7 membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-8alkyl and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl;o is 0-3; andu is 1-5.

44. The compound or pharmaceutically acceptable salt thereof of any of claims 28-43, wherein Z is phenyl, pyridinyl, or indolyl, wherein said phenyl or pyridinyl may be optionally substituted with halo, phenyl, -[O(CH2)2]2-NH2, Ci-?alkyl which may be optionally substituted with OH and / or NH2, C2-4alkynyl which may be optionally substituted with OH, 6-membered heterocycloalkyl, or 6-membered heterocycloalkenyl, wherein said 6-membered heterocycloalkyl or 6-membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl and / or -CH2-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-4alkyl; ando is 0-3.

45. A synthetic intermediate of Formula (W-6-Int):Formula (W-6-Int)or a pharmaceutically acceptable salt thereof; wherein:Li is -C(=O)-;L2, L3, L4 are as defined in any of claims 28-40; andZ is Cearyl; 6-10 membered heteroaryl; 6-10 membered heteroaryl-Cearyl; 6-10 membered heteroaryl-Ci-salkyleneCearyl; 5-6 membered heterocycloalkyl, 5-6 membered heterocycloalkenyl-Cearyl; or 5-6 membered heterocycloalkenyl-Ci-salkyleneCearyl; wherein any of said Cearyl, 6-10 membered heteroaryl, 6-10 membered heteroaryl-Cearyl, 6-10 membered heteroaryl-Ci-salkyleneCearyl, 5-6 membered heterocycloalkenyl, 5-6 membered heterocycloalkenyl-Cearyl, or 5-6 membered heterocycloalkenyl-Ci-salkyleneCearyl may be optionally substituted with Ci-3alkyl, oxo, and / or one three or four reactive groups, for example -NH2, -CN, -C(=O)OH, - C(=0)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;n is 1; andu is 1-5.

46. The synthetic intermediate or pharmaceutically acceptable salt thereof of claim 45, wherein the reactive group is independently selected from -NH2, -CN, -C(=O)OH, -C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2.

47. The synthetic intermediate or pharmaceutically acceptable salt thereof of claim 45 or46, whereinwhich may be optionallysubstituted with Ci-3alkyl, oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, - C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2.

48. A synthetic intermediate of Formula (W-7-Int):Formula (W-7-Int)or pharmaceutically acceptable salt thereof, wherein:R7aR7bR7CancjR7dare each, in(iepen(ienly3H, OH, Ci-3alkyl or Ci-3alkoxy;L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci.3alkyl)C(=O)Ci.3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl,-C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci- salkyleneCearyl, -C(=O)NH-Cearyl, and / or -NHC(=O)-Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; -Cs-ecycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;Z is -NH2; Ci-salkyl; Ci-shaloalkyl; Ci-3alkoxy; Cearyl optionally substituted with (i) OH, (ii) -C2-6alkylene-Cearyl, (iii) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (iv) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (v) -Cs-9alkylene-NH2, and / or (vi) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-salkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; heteroaryl wherein the heteroaryl contains 5 to 12 ring atoms, and wherein said heteroaryl may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Cishy droxy alkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; Ce-locycloalkyl optionally substituted with halo; or heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-shydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-salkylene-O-Ci-salkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl;and wherein, for Z, any of said aryl, alkylene, alkyl, heterocycloalkyl, heteroaryl, heterocycloalkyl, hydroxyalkyl, cycloalkyl or haloalkoxy may be optionally substituted with one, three or four reactive groups, for example -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2;m is 1-2;n is 1;o is 1-8;r is 0-2; andu is 1-5.

49. The synthetic intermediate of claim 48, wherein the reactive group is independently selected from -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2.

50. A synthetic intermediate of Formula (W-8-Int):Formula (W-8-Int)or a pharmaceutically acceptable salt thereof; wherein:L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Cisalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-salkyl, -C(=O)Cearyl, -C(=O)OCearyl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains 5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-salkoxy;L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;L4 is absent, or -C 1-3 alkylene-;Z is Ce-ioaryl which may be optionally substituted with Ci-salkyl, and / or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-3alkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;and wherein, for Z, any of said aryl, alkyl, heteroaryl, alkylene or heterocycloalkenyl may be optionally substituted with one three or four reactive groups, for example, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]u-NH2;n is 1;m is 1-2; andu is 1-5.

51. The synthetic intermediate of claim 50, wherein the reactive group is independently selected from -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, and / or -[O(CH2)2]U-NH2.

52. A synthetic intermediate of Formula (W-9-Int):Formula (W-9-Int)or a pharmaceutically acceptable salt thereof, wherein:L2is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-6cycloalkyl, wherein said C3-6cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-3alkyl;L3is absent, -NHC(=O)- or -C(=O)NH-;Z is Ce-ioaryl, heteroaryl, wherein said heteroaryl contains 5 to 10 ring atoms, heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 10 ring atoms, or heterocycloalkenyl, wherein said heterocycloalkenyl contains 4 to 10 ring atoms wherein said Ce-ioaryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl may be optionally substituted with oxo, phenyl, and / or one, three or four reactive groups, for example, -NH2, Ci-9alkylene-NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]U-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2; m is 1-3;n is 1; andu is 1-5.

53. The synthetic intermediate of claim 52, wherein the reactive group is independently selected from oxo, -NH2, Ci-9alkylene-NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, -[O(CH2)2]U-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2.

54. A synthetic intermediate of Formula (W-10-Int):Formula (W-10-Int)or a pharmaceutically acceptable salt thereof, wherein:Z is phenyl, 6-10 membered heteroaryl, Ci-ioalkyl, C2-salkynyl, C2-5alkenyl, 5-7 membered heterocycloalkyl, 5-7 membered heterocycloalkenyl, 5-7 membered heterocycloalkyl-Ci-3alkylene-6-membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl-Ci-3alkylene-6-membered heterocycloalkyl;wherein said phenyl, 6-10 membered heteroaryl, Ci-ioalkyl, C2-salkynyl, C2-5alkenyl,5-7 membered heterocycloalkyl, 5-7 membered heterocycloalkenyl, 5-7 membered heterocycloalkyl-Ci-3alkylene-6-membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl-Ci-3alkylene-6-membered heterocycloalkyl may be optionally substituted with a reactive group, for example, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]U-NH2, or Ci- walkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]U-NH2;o is 0-3; andu is 1-5.

55. The synthetic intermediate of claim 54, wherein the reactive group is -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, -[O(CH2)2]U-NH2, or Ci-ioalkyl optionally substituted with oxo, -NH2, -CN, -C(=O)OH, - C(=O)NH2, -OH, -SH, -N3, -C(=O)H, -C(=O)Ci-3alkyl, -C(=O)halo, -N=C(=O), -N=C(=S), halo, phenyl, and / or -[O(CH2)2]u-NH2.

56. A method of making a PROTAC comprising reacting a warhead of Formula (W-l-ii):Formula (W-l-ii)or a pharmaceutically acceptable salt thereof with a linker and a moiety that binds to a target protein;wherein Ring A is phenyl; or a 5-6 membered heteroaryl ring, wherein 1-4 ring atoms are each independently selected from N, O or S; wherein said phenyl or 5-6 membered heteroaryl ring may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, NH(Ci-3alkyl) and / or -N(Ci-3alkyl)(Ci-3alkyl);n is 0 or 1;R8aand R8bare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), or Cearyl;R8Cand R8dare each, independently, H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl);R8eis H, OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or-N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;R8fand R8gare each, independently H; or Ci-3alkyl; andRGforms a reactive group with the warhead that forms a linkage with the linker.

57. The method of claim 56, wherein the warhead is a compound of Formula (W-2-ii):Formula (W-2-ii)or a pharmaceutically acceptable salt thereof; wherein:R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;R8Cand R8dare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); andR8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form Cs-ecycloalkyl.

58. The method of claim 56 or 57, wherein RGis H.

59. The method of claim 56, wherein the warhead is a compound of Formula (W-3-ii):Formula (W-3-ii)or a pharmaceutically acceptable salt thereof; and RGforms a reactive group with -C(=O)-that forms a linkage the linker.

60. The method of claim 59, wherein the warhead is a compound of Formula (W-4-ii):Formula (W-4-ii)or a pharmaceutically acceptable salt thereof; and RGforms a reactive group with -NH- that forms a linkage the linker.

61. A method of making a PROTAC of Formula (V-i):Formula (V-i)comprising reacting a warhead of Formula (W-5) as defined in claim 9, or a reactive derivative thereof, with a linker and a moiety that binds to a target protein, wherein:L1is absent; -CH(C1-3alkyl)-; -C(C1-3alkyl)2-; -CH2-, or -C(=O)-;L2 is absent; -(CRlaRlb)m-; -C3-8cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), or -N(Ci-3alkyl)(Ci-3alkyl); and / or -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 8 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=O)OCi-6alkyl;Rlaand Rlbare each, independently for each occurrence, H; Ci-ioalkyl; Ci-shydroxyalkyl; -CN; -Ci-salkylene-Cearyl, wherein the Cearyl is optionally substituted with OH, NO2, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); -Ci-3alkylene-heteroaryl, wherein the heteroaryl contains 5-10 ring atoms, and wherein said heteroaryl may be optionally substituted with Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-8cycloalkyl, wherein said C3-8cycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci- 3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with (i) -Ci-3alkyl, (ii) -Ci-salkylene-Cearyl wherein said Cearyl may be optionally substituted with -Ci-3alkoxy, (iii) -C(=O)OC1-6alkyl, (iv) -C(=O)Ci-3alkyl, (v) -C(=O)C3-8cycloalkyl, (vi) -C(=O)NH-C3-8cycloalkyl, (vii) -C(=O)C3-8heterocycloalkyl wherein said heterocycloalkyl may be optionally substituted with -C(=O)OC1-6alkyl, (viii) -C(=O)OCi-4alkylene-C3-8heterocycloalkyl, (ix) -C(=O)C6aryl wherein said C6aryl may be optionally substituted with halo, (x) -C(=O)Ci-3alkylene-Cearyl, (xi) -C(=O)OC6aryl, (xii) -C(=O)OCi-4alkylene-Cearyl, (xiii) -C(=O)NH-Cearyl, (xiv) -C(=O)-N(Ci-3alkyl)-Cearyl, (xv) -C(=O)NHCi-4alkylene-Cearyl, (xvi) -SO2-Cearyl, (xvii) -C(=O)C5-9heteroaryl, and / or (xviii) Cs-9heteroaryl which may be optionally substituted with halo and / or Ci-3alkyl;L3is absent; (a) -NHC(=0)NH-; (b) -NCi-5alkylC(=O)NCi-5alkyl-; (c) -NHC(=O)NCi-5alkyl; (d) -NCi-5alkylC(=O)NH-; (e) -NHC(=O)NC3-8cycloalkyl-; (f) -NC3-8cycloalkylC(=O)NH-; (g) -NC3-8cycloalkylC(=O)NC3-8cycloalkyl-; (h) -NH-; (i) -NC1-3alkyl-; (j) -O-;(k) -C(=O)NH-; (1) -C(=O)NCi-3alkyl-; (m) -NHC(=O)-; (n) -NCi-3alkylC(=O)-;(o) -heterocycloalkylene-, wherein the heterocycloalkylene contains 5 to 7 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, C1-3alkyl, C1-3alkoxy; C1-3haloalkyl, OC1-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (p) -C(=O)-; (q) -NHSO2-; (r) -NHC(=O)O-; (s) -SO2-; (t) -OCi-5alkylene-; (u) -NHSO2NH-; (v) -NHSO2NCi-3alkyl-; (w) -Cs-ecycloalkylene- which may be optionallysubstituted with OH, CN, NH2, halo, Ci-salkyl, Ci-3alkoxy, Ci-shaloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); (x) -NHC(=O)N(Ci-4alkylene-C6aryl)-; and / or (y) -N(Cearyl)-;L4 is, independently, for each occurrence, -(CR4aR4b)0-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-shaloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), and / or -C(=0)NH2; -O-; -(CH2CH2O)q-; -NHC(=O)O-; -NHC(=O)-; -(CH2)tO-; -NH-; -C(=O)NH-; -SO2-; or -C3-6cycloalkylene-, wherein the cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), and / or -N(Ci-3alkyl)(Ci-3alkyl); R4aand R4bare each, independently for each occurrence, H; OH; Ci-salkyl; Ci-3haloalkyl; or Ci -3 alkyl -heteroaryl, wherein the heteroaryl contains 6 to 12 ring atoms; or R4aand R4btogether with the carbon atom to which they are attached, form C3-10cycloalkyl, or heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 8 ring atoms;R7aisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7bisH; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R7Cis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or -(OCH2CH2)P-R9;R7dis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); or -N(Ci-3alkyl)(Ci-3alkyl);R8aand R8bare each, independently, H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-shaloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or Cearyl;R8cand R8dare each, independently, H; OH; CN; NH2; halo; C1-3alkyl; C1-3alkoxy; C1-3haloalkyl; OC1-3haloalkyl; NH(C1-3alkyl); -N(C1-3alkyl)(C1-3alkyl); or one of R8cor R8dand one of Rlaor Rlb, together with the carbon atoms to which they are attached, form pyrrolidone, such that Li is -C(=O)-;R8eis H; OH; CN; NH2; halo; Ci-3alkyl; Ci-3alkoxy; Ci-3haloalkyl; OCi-3haloalkyl; NH(Ci-3alkyl); -N(Ci-3alkyl)(Ci-3alkyl); or R8eand one of R8aor R8b, together with the carbon atoms to which they are attached, form C3-6cycloalkyl;R8fand R8gare each, independently, H or Ci-3alkyl;m is 1-4;n is 0, 1 or 2;o is 1-8;p is 1-5;q is 1-5;r is 0, 1 or 2;t is 1-5;Z is absent or:(I) -Ci-2oalkylene-;(II) -NH; or -N(Ci-3alkyl)-;(III) -OCi-salkylene;(IV) -Ci-shaloalkylene-;(V) -C3-11cycloalkylene- which may be optionally substituted with halo; -C(=O)OC1-3alkyl; C1-3alkoxy; C1-3haloalkyl; and / or C1-3alkyl-C6aryl;(VI) -C6-18arylene- which may be optionally substituted with (a) C1-6alkyl; (b) -OH; (c) -CN; (d) -NH2; (e) halo; (f) C1-3alkoxy; (g) Ci-3haloalkyl; (h) -OCi-3haloalkyl; (i) -C(=O)OCi-4alkyl; (j) -NHC(=O)OCi-8alkyl; (k) -C(=O)NH2; (1) -C2-6alkylene-C6aryl, wherein said Cearyl may be optionally substituted with halo; (m) -C2-ealkylene- heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (n) -C2-6alkenylene-C6aryl, wherein said C6aryl may be optionally substituted with halo; (o)-C2-ealkenylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (p) -C2- ealkynylene-Cearyl, wherein said Cearyl may be optionally substituted with halo; (q) -C2-6alkynylene-heteroaryl, wherein the heteroaryl contains 5 to 8 ring atoms; (r) -(OCH2CH2)P-R9; (S) -OC4-8alkylene-NH2; (t) -SO2NH2; (u) -OC6aryl; (v) C3- scycloalkyl; (w) -OCi-3alkyleneCi-3haloalkyl; (x) -SCi-3alkyl; (y) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl and / or oxo; (z) Ci-4hydroxy alkyl; (ai) -SChNHCi-salkyl; (bi) -SO2C1-3alkyl; (ci) -O-heteroaryl, wherein the heteroaryl contains 5 to 6 ring atoms; (di) -OC6aryl, wherein said C6aryl may be optionally substituted with halo or Ci-3alkoxy; (ei) C6aryl, wherein said C6aryl may be optionally substituted with halo; (fi) -Ci-4alkyleneNHC(=O)OCi-ealkyl; (gi) - NHCearyl; (hi) -OC3-6cycloalkyl; (ii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with C1-3 alkyl; (ji) -C5-9alkyleneNHC(=O)OCi-4alkyl; (ki) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 5 to 7 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with Ci-3alkyl; (li) -C(=O)NHCi-salkyl; (mi) -N(Ci-3alkyl)(Ci-3alkyl); (ni) NO2; (oi) -C(=0)0H; (pi) -Ci-3alkylene-N(Ci-3alkyl) (Ci-3alkyl); (qi) -OC1-3alkylene-C6aryl; (ri) -C4-8alkylene-NH2; (si) -OC4-8alkylene-NHC(=O)OC1-4alkyl; (ti) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -C(=O)OCi-4alkyl; (ui) -C2-4hydroxyalkynyl; (vi) heterocycloalkenyl, wherein the heterocycloalkenyl contains 4 to 6 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl; and / or (wi) heterocycloalkyl which may be optionally substituted with -Ci-4alkylene-heterocycloalkyl and / or -Ci-4alkylene-heterocycloalkylene-C(=O)OCi-4alkyl wherein any of said heterocycloalkyls and heterocycloalkylene contain 4 to 6 ring atoms; (VII) -heteroarylene-, wherein the heteroarylene contains 4 to 15 ring atoms, and wherein said heteroarylene may be optionally substituted with (a) halo; (b) C1-4alkyl; (c) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 8 ring atoms; (d) -O-heterocycloalkyl, wherein the heterocycloalkyl contains 3 to 6 ring atoms; (e) Cearyl which may be optionally substituted with halo and / or Ci-3alkyl; (f) -Ci-3alkyleneC3-scycloalkyl; (g) -NHC(=O)Ci-3alkyl; (h) Ci-3haloalkyl; (i) C1-3alkoxy; (j) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)3; (k) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)2(C1-3alkyl); (l) -C1-3alkylene-O-C1-3alkylene-Si(C1-3alkyl)(C1-3alkyl)(C1-3alkyl); (m) oxo; (n) -C(=O)OCi-4alkyl; (o) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (p) -C1-5alkylene-C6aryl, wherein the C6aryl may be optionally substituted with halo; (q) -O-C6aryl; (r) -C1-3alkyl optionally substituted with OH; (s) -C(=O)C6aryl; (t) C4-8cycloalkyl; (u) -C4-8alkyl optionally substituted with NH2; (v) -C(=O)NH-C6aryl, wherein the C6 aryl may be optionally substituted with halo; (w) -C5-9alkylene-NHC(=O)OC1-4alkyl; (x) Ci-4hydroxyalkyl; (y) -C2-4hydroxyalkynyl; (z) -Ci-4alkylene-O-Ci-3alkyl; and / or (ai) -Ci-4alkylene-O-Ci-shaloalkyl;(VIII) -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 15 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with (a) -Ci-salkyleneCearyl; (b) -C(O)NHCi-4alkyl; (c) C1-8alkyl; (d) halo; (e) -OCi-4alkyl; (f) -C(=O)C1-5alkyl; (g) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms; (h) -C(=O)OC1-6alkyl; (i) Ci-3haloalkyl; (j) -Ci-3alkylene-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; (k) -NHC(=O)Ci-4alkyl; (1)-NHCi-3alkylene-Ci-3haloalkyl; (m) Ce aryl optionally substituted with halo; (n)-C(=O)-heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms; and / or (o) -SO2Ci-3alkyl;(IX) -Ci5-i9cycloalkenylene- which may be optionally substituted with oxo and / or Ci- salkyl;(X) heterocycloalkenylene containing 6-10 ring atoms which may be optionally substituted with Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, - OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9; or(XI) -C(=O)O-; andR9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2;L is a linker; andBm is a moiety that binds to a target protein;wherein one of Li, L2, L3, L4 or Z of said warhead is a reactive group that attaches to the linker, or is derivatised to form a reactive group that attaches to the linker.

62. The method of claim 61, wherein the reactive group that attaches to the linker is an amine, nitrile, carboxylic acid, amine, alcohol, thiol, azide, aldehyde, ketone, isocyanate, isothiocyanate, acyl halide, alkyl halide or aryl halide.

63. The method of claim 61 or 62, wherein the reactive group that attaches to the linker is an amine, alcohol, aldehyde, ketone, carboxylic acid, aryl halide or an alkyl halide.

64. The method of any of claims 61-63, wherein the PROTAC is of Formula (V-ii):Formula (V-ii)or a pharmaceutically acceptable salt thereof;the method comprising reacting a warhead of Formula (W-6) as defined in claim 30 or a synthetic intermediate of Formula (W-6-Int) as defined in any of claims 45-47 with a linker (L) and a moiety that binds to a target protein (Bm);wherein Z is Cearyl which may be optionally substituted with halo; heteroaryl, wherein said heteroaryl contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-3alkyleneCearyl; or heterocycloalkenyl, wherein said heterocycloalkenyl contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl.

65. The method of claim 64, whereinwherein R18a, R18c, R18dand R18eare each, independently, (a) H; (b) Ci-ealkyl; (c) -OH; (d) -CN; (e) -NH2; (f) halo; (g) Ci-salkoxy; (h) Ci-3haloalkyl; (i) -OCi-3haloalkyl; (j) -C(=O)OCi-3alkyl; (k) -NHC(=O)OCi-8alkyl; (1) -C(=O)NH2; or (m) -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andp is 1-5.

66. The method of claim 64, whereinwherein R119, R120and R121are each, independently H, Ci-ealkyl, oxo, -OH, -CN, -NH2, halo, Ci-5alkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9; or R119and R120together with the carbon atoms to which they are attached, join to form Cearyl which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, -C(=O)NH2, or -(OCH2CH2)P-R9;R9is -Ci-3alkylene-NH2, -NHC(NH)NH2, or -NHC(=O)NH2; andp is 1-5.

67. The method of claim 66, wherein68. The method of any of claims 61-63, wherein the PROTAC is of Formula (V-iii):Formula (V-iii)or a pharmaceutically acceptable salt thereof;the method comprising reacting a warhead of Formula (W-7) as defined in claim 34 or a synthetic intermediate of Formula (W-7-Int) as defined in claim 48 or 49 with a linker (L) and a moiety that binds to a target protein (Bm);R7aR7bR7CancjR7dare each, in(iepen(ienly3H, OH, Ci-3alkyl or Ci-3alkoxy;L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) C3-scycloalkyl, wherein said Cs-scycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci-3alkyl)(Ci-3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci.3alkyl)C(=O)Ci.3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 8 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl,-C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci- salkyleneCearyl, -C(=O)NH-C6aryl, and / or -NHC(=O)-C6aryl, wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;L3is -C(=O)-, -NHC(=O)-, or -C(=O)NH-;L4 is, independently, for each occurrence, -(CR4aR4b)0-, wherein R4aand R4bare each, independently for each occurrence, H or Ci-3alkyl; -NH(C=O)O-; -heterocycloalkylene-, wherein the heterocycloalkylene contains 3 to 6 ring atoms, and wherein the heterocycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-salkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; -Cs-ecycloalkylene-, wherein said cycloalkylene may be optionally substituted with OH, CN, NH2, halo, Ci-3alkyl, Ci-3alkoxy, Ci-3haloalkyl, OCi-3haloalkyl, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=0)NH2, and / or oxo; or R4aand R4btogether with the carbon atom to which they are attached, form heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms;Z is -NH-; -Ci-salkylene-; -Ci-shaloalkylene-; -Ci-3alkoxylene-; -Cearylene- optionally substituted with (i) OH, (ii) halo, (iii) -C2-6alkylene-Cearyl, (iv) -C5-9alkyleneNHC(=O)O-Ci-4alkyl, (v) heterocycloalkyl, wherein the heterocycloalkyl contains 4 to 6 ring atoms, (vi) -Cs-9alkylene-NH2, and / or (vii) heteroaryl, wherein the heteroaryl contains 5 or 6 ring atoms, and wherein said heteroaryl may be optionally substituted with OH, Ci-3alkyl, -OCi-salkyleneCearyl, and / or heterocycloalkyl containing 4-6 ring atoms, wherein said heterocycloalkyl may be optionally substituted with Ci-4alkyl; -heteroarylene- wherein the heteroarylene contains 5 to 12 ring atoms, and wherein said heteroarylene may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-3hydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkyl contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, and / or (xiv) Ci-4haloalkoxy; -Ce-iocycloalkylene- optionally substituted with halo; -heterocycloalkylene-, wherein said heterocycloalkylene contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Cishy droxy alkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkylene contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-ealkyl; or -heterocycloalkenylene-, wherein said heterocycloalkenylene contains 3 to 8 ring atoms and may be optionally substituted with (i) OH; (ii) halo, (iii) Ci-4alkyl, (iv) Ci-shydroxyalkyl, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) Ci-salkylene-Cearyl, (ix) -Cs-9alkylene-NH2, (x) heteroaryl, wherein said heteroaryl contains 5 to 6 ring atoms, (xi) heterocycloalkyl, wherein said heterocycloalkylene contains 4 to 8 ring atoms, (xii) Cs-7cycloalkyl, (xiii) -Ci-3alkylene-O-Ci-3alkyl, (xiv) Ci-4haloalkoxy, and / or (xv) -C(=O)Ci-6alkyl;m is 1-2;n is 0 or 1;o is 1-8; andr is 0-2.

69. The method of any of claims 61-68, wherein L2 is -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form C3-4cycloalkyl, azetidinyl or piperidinyl, wherein said azetidinyl or piperidinyl may be optionally substitutedwith -Ci-3alkyl, -C(=O)OCi-4alkyl, -C(=O)Me, -C(=O)C6aryl, -C(=O)CH2C6aryl, -CH2C6aryl, -C(=O)NHCearyl, and / or -NHC(=O)Cearyl, wherein any of said Cearyl may be optionally substituted with halo and / or -OMe.

70. The method of any of claims 61-69, wherein Z is phenylene, 5-10 membered heteroarylene or 5-6 membered heterocycloalkenylene; wherein said phenylene may be optionally substituted with (i) halo, (ii) -Cs-salkylene-Cearyl, (iii) -Ce 8alkyleneNHC(=O)OCi-4alkyl, (iv) 6-membered heterocycloalkyl, (v) -Ce-8alkylene-NH2, and / or (vi) 5-6-membered heteroaryl which may be optionally substituted with Ci-3alkyl, -OCH2Cearyl, and / or 6-membered heterocycloalkyl which may be optionally substituted with Ci-3alkyl; wherein said 5-10 membered heteroarylene or 5-6 membered heterocycloalkenylene may be optionally substituted with (i) OH, (ii) halo, (iii) Ci-3alkyl, (iv) -CH2OH, (v) oxo, (vi) Cearyl optionally substituted with halo, (vii) -OCearyl, (viii) -CH2Cearyl, (ix) -Ce-8alkylene-NH2, (x) pyridinyl, (xi) 5-6-membered heterocycloalkyl, (xii) cyclohexyl, (xiii) -(CH2)2OMe, and / or (xiv) -(CH2)2CF3.

71. The method of any of claims 61-63, wherein the PROTAC is of Formula (V-iv):Formula (V-iv)or a pharmaceutically acceptable salt thereof;the method comprising reacting a warhead of Formula (W-8) as defined in claim 37 or a synthetic intermediate of Formula (W-8-Int) as defined in claim 50 or 51 with a linker (L) and a moiety that binds to a target protein (Bm);L2is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Cisalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-salkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-salkyl, -C(=O)C6aryl, -C(=O)OC6aryl, -C(=O)Ci-3alkylene-C6aryl, -Ci-salkyleneCearyl, -C(=O)NH-Cearyl, -C(=O)C4-8cycloalkyl, -C(=O)heteroaryl, wherein said heteroaryl contains5-6 ring atoms, -C(=O)NH-Ci-3alkylene-C6aryl, and / or -C(=O)OCi-3alkylene-heterocyloalkyl, wherein said heterocycloalkyl contains 5 to 7 ring atoms, and wherein any of said Cearyl may be optionally substituted with halo and / or Ci-3alkoxy;L3is -NHSO2-, -NHC(=O)O-, -NHC(=O)NH-, -NHC(=O)- or -C(=O)NH-;L4 is absent, or -C 1-3 alkylene-;Z is -Ce-ioarylene- which may be optionally substituted with halo, Ci-3alkyl, and / or heteroaryl, wherein said heteroaryl contains 5-6 ring atoms; -heteroarylene-, wherein said heteroarylene contains 6-10 ring atoms and is optionally substituted with oxo, Ci-3alkyl, Cearyl, and / or -Ci-3alkyleneCearyl; -heterocycloalkenylene-, wherein said heterocycloalkenylene contains 5 to 6 ring atoms and is optionally substituted with oxo, Cearyl and / or -Ci-3alkyleneCearyl;n is 0 or 1; andm is 1-2.

72. The method of any of claims 61-71, wherein L2 is -CH2-; or -(CRlaRlb)- wherein Rlaand Rlb, together with the carbon atom to which they are attached form azetidinyl, tetrahydropyranyl or pyrrolidinyl, wherein said azetidinyl may be optionally substituted with -C(=O)OCi-4alkyl, -C(=O)C6aryl, -C(=O)OC6aryl, -C(=O)CH2C6aryl, -CH2C6aryl, -C(=O)NHC6aryl, -C(=O)NHCH2C6aryl, -NHC(=O)C6aryl, -C(=O)C5-ecycloalkyl, -C(=O)-pyridinyl, and / or -C(=O)OCH2-tetrahydropyranyl; wherein any of said Cearyl may be optionally substituted with halo and / or -OMe, and any of said tetrahydropyranyl or pyrrolidinyl may be optionally substituted with -C(=O)Me.

73. The method of any of claims 61-63, wherein the PROTAC is of Formula (V-v):Formula (V-v)or a pharmaceutically acceptable salt thereof;the method comprising reacting a warhead of Formula (W-9) as defined in claim 40 or a synthetic intermediate of Formula (W-9-Int) as defined in claim 52 or 53 with a linker (L) and a moiety that binds to a target protein (Bm);L2 is absent or -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci- 3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)C6aryl, and / or heteroaryl, wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or Ci-salkyl;L3is absent, -NHC(=O)- or -C(=O)NH-;Z is (i) Ce-ioarylene which may be optionally substituted with Ci-ealkyl, -OH, -CN, -NH2, halo, Ci-salkoxy, Ci-3haloalkyl, -OCi-3haloalkyl, -C(=O)OCi-3alkyl, -NHC(=O)OCi-8alkyl, and / or -C(=O)NH2; (ii) heteroarylene, wherein said heteroarylene contains 5 to 10 ring atoms, and wherein said heteroaryl may be optionally substituted with halo, Ci-3alkyl, and / or oxo; (iii) heterocycloalkylene, wherein said heterocycloalkylene contains 4 to 10 ring atoms, and wherein said heterocycloalkylene may be optionally substituted with halo, Ci-3alkyl, and / or oxo; or (iv) heterocycloalkenylene, wherein said heterocycloalkenylene contains 5 to 10 ring atoms, and wherein said heterocycloalkenyl may be optionally substituted with halo, Ci-3alkyl, and / or oxo;m is 1-3; andn is 0 or 1.

74. The method of any of claims 61-73, wherein Rlaand Rlb, together with the carbon atom to which they are attached, form (a) Cs-ecycloalkyl, wherein said Cs-ecycloalkyl may be optionally substituted with -NH2, Ci-3alkyl, Ci-3alkoxy, NH(Ci-3alkyl), -N(Ci-3alkyl)(Ci-3alkyl), -C(=O)NH2, -C(=O)NHCi-3alkyl, -C(=O)N(Ci.3alkyl)(Ci.3alkyl), NHC(=O)Ci-3alkyl, and / or N(Ci-3alkyl)C(=O)Ci-3alkyl; or (b) heterocycloalkyl, wherein said heterocycloalkyl contains 3 to 6 ring atoms, and wherein said heterocycloalkyl may be optionally substituted with -Ci-3alkyl, -C(=O)OCi-6alkyl, -C(=O)Ci-3alkyl, -C(=O)Cearyl, and / or heteroaryl,wherein said heteroaryl contains 5 to 9 ring atoms and which may be optionally substituted with halo and / or C 1-3 alkyl.

75. The method of any of claims 61-74, wherein L2 is -(CRlaRlb)m-, wherein Rlaand Rlbare each, independently for each occurrence, H or Ci-3alkyl.

76. The method of any of claims 61-63, wherein the PROTAC is of Formula (V-vi):Formula (V-vi)or a pharmaceutically acceptable salt thereof;the method comprising reacting a warhead of Formula (W-10) as defined in claim 43 or a synthetic intermediate of Formula (W-10-Int) as defined in claim 54 or 55 with a linker (L) and a moiety that binds to a target protein (Bm);Z is phenylene or 6-10 membered heteroarylene, wherein said phenylene or 6-10 membered heteroarylene may be optionally substituted with halo, phenyl, -[O(CH2)2]u-NH2, Ci-ioalkyl which may be optionally substituted with OH and / or NH2, C2-salkynyl which may be optionally substituted with OH and / or NH2, C2-salkenyl which may be optionally substituted with OH and / or NH2, 5-7 membered heterocycloalkyl, or 5-7 membered heterocycloalkenyl, wherein said 5-7 membered heterocycloalkyl or 5-7 membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-8alkyl and / or -Ci-3alkylene-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-8alkyl;o is 0-3; andu is 1-5.

77. The method of any of claims 61-76, wherein Z is phenylene, pyridinylene, or indolylene, wherein said phenylene or pyridinylene may be optionally substituted with halo, phenyl, -[O(CH2)2]2-NH2, Ci-?alkyl which may be optionally substituted with OH and / or NH2, C2-4alkynyl which may be optionally substituted with OH, 6-membered heterocycloalkyl, and / or 6-membered heterocycloalkenyl, wherein said 6-memberedheterocycloalkyl or 6-membered heterocycloalkenyl may be optionally substituted with -C(=O)OCi-4alkyl and / or -CH2-6-membered heterocycloalkyl which may be optionally substituted with -C(=O)OCi-4alkyl; ando is 0-3.

78. The method of any of claims 56-77, comprising a first reaction between the warhead and the linker to form a warhead-linker intermediate, and a second reaction between said warhead-linker intermediate and a moiety that binds to a target protein.

79. The method of any of claims 56-77, comprising a first reaction between the linker and a moiety that binds to a target protein to form a linker-binding moiety intermediate, and a second reaction between said linker-binding moiety intermediate and the warhead.

80. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of any of claims 1-79, wherein n is i.

81. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of any of claims 1-80, wherein R7a, R7b, R7cand R7dare all H.

82. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of any of claims 1-81, wherein R8a, R8b, R8c, R8dand R8eare all H.

83. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of any of claims 1-82, wherein R8fand R8gare both H.

84. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of any of claims 1-83, wherein Ring A is phenyl.

85. The PROTAC or pharmaceutically acceptable salt thereof of any of claims 1-27 or 80-84, or the method of any of claims 56-84, wherein L comprises LA, wherein LA comprises at least one of Li, L2, L3, L4 or Z as defined in any preceding claim.

86. The PROTAC or pharmaceutically acceptable salt thereof of any of claims 1-27 or 80-85, or the method of any of claims 56-85, wherein L consists of LA and / or LB, wherein LBis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR-, -SiR2-, -Si(OH)R-, -Si(OH)2-, -P(O)OR-, -P(O)R-, -P(O)NR2-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2-, -NRS(O)2-, -S(O)2NR-,,each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-7 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur;each R is independently hydrogen, or an optionally substituted group selected from C1-6aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or;two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur, and;each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;wherein at least one of LA or LB is present.

87. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 86, wherein LB is absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-20 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -CHF-, -CF2-, -O-, -NR-, -SiR2- -Si(OH)R-, -Si(OH)2-, -P(O)OR-, -P(O)R-, -P(O)NR2-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2-, -each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfureach R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur, and; each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

88. The PROTAC or pharmaceutically acceptable salt thereof of any of claims 1-27 or 80-84, or the method of any of claims 56-79, wherein L is:-LG-LH-LJ-LK-wherein:LGis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLG-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;LHis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLH-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;LJis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLJ-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;LKis absent or an optionally substituted bivalent, saturated or partially unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 1-2 methylene units of LGare optionally and independently replaced by -CyLK-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or -NRC(O)O-;wherein each R is independently H, or an optionally substituted group selected from C1-6aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from N, O and S, and a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from N, O and S; or two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from N, O and S; andeach of -CyLG-, -CyLH-, -CyLJ-, and -CyLK- is independently -Cyx-;.wherein -Cyx- is an optionally substituted ring selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclylenyl or heterocyclylenyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-9 membered monocyclic or bicyclic heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

89. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 88, wherein LGis -CyLG-, wherein -CyLG- is phenyl or pyridinyl, wherein said phenyl may beoptionally substituted with halo, CN, C1-4 alkyl, C1-4alkoxy, C1-4haloalkyl, C1-4haloalkoxy, and wherein said pyridinyl may be optionally substituted with halo, Ci-4haloalkyl, or Ci-4haloalkoxy, optionally wherein -CyLG-is:wherein R111, R112, R113and R114are each independently selected from H, halo, CN, Ci-4 alkyl, Ci-4alkoxy, Ci-4haloalkyl, or Ci-4haloalkoxy.

90. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 89, wherein R111and R112are each independently selected from H, halo, CN, C1-4 alkyl, C1-4alkoxy, C1-4haloalkyl, or C1-4haloalkoxy; and R113and R114are each independently selected from H, halo, C1-3alkyl, or C1-3haloalkyl.

91. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 88-90, wherein LHis -CyLH-, wherein -CyLH- is a 4 to 12 membered monocyclic, bridged, bicyclic, or bridged bicyclic heterocyclylenyl containing one or two nitrogen ring atoms; or a C3-7carbocyclylenyl; wherein said heterocyclylenyl may be optionally substituted with halo, C1-3 alkyl or oxo.

92. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 91, wherein -CyLH- is:wherein R115, R116, R117and R118are each independently selected from H, halo, C1-3alkyl and oxo.

93. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 92,wherein R115, R116and R118are all H, and R117is H, halo, C1-3alkyl or oxo.

94. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 88-93, wherein LKcomprises:wherein Rlaand Rlbare each independently H, halo, C1-3alkyl, C1-3alkoxy, or C1-3haloalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, join to formcyclopropyl or cyclobutyl; and whereinis the point of attachment to the warhead.

95. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 88-94, wherein LKcomprises:wherein Rlaand Rlbare each independently H, halo, C1-3alkyl, C1-3alkoxy, or C1-3haloalkyl; or Rlaand Rlb, together with the carbon atom to which they are attached, join to formcyclopropyl or cyclobutyl; and whereinis the point of attachment to the warhead.

96. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 94 or 95, wherein Rlaand Rlbare both H.

97. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims85-97, wherein L comprises:, whereinis the point of attachment to the moiety that binds to a target protein.

98. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims85-97, wherein L comprises:; whereinis the point of attachment to the moiety that binds to a target protein andis the point of attachment to the warhead.

99. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims85-98, wherein L is selected fromwherein R111, R112, R113and R114are each independently selected from H, halo, CN, C1-4 alkyl, C1-4alkoxy, C1-4haloalkyl, C1-4haloalkoxy;R115, R116, R117and R118are each independently selected from H, halo, C1-3alkyl and oxo; xs and ys are independently 0-4;LHand LJare each independently absent or a bivalent, saturated or partially unsaturated, straight or branched C1-6hydrocarbon chain, wherein 1-3 methylene units are optionally and independently replaced by -phenylene-, -O-, -NR-, -S-, -OC(O)-, -C(O)O-, - C(O)-, -S(O)-, -S(O)2, -NRS(O)2, -S(O)2NR, -NRC(O)-, -C(O)NR-, -OC(O)NR-, or - NRC(O)O-; wherein each R is independently H, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from N, O and S, or a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from N, O and S; andwherein isthe point of attachment to the warhead.

100. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein L is absent and at least one of Li, L2, L3, L4 and Z are present.

101. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 100, wherein Li is present.

102. The PROTAC, pharmaceutically acceptable salt thereof or method of claim 100, wherein Li, L2, L3, L4 and Z are present.

103. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the linker is attached to the warhead through Z, if Z is present.

104. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the linker is attached to the warhead through L4, if L4 is present.

105. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the linker is attached to the warhead through L3, if L3 is present.

106. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the linker is attached to the warhead through L2, if L2 is present.

107. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the linker is attached to the warhead through Li, if Li is present.

108. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the linker is attached to the warhead through the isoquinoline amine.

109. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 79-91, wherein LGis attached to the warhead through Z, if Z is present.

110. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 87-99, wherein LGis attached to the warhead through L4, if L4 is present.

111. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 87-99 wherein LGis attached to the warhead through L3, if L3 is present.

112. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 87-99, wherein LGis attached to the warhead through L2, if L2 is present.

113. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 87-99, wherein LGis attached to the warhead through Li, if Li is present.

114. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 87-99, wherein LGis attached to the warhead through the isoquinoline amine.

115. The PROTAC, pharmaceutically acceptable salt thereof or method of any of claims 87-99, wherein Li, L2, L3, and L4 are absent and Z is H or absent.

116. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein at least one of Li, L2, L3, L4 and Z form part of the linker.

117. The PROTAC, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein Li, L2, L3, L4 and Z form part of the linker.

118. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of any preceding claim, wherein the chiral centre at the 3 position of the tetrahydroisoquinoline ring has the following configuration:

119. The PROTAC, compound, synthetic intermediate, pharmaceutically acceptable salt thereof or method of claim 118, wherein R8eis H, and the chiral center at position 3 of the tetrahydroisoquinoline ring is in the (S) configuration.

120. Use of a PROTAC, compound, or pharmaceutically acceptable salt thereof as defined in any of any of claims 1-44 or 56-119 for the manufacture of a medicament.

121. A PROTAC, compound, or pharmaceutically acceptable salt thereof of any of claims 1-44 or 56-119 for use in therapy.

122. Use of a synthetic intermediate of any of claims 45-55, or a pharmaceutically acceptable salt thereof, for the manufacture of a PROTAC.

123. Use of a compound of any of claims 28-44, or a pharmaceutically acceptable salt thereof, for the manufacture of a PROTAC.

124. Use of a synthetic intermediate of any of claims 45-55, or a pharmaceutically acceptable salt thereof, for the manufacture of a molecular glue degrader.

125. Use of a compound of any of claims 28-44, or a pharmaceutically acceptable salt thereof, for the manufacture of a molecular glue degrader.

126. A pharmaceutical dosage form comprising a PROTAC, compound or pharmaceutically acceptable salt thereof as defined in any preceding claim, wherein the pharmaceutical dosage form is a pill, tablet or capsule.

127. The pharmaceutical dosage form of claim 126, wherein the pharmaceutical dosage form is a pill.

128. The pharmaceutical dosage form of claim 126, wherein the pharmaceutical dosage form is a tablet.

129. The pharmaceutical dosage form of claim 126, wherein the pharmaceutical dosage form is a capsule.